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ABSTRACT 
 
Multi-drug resistant Enterococcus faecium, staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp termed ESKAPE 
pathogens are commonly implicated in difficult-to-treat infectious diseases in developed and 
developing countries. The prevalence, risk factors, phenotypic and genotypic profiles including 
but not limited to clonal relatedness, genetic diversity, resistance and virulence associated with 
ESKAPE bacteria were investigated in carriage and clinical isolates from patients in a rural, district 
and an urban tertiary hospital in the public health sector in uMgungundlovu District, Kwazulu-
Natal, South Africa. 
The overall carriage of MDR ESKAPE Gram-negative bacteria in both hospitals was 37.21%, 
42.31% and 57.14% at admission, after 48 hours and at discharge, respectively. The prevalence of 
MDR ESKAPE Gram-negative bacteria in faecal carriage (46%) was higher than clinical samples 
(28%) and colonization was mainly associated with referral from the district to the tertiary hospital 
with high statistical significance (OR: 14.40, 95% CI 0.98-210.84). blaCTX-M-group-9, blaCTX-M-group-1 
and blaSHV were the main resistance genes identified. Similarly, the overall prevalence of faecal 
VRE carriage was 53% with patients at the district hospital being more likely to be colonized by 
VRE at admission (44%), after 48 hours (64%) and discharge (100%) than those of the tertiary 
level. Fifteen (39%) E. faecium and 23 (61%) E. faecalis, were detected and displayed high level 
of antibiotic resistance. Extensive genetic diversity of E. faecalis and E. faecium and clonal 
dissemination of various lineages were observed across wards and within hospitals. The high 
levels of resistance in S. aureus were attributed to the multi-drug resistant efflux pumps mepA, 
mexE, AcrB, MATE, qac and qacA. Whole genome analysis revealed that the circulating S. aureus 
isolates belonged to the extremely virulent ST121 clone that harboured a total of 18 virulence 
genes. 
The high prevalence, genetic diversity and virulence of antibiotic-resistant ESKAPE bacteria 
elucidated in this study necessitates routine screening and surveillance in communities and 
hospitals, stringent infection prevention and control measures and antibiotic stewardship to 
monitor epidemiological changes, to contain their spread and inform appropriate antibiotic 
treatment options respectively.    
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CHAPTER I. INTRODUCTION 
I. Preamble 
Bacteria are microorganisms which are found in humans, animals, and the environment. They are 
present as commensal or pathogenic organisms depending on the immune system and site of 
colonization or infection in humans and animals (Hart, 2004). Several actions have been 
undertaken to combat pathogenic microorganisms, the most important of which has been the 
discovery and use of potent and safe antibiotics (Rice, 2008). Health care advances could not be 
possible without the availability of these effective antibiotic medicines (Rice, 2008). These 
substances have rapidly contributed to the reduction of morbidity and mortality associated with 
formerly fatal infectious diseases as well as other diseases such as serious heart diseases, cancers, 
and organ failures requiring prophylactic antibiotics for surgery and transplants respectively (Rice, 
2008). However, the selective pressure exerted by the use —appropriate and/or inappropriate— of 
the antibiotics, has led to the emergence of antibiotic resistance (ABR) (Omulo et al., 2015). ABR 
is the ability of bacteria to grow despite the presence of antibiotics normally active against them 
via a range of resistance mechanisms (modification of target, enzyme production, efflux pumps, 
etc.) and resistance genes (World Health Organization, 2014). All classes of antibiotics and all 
types of bacteria are affected by the ABR. ABR has been identified as one of the greatest public 
health threats to the human health by the World Health Organization (WHO) (World Health 
Organization, 2014). 
 A small group of pathogens namely Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. termed 
“ESKAPE pathogens” have been identified as amongst the main causes of difficult-to-treat 
infectious diseases in both developed and developing countries (World Health Organization, 
2014). These bacteria are also increasingly involved in multi-drug resistant (MDR) infections 
globally (World Health Organization., 2014). Several reports have confirmed a rapid increase in 
rates of infections due to methicillin-resistant S. aureus (MRSA), extended-spectrum β-lactamase 
(ESBL) and carbapenemase-producing K. pneumoniae, metallo-beta-lactamase-producing A. 
baumannii, metallo-beta-lactamase-producing P. aeruginosa (MBL-PA), and extended-spectrum 
beta-lactamase (ESBL) producing Enterobacter spp.  (Slavcovici et al., 2015; Rajagunalan et al., 
2013). ESKAPE pathogens are simultaneously able to “escape” the activity of other antibiotic 
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classes frequently used in medicine, notably aminoglycosides and fluoroquinolones via a diversity 
of resistance mechanisms (Ramirez et al., 2014; Rice., 2008). 
II. Background and rationale 
The widespread availability and indiscriminate consumption of antibiotics favours the emergence 
of resistant bacteria around the world. Drug resistant ESKAPE pathogens have all been detected 
in the developed and developing world, but the threats posed by these bacteria are worse in the 
latter. In fact, given the high rate of infectious diseases, the lack of surveillance, infection, 
prevention and control measures and antimicrobial stewardship programmes in healthcare settings 
and communities in Africa, it is extremely probable that the prevalence and transmission rates of 
ESKAPE pathogens and MDR strains are under-estimated within populations in the region 
(Tansarli et al., 2014; Ndihokubwayo et al., 2013) and strategies to contain their emergence and 
spread are limited (Joloba et al., 2010). Heightening awareness of policy-makers, health and 
veterinary professionals, laboratory scientists, and the general population about the consequences 
of antibiotic use, and the risk associated with antibiotic resistance is essential to preserve potent 
antibiotics for health of future generations (Tansarli et al., 2014; Ndihokubwayo et al., 2013). 
In South Africa, the problems posed by ABR in general and MDR ESKAPE pathogens in 
particular, are among others (i) limited measures for the prevention and control of infectious 
diseases leading to increases spread of infections caused by MDR ESKAPE pathogens (ii) lack of 
knowledge and poor communication between health care workers and different sectors (iii) limited 
implementation of antibiotic stewardship measures to prevent and/or contain ABR and (iv) high 
levels of antibiotic use in agriculture and veterinary health. Accordingly, drug resistant ESKAPE 
pathogens are no longer an exclusive HA-problem which can be solved by infection, prevention 
and containment measures in the hospitals, but requires an all- inclusive approach involving all 
role-players of the animal-human-environment continuum (Stefani et al., 2012). Studies are for 
that reason required to raise awareness concerning (i) the consequences posed by ABR and 
ESKAPE pathogens, (ii) the need to establish and/or enforce surveillance and infection prevention 
and control policies/programs, (iii) the need to implement appropriate strategies for better use of 
antibiotics, and (iv) the importance of developing and implementing antibiotic stewardship 
programs in healthcare settings and communities (Carlet et al., 2012). The study generated 
evidence for the development and/or implementation of national strategies and programmes for 
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the prevention and containment of ABR, as well as for strengthening policies promoting the 
rational use of antibiotics and monitoring ABR in the country, according to the World Health 
Organization’s (WHO) Global Action Plan (GAP) and One Health Concept. 
III. Literature review 
1. Global situation of antimicrobial drug resistance 
Antibiotics which were initially effective for the treatment of bacterial infectious diseases have 
lost their activity following the development of resistance by many microorganisms. The 
emergence and spread of resistant bacteria constrains the clinical use of antibiotics and impacts 
negatively on patient outcome as well as national and global health, leading to an urgent 
requirement for monitoring systems and the routine surveillance of antibiotic use and antibiotic 
resistance (Joloba et al., 2010). The sections below discuss the emergence, risk factors and 
transmission routes as well as prevention and control measures related to ABR. 
1.1.Emergence of antimicrobial drug resistance 
The most significant advancement in health care has been the discovery of potent and safe 
antimicrobial agents. These agents have saved countless lives and rapidly reduced the morbidity 
and mortality associated with a group of previously fatal diseases (World Health Organization, 
2014). Since their discovery and the assurance that they could prevent and treat many infections, 
they have been considered as seminal to the improvement of public health by optimizing the 
management of infectious diseases (World Health Organization, 2014). The extensive use, misuse 
and inappropriate use of these agents has however resulted in the emergence of antimicrobial 
resistance in several pathogens (World Health Organization, 2014). Antimicrobial resistance 
(AMR) is the ability of microorganisms to counteract the antimicrobial drugs and grow despite 
their presence in the organism’s environment (World Health Organization, 2014). AMR can affect 
viruses, parasites, fungi and bacteria in humans, animals and the environment. It impedes the 
control of infections, increases the mortality and costs, deteriorates economies and threatens global 
health security (World Health Organization., 2014). By 2050, about 10 million deaths will be 
caused by these infections and the Gross Domestic Product (GDP) of the world will decrease by 2 
to 3.5% if nothing is done to contain AMR (O’neill., 2015).  
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Several reports have showed the worldwide concern posed by AMR in general and ABR, in both 
community and health care settings (World Health Organization., 2014). Alexander Fleming who 
discovered penicillin was the first to reveal during his Nobel Prize elocution in 1945 that resistance 
would occur if antibiotics were extensively used (World Health Organization, 2014; Rice, 2008). 
In fact, it is the selective pressure (environmental conditions promoting or inhibiting the growth 
of bacteria with specific characteristics) exerted by the widespread consumption of these 
components which has led to the emergence and spread of resistant bacteria around the world 
(Perovic et al., 2015; World Health Organization., 2014; Zafer et al., 2014; Rice., 2008). Antibiotic 
use is thus the main driver of ABR. Large quantities of antibiotic medicines are needlessly used 
across the world contributing to the increasing incidence and subsequent prevalence of bacterial 
resistance.  
1.2.Risk factors and transmission routes of antibiotic resistance 
The prevalence of AMR differs between and within continents, countries and amongst different 
pathogens (Joloba., 2010). Several factors can be associated with variations in the prevalence and 
spread of drug resistant bacteria around the world. The main risk factors for AMR in community’s 
settings are poor socio-economic conditions, limited access to health care facilities. ineffective law 
enforcement, inadequate diagnostic and hospital capacity, inappropriate use and counterfeit quality 
of drugs, limitations in the antimicrobials supply chain and poor infection control contribute to 
increase AMR in settings (Laxminarayan and Heymann., 2012). In hospitals, these risk factors 
include previous hospitalisation, antibiotic treatment, stay in the intensive care unit (ICU), location 
in the hospital, duration of hospital stay, urinary catheterisation, injuries and surgeries, respiratory 
tract infection (RTI), naso-gastric intubation, mechanical ventilation, and central veno us and 
peripheral catheters. Other factors such as the gender, age, frequent urinary tract infections, co-
morbidities such as, diabetes mellitus, malaria, HIV/AIDS and tuberculosis are also considered as 
risk factors for the emergence and spread of AMR (Laxminarayan and Heymann, 2012). 
Furthermore, the risk of developing AMR is particularly elevated in countries where monitoring 
systems, regulatory authorities, surveillance and legislation concerning the use of drugs are 
inadequate or non-existent. This is generally evident in low- and middle-income countries (LMIC) 
and particularly in Africa, where antibiotics are the most commonly purchased and consumed 
drugs (Joloba and Bwanga, 2010). AMR is accordingly a complex interaction of many factors and 
can be transmitted via different pathways within and between hospital and community settings. 
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Once the resistance has emerged, the transmission of AMR is possible via indirect and direct 
contacts in the population. Direct or person-to-person contact comes from immediate exposure to 
the pathogens via hands and biological substances. Direct contact rapidly and easily spreads drug 
resistant bacteria and enhances the risk of potential outbreaks in communities and hospitals across 
the world (Laxminarayan et al., 2016; World Health Organization., 2015a; World Health 
Organization, 2014; Laxminarayan et al., 2013). Additionally, there is a great concern regarding 
the indirect transmission of resistance pathogens. Indirect transfer occurs by exposure to 
contaminated objects such as medical equipments and the environment including dust, air, water 
and soil which are often unsuspected reservoirs. In fact, the environment has been established as 
an important reservoir due to the frequent dissemination of active metabolites of antibacterial drugs 
via biological substance such as urine, blood, semen, saliva and faeces. In developing countries, 
MDR bacteria significantly increase mortality while in developed countries the same pathogen 
increases mainly treatment expenses. Indeed, in the latter, numerous strategies and policies have 
been implemented for the containment of AMR and rational drug use while in developing world 
there is inadequate surveillance and prevention measures related to infectious diseases, and a 
dearth of policies concerning antibiotic consumption thereby exacerbating the problem 
(Laxminarayan et al., 2013; Okeke and Sosa, 2010). Is thus imperative to develop and implement 
global policies, guidelines, activities and recommendations addressing the prevention and 
containment of AMR around the world and mainly in LMICs. 
2. Prevention and control of antimicrobial drug resistance 
AMR is a global public health issue of great importance and the selective pressure exerted by 
antibiotic use in human, animal and in the environment, has always been regarded as the key 
driving factors leading to its emergence and spread.  “Antimicrobial stewardship is a key strategy 
to effectively contain AMR” by a group of systematic coordinated and all-inclusive actions, 
concomitant interventions and guidelines enhancing the rational use of drugs in all sectors. It 
advocates prudent, responsible and optimal drug use to: (i) improve patient safety (ii) improve 
patient outcomes (iii) limit the emergence of resistance and (iv) reduce associated costs (Kimang’a, 
2012). Antimicrobial stewardship programs (ASPs) are thus an effort to revolutionize cultural, 
social and behavioural norms and attitudes to antimicrobial use. 
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The WHO Global Antimicrobial Surveillance System (GLASS) recommends the following 
measures to monitor, prevent and contain AMR in all nations (World Health Organization, 2015b):  
- Encourage national surveillance systems using uniform global standards. 
- Estimate the extent and burden of AMR globally through selected indicators. 
- Analyse and report global data on AMR on a regular basis. 
- Detect emerging resistance and its international spread.  
- Inform and implement targeted prevention and control programmes. 
- Evaluate the impact of intervention. 
Similarly, the WHO Global Action Plan of Antimicrobial resistance set out five strategic 
objectives for containment of ABR (World Health Organization, 2015a): 
- Heighten awareness and understanding of AMR using effective education, communication, 
and training. 
- Strengthen knowledge and evidence base using surveillance and research.  
- Lessen the incidence of infection through effective hygiene and infection prevention 
measures.  
- Optimize rational antibiotic use in human and animal health.  
- Ensure sustainable investment in containing AMR. 
3. Worldwide emergence of multidrug resistant ESKAPE pathogens 
The group of ESKAPE pathogens have been reported to develop multidrug resistance and 
extensive drug resistance in many developed and developing countries. MDR bacteria are 
pathogens resistant to one or more antibiotics from three or more antibiotic classes; and those 
resistant to all antibacterial drugs are identified as extensively drug resistance bacteria (Kallen., 
2010; Bassetti et al., 2013). The following sections elaborate on antibiotic resistant ESKAPE 
pathogens.  
3.1. Vancomycin resistant Enterococcus spp. 
Enterococcus spp. are Gram-positive cocci, known to be common residents of human and animal 
gastrointestinal tracts. About 16 species have been identified but only 2, namely E. faecalis and E. 
faecium have emerged as one of the clinical challenges for physicians, because they are involved 
in serious life-threatening infections such as endocarditis, urinary tract infections (UTI), 
bacteraemia, neonatal sepsis, meningitis, surgical wound infections and intra-abdominal and 
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pelvic infections (Abebe et al., 2014). Amongst all enterococcal species, E. faecium and faecalis 
represent the most clinically important. E. faecium exhibits more resistance to antibiotics than E. 
faecalis whereas the latter is generally more virulent (Abebe et al., 2014). The emergence and 
spread of resistant enterococci is attributed to several features including their efficient ability to 
express resistance to antibiotics, their diversity of virulence factors, their capability of biofilm 
formation, their noteworthy genome plasticity with the carriage of plasmids, transposons, and 
insertion sequences and their ability to horizontally transfer virulence and resistance genes to other 
bacteria. Enterococci are considered clinically importance because of the: (i) emergence of 
vancomycin-resistant enterococci (VRE), (ii) high-level of resistance to multiple antibiotics, (iii) 
transfer of resistance genes from VRE to S. aureus, (iv) presence of different selective pressures 
that increase the rapid proliferation of VRE, (v) few therapeutic options for disease management, 
and (vi) limited success of VRE containment measures (Abebe et al., 2014; Gozalan et al., 2015 ).  
VRE become resistant to the glycopeptide family following production of new precursors D-Ala-
D-Lac or D-Ala-D-Ser encoding for low-glycopeptide affinity. VREs express eight different 
phenotypes VanA, VanB, VanD, VanE, VanG, VanL, VanM, and VanN depending on the level 
of resistance to teicoplanin and vancomycin, as well as the origin and transferability of the 
resistance genes (Iweriebor et al., 2015; Sujatha and Praharaj, 2012). The operon vanA responsible 
for the VanA cluster is carried by the highly heterogeneous element Tn1546 generally located on 
chromosomes or plasmids and transferred among Enterococci (Sujatha  and Praharaj., 2012; 
Gozalan et al., 2015 ; Iweriebor et al., 2015). The phenotype VanA demonstrates an elevated 
resistance to both teicoplanin and vancomycin, while strains harbouring the vanB phenotype 
express resistance to vancomycin but are susceptible to teicoplanin. The cluster vanD is 
characterized by its inducible resistance nature, and by low-level teicoplanin resistance and 
moderate- to high-level vancomycin resistance. The other phenotypes vanG and VanE express 
inducible resistance and low-level of resistance to vancomycin (Corso et al., 2007; Gozalan et al., 
2015 ; Iweriebor et al., 2015). Among these, the vancomycin-resistance genes vanA and vanB are 
most commonly involved in VRE infections (Sujatha  and Praharaj., 2012; Gozalan et al., 2015 ; 
Iweriebor et al., 2015).  
E. faecium isolates with the VanA phenotype were first detected from clinical cases of VRE 
infections in Europe in 1986; and were associated with outbreaks in hospitals, particularly in 
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patients with severe underlying disease or immunocompromised status (Abebe et al., 2014; Corso 
et al., 2007). In Africa, the first cases of VRE infection were described in South Africa with a 
10.9% prevalence of colonized patients in hospitals in 1997 (Gottberg., 2010). In early 2000, VRE 
colonization and infection became a serious threat when the first case of vancomycin-resistant S. 
aureus harbouring the vanA resistance gene of VRE was reported in clinical isolates in England 
and France by O’Driscoll et al. (2015) (Crank., 2015). The overuse of glycopeptides and extended-
spectrum cephalosporins in hospital settings has probably contributed to the global increase and 
spread of VRE strains (Shafiyabi et al., 2013). The therapeutic options available for VRE 
infections are limited.  
VRE infections are associated with some risk factors including length of stay (≥7 days), previous 
antibiotic treatment, prolonged antimicrobial regimens and duration of vancomycin use (≥7 days), 
stay in intensive care units (ICU) or surgical units, the presence of indwelling urinary or central 
venous catheter, intra-abdominal or cardio-thoracic surgical procedures, HIV/AIDS, higher 
severity-of-illness scores and co-morbidities such as renal failure and diabetes (Abebe et al., 2014). 
VRE have been significantly involved in nosocomial infections and have spread globally (Abebe 
et al., 2014). In 2013, a high prevalence of VRE has been reported from various clinical samples 
—these include respiratory samples (70%), blood culture (97%), pus (100%) and urine (100%) — 
in a tertiary hospital in India. Among these VREs, a 23% rate of high level aminoglycoside 
resistance (HLAR) and 100% resistance to linezolid were observed (De et al., 2015). E. faecium 
has been shown to express HLAR in combination with ampicillin-resistance (53%) in children 
with systemic infections in Tanzania (Aamodt et al., 2015). The majority of these infections were 
hospital-acquired, i.e. infection occurring ≥48 after hospital admission (Aamodt et al., 2015).  
However, the foremost clinical relevance of VRE is its colonization in the gastrointestinal tract of 
humans and animals, representing the reservoirs and main route of exposure for VRE transmission 
(Corso et al., 2007). The enterococcal colonization among HIV positive patients in a study in 
Ethiopia was seen to be 91%, with 8 and 90% of VRE and MDR isolates respectively. A report 
from Argentina showed a 77% prevalence of VRE from rectal swabs of hospitalized patients, with 
the ICU (47%) and general medicine wards (36%) being the main affected units. A 25% prevalence 
of VRE infections from paediatric patients and 10% VRE colonization rate of healthcare workers 
was reported in Egypt (Abebe et al., 2014). Despite a low level of E. faecium resistance to linezolid, 
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vancomycin and teicoplanin from burn patients in China, more than 50% of the enterococcal 
isolates were multi-drug resistant (Jia et al., 2014). There is insufficient data available on the 
epidemiology and risk factors of VRE in Africa.  
The main concern posed by the VRE is the transmission of the vanA resistance gene to S. aureus 
and the consequent emergence of vancomycin-resistant S. aureus described in early 2000 (Crank., 
2015). Despite the fact that VRE is considered as a serious pathogen around the world, in South 
Africa, the threat caused by the VRE is relatively unknown in South Africa as there is a scarcity 
of information concerning colonization and infections with VRE in both communities and 
hospitals. Studies are thus needed to provide epidemiological data and improve the understanding 
of these drug resistant bacteria. 
3.2. Methicillin Resistant Staphylococcus aureus (MRSA) 
The Gram-positive bacterium S. aureus is a ubiquitous colonizer of the skin micro-biota and 
mucosa —anterior nares and axillae. About 20-30% of the human population is generally 
colonized by S. aureus and they are known as asymptomatic carriers. S. aureus is also the foremost 
wound pathogen responsible of both acute and chronic infections, as well as minor to life-
threatening infections —including boils, pimples, abscesses, septicemia, meningitis, pneumonia, 
toxicosis— due to the formation of a biofilm and an arsenal of virulence factors (Kejela et al., 
2013). The majority of S. aureus strains produce proteases, hemolysins, hyaluronidase, biofilm, 
collagenase and various toxins such as toxic shock syndrome toxin (tsst-1), staphylococcal 
enterotoxin (sea, seb, sec, sed, see, sef, seg, seh), the Panton-Valentine Leukocidin (PVL) and 
staphyloxanthin (Pendleton et al., 2013). Most of these features are located on mobile genetic 
elements (MGEs) like plasmids, transposons, integrons, genetic islands, insertion sequence and 
phage-related elements (Stefani et al., 2012).  
S. aureus has also an exceptional capacity to acquire and develop resistance to antibiotics (Kejela 
& Bacha., 2013). Penicillin became ineffective for S. aureus infections within 10 years of its 
introduction due to the acquisition of a plasmid-borne beta-lactamase (Kejela & Bacha., 2013). 
The beta-lactam antibiotic methicillin, developed in response to penicillin resistance to palliate the 
failure of the penicillin, lost its activity against S. aureus two years after its introduction into 
clinical practice in 1961. These resistant isolates have been termed methicillin-resistant S. aureus 
(MRSA) or oxacillin-resistant S. aureus (ORSA). MRSA is responsible for a number of serious 
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difficult-to-treat and multidrug resistant infections in humans and generally confer resistance to 
the whole β-lactam antibiotics family including penicillins, cephalosporins (active against S. 
aureus), carbapenems and beta-lactam inhibitors, following the insertion of a naked DNA 
fragment called Staphylococcal Chromosome Cassette mec (SCCmec). The SCCmec harbours the 
mec A gene encoding for a PBP 2a or PBP’ with low β-lactam affinity and therefore responsible 
of methicillin resistance (Stefani S et al., 2012). MRSA can also colonize the skin, anterior nares, 
nasopharynx, and the rectum without any infections, and disseminate among people directly by 
person-to-person contact via contaminated hands, skin lesions, nasal discharge or other biological 
fluids or indirectly via contaminated air, inanimate objects, dust, and food (Kejela & Bacha., 
2013). MRSA was first associated with hospital-acquired infections (HA-MRSA) involving 
several MDR clones like the Brazilian, Iberian, Hungarian, pediatric and New York/Japan clones, 
which represent the main HA-MRSA (Gordon et al., 2008). Community-acquired MRSA (CA-
MRSA) infections were subsequently reported in Australia and America in people without 
previous risk factors for MRSA colonization and/or infection (Gordon et al., 2008). These 
infections have progressively emerged and spread around the world and even in health care 
settings, changing the equilibrium between HA-and CA-MRSA clones (Gordon et al., 2008). 
HA-MRSA is generally more resistant than CA-MRSA while the latter is more virulent than HA-
MRSA due to the enterotoxin Panton-Valentin leukocidin (PVL) (Gordon et al., 2008). Both 
strains are present in developed and developing countries with some variations among different 
regions. In Latin America, a prevalence of 43.8% and 37% of MRSA has been reported in 
Paraguay and Argentina, respectively (Cabrera et al., 2011). In Africa, data on MRSA infections 
are relatively limited, with few reports showing high isolation rate in Ethiopia (42.8%), Nigeria 
(29.6%), Kenya (27.7%), Ivory Cost (16.8%), Morocco (14.4%), Cameroon (72%) and South 
Africa (52%) (Kejela & Bacha., 2013; Njoungang et al., 2015; World Health Organization., 2014). 
The global emergence and/or dissemination of HA- and CA-MRSA, VISA and VRSA has led 
MRSA being ranked among the principal ESKAPE pathogens involved in human infections 
worldwide with some variations between regions (Gordon et al., 2008; Monecke et al., 2012). 
MRSA claims over 25% of S. aureus infections in more than a third of EU countries, with 
prevalence greater than 50% reported from Portugal, Northern Ireland, Great Britain, Greece, 
France and Spain (Pendleton et al., 2013; Stefani et al., 2012). In other parts of Europe like in 
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Netherlands, Norway, Denmark and Scandinavia, where strategies for screening and control of 
MRSA in humans have been successfully implemented, the MRSA prevalence is very low <2% 
(Pendleton et al., 2013; Stefani et al., 2012). In USA, MRSA alone claims more deaths than HIV 
and tuberculosis (Klevens., 2007). Human MRSA prevalence varies from 5-10% in Canada to 25-
50% in the USA (Klevens., 2007). In low- and middle-income countries (LMIC) where poverty, 
malnutrition, poor hygienic measures facilitate the emergence and spread of these resistant 
bacteria, the MRSA prevalence is difficult to determine but appears to be clearly higher than in 
high-income countries. Reports from Asia showed a prevalence of more than 50% in Malaysia, 
Taiwan, Nepal, Singapore, Japan and Hong-Kong, a rate of 40% in India, and 24% in Pakistan 
(Mukhiya et al., 2013; Ray et al., 2011). In China, 82.9% prevalence of MRSA was detected in 
ICU-acquired pneumonia (ICU-AP) and ventilator-associated pneumonia (VAP) (Zhang et al., 
2014).  
The glycopeptides are the common first-line treatment for MRSA infections worldwide. However, 
the selective pressure exerted by the extensive use of these drugs has led to the emergence of 
strains with reduce susceptibility for vancomycin and are either called vancomycin-intermediate-
resistant S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA). VISA has emerged 
following fundamental changes in cell wall composition and thickness, “trapping” vancomycin 
and reducing its permeability in the bacteria. VISA strains are generally resistant to teicoplanin 
and virtually resistant to all antibacterial drugs (Pendleton et al., 2013). They were first identified 
in Japan in 1990s and have spread across the world with isolates detected in Europe, Asia and USA 
(Pendleton et al., 2013). VRSA emerged instead through interspecies transfer of resistance genes 
from VRE. MDR VRSA strains exhibit both mecA and vanA genes with resistance transferred via 
the same mechanisms as MRSA and VRE, respectively (Pendleton et al., 2013). 
In addition to its implication in human pathogenesis, S. aureus, including MRSA are involved in 
the infections of livestock, wildlife, and domestic animals including bovine mastitis among dairy 
cattle, lameness in poultry and rabbits. Many studies have identified MRSA and livestock-
associated S. aureus (LA-MRSA) isolates in humans and animals. Tracy et al., (2013) and Chen 
(2013) has observed the transfer of LA-MRSA isolates from animal to human due to contact and 
persistent nasal colonization. LA-MRSA is frequently detected in individuals with direct animal 
exposure (Chen., 2013; Nicholson et al., 2013; Van et al., 2011). Accordingly, MRSA it is no 
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longer an exclusive HA-problem which can be solved by infection prevention and containment 
measures only in hospitals, but requires an all-inclusive approach involving all players of health 
care settings (Stefani et al., 2012).  
In South Africa, the epidemiology of MRSA is quite complex, and the prevalence depends on the 
geographical location, population and medical practices. Mortality associated with MRSA 
infections varies from 29% to 63%. A 36% prevalence was recently identified from hospital 
patients in Guateng during 2012-2013. A laboratory based surveillance mapping of AMR further 
demonstrated a 46% prevalence of MRSA with rates declining significantly from 53% in 2010 to 
40% in 2012, but with more resistance to other classes of antibiotics such as aminoglycosides and 
fluoroquinolones which may be linked to the mobile genetic elements (Perovic et al., 2015). The 
study showed the presence of various HA-MRSA clones including ST612/CC8, ST36/CC30, 
ST239/CC8, ST5/CC5 (Perovic et al., 2015). It is therefore, it is important to determine risk factors 
that are associated with MRSA infection to reduce MRSA infection and to assist clinicians in 
choosing appropriate antibiotics. 
3.3.Multidrug resistant Gram-negative ESKAPE bacteria 
Of the 6 infamous “ESKAPE pathogens, 4 are Gram negative bacteria —K. pneumoniae, A. 
baumannii, P. aeruginosa, and Enterobacter spp. They have been associated with three major 
types of multi-drug resistance namely ESBL-producing K. pneumonia and Enterobacter spp., 
carbapenemase-producing A. baumannii and P. aeruginosa, and MDR A. baumannii and P. 
aeruginosa (Wang et al., 2017; Pendleton et al., 2013; Rice., 2008).  
3.3.1. Resistance mechanisms involved in the MDR of Gram-negative ESKAPE 
bacteria 
Diverse biochemical and physiological mechanisms have been associated with the emergence of 
MDR Gram-negative ESKAPE bacteria. The bacterial production of enzymes hydrolysing 
antibiotics, particularly β-lactam antibiotics, is the most important mechanism of resistance in 
ESKAPE Gram-negative bacteria. The β-lactamase enzymes have emerged following 
chromosomal mutation and acquisition of resistance genes harboured by MGEs like plasmids, 
integrons, insertion sequences, transposons, genomic islands and bacteriophages (Dantas & 
Sommer., 2014). These MGEs carrying resistance genes can be transferred vertically within the 
same population or horizontally among bacteria of the microbial flora through conjugation, 
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transformation and transduction increasing the complexity and diversity (Dantas & Sommer., 
2014).  
Two systems have been described for the β-lactamase classification: (i) The Ambler scheme based 
on the amino-acid sequence (molecular classification) and (ii) The Bush-Medeiros-Jacoby system 
based on the substrate and inhibitor profiles (functional classification). The molecular 
classification is commonly used and divides the β-lactamases into 4 different classes (A, B, C and 
D). The classes A, C and D require serine in their active site to hydrolyse the beta-lactam 
antibiotics while the class B metallo-enzymes utilize divalent zinc ions for substrate hydrolysis. 
ESBLs are Ambler class A enzyme hydrolyzing several β-lactam drugs including penicillin, 
aminopenicillin, 1st, 2nd, 3rd and 4th generation cephalosporins. They are generally inhibited by 
beta-lactamase inhibitors and inactive against cephamycins and carbapenems (Curcio., 2014).  
Numerous ESBL variants have been identified globally and grouped into 3 different ESBL types: 
Temoneira (TEM), Sulfhyldryl-variable (SHV) and Cefotaximase-München (CTX-M) (Jacoby 
and Bush, 2010). K. pneumoniae has been identified as the foremost ESBL-producer. Other 
clinically relevant enzymes are Amp-C beta-lactamases and metallo beta-lactamases (MBLs). 
Class C Amp-C beta-lactamases including FOX and MOX, differ from the ESBLs in their ability 
to inactivate cephamycins and are unaffected by currently available β-lactam inhibitors. The MBLs 
are Ambler’s class B, enzymes possessing a metal ion on their active site to catalyse the β-lactams. 
They can inactivate the entire β-lactam family except for aztreonam. The most common MBLs 
involved in clinical Gram-negative infections are Klebsiella pneumoniae carbapenemase (KPC), 
imipenemase (IMP), Veronera integron encoded metallo-beta-lactamase (VIM), Serratia 
marcescens enzyme (SME), New-Delhi metallo-beta-lactamase (NDM) and oxacillin-hydrolyzing 
carbapenemases (OXA-types). They have been identified mainly in K. pneumonia, P. aeruginosa, 
A. baumannii, Enterobacter spp. and E. coli (Curcio., 2014).  
3.3.2. ESBL-producing K. pneumoniae 
The rates of ESBL-producing K. pneumoniae in various regions of the world suggests a lower 
resistance level in USA, Canada, Northwest Europe, and increasing resistance in the developing 
countries of Southeast Europe, Latin America, Asia and Africa (Curcio., 2014). The 2014’s WHO 
report on AMR presented a 45% prevalence of deaths in both Africa and South-East Asia related 
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to MDR infections. It further confirmed that these diseases were associated with 77%, 50%, 81% 
and 72% approximately of K. pneumoniae resistant to third generation cephalosporins in Africa, 
the Eastern Mediterranean region, South East Asia and the Western Pacific region respectively, 
with 4%, 54%, 8%, 8%prevalence of K. pneumoniae resistant to carbapenems respectively 
identified in the same regions (World Health Organization., 2014). 
Several authors have highlighted hospital settings as a potential reservoir and source of nosocomial 
infections in their studies, ESBL-producing K. pneumoniae increased from 11.7 to 77.8% in two 
hospitals in Tunisia from 1999-2005 and in 2010 (Mahrouki et al., 2012). In some Algerian 
hospitals, Amp-C β-lactamases, mainly DHA-1 and CMY-2, were most commonly observed in 
Enterobacter spp. The National Healthcare Safety Network (NHSN) has recently indicated the 
implication of drug resistant Gram-negative bacteria in more than 30% of hospital acquired 
infections (HAI), with a predominance in cases of ventilator-associated pneumonia (47%) and 
urinary tract infections (45%) in USA in 2010 (Kanerva et al., 2012). The European Centre for 
Disease Prevention and Control (ECDC) and European Medicines Agency (EMEA), reported 
25 000 deaths associated with 7% being MDR K. pneumoniae.  
Furthermore, Kanerva et al., (2010) reported 6% prevalence of HAI resulting in 3.2% of deaths 
due to K. pneumoniae, Acinetobacter spp., P. aeruginosa and Enterobacter spp. in Finland 
(Kanerva et al., 2012). Reports from Egypt showed a 76% prevalence of ESBL-producing K. 
pneumoniae in bloodstream infections (BSIs) (Saied & Elkholy ., 2011). In addition, carbapenem 
resistance has been identified in nosocomial ESBL-producing K. Pneumoniae. A 21.6% 
prevalence of ESBL-producing-K. Pneumonia and 9.3% carbapenemase-producing-K. 
pneumoniae have been reported from various clinical samples in Nigeria (Motayo et al., 2013). 
A national sentinel surveillance study investigating K. pneumoniae in 13 academic centres serving 
the public health sector in five South African provinces from mid-2010 to mid-2012 revealed that 
the prevalence of ESBL-producing K. pneumoniae among bacteraemic patients was 68.7% with 
isolates showing high resistance to third and fourth generation cephalosporins, aminoglycosides 
and fluoroquinolones (Perovic et al., 2014). Likewise, another South African study revealed that 
60% of referral Enterobacteriaceae were K. pneumoniae during a four-year period (2012-2015) 
(Perovic et al., 2016). The study showed that among these, 68% of K. pneumoniae were 
carbapenemase-producers with blaNDM being the main carbapenemase gene identified (Perovic et 
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al., 2016). These reports thus point to rapid and global dissemination of resistant K. pneumoniae 
and require the urgent implementation of infection prevention and control measures in South 
African settings. 
3.3.3. Multi-drug resistant A. baumannii 
A. baumannii is another worldwide public health threat which hampers the control of infectious 
diseases. The latter epitomizes the successful ability of pathogens to escape antibiotics and 
deserves close attention. It exhibits resistance mechanisms to all available antibiotic families as 
well as an exceptional ability to acquire new resistance determinants (Andriamanantena et al., 
2010; Chan et al., 2014; Perez et al., 2007). There is evidence of the increasing emergence of MDR 
A. baumannii (MDRAB) and extensively drug-resistant A. baumannii (XDRAB) resistant to the 
entire β-lactam family including broad-spectrum cephalosporins and carbapenems, 
aminoglycosides, fluoroquinolones and, oxazolidinones (Andriamanantena et al., 2010). β-lactam 
resistance is of great concern. Several strains harboring TEM-1 beta-lactamase, a variety of 
ESBLs, PER-1, IMP-1, IMP-2, IMP-4, IMP-5, IMP-6, IMP-11, OXA-23, OXA-24, OXA-58, and 
OXA-51, and chromosomally encoded AmpC genes have been detected in A. baumannii across 
the world (Chan et al., 2014; Perez et al., 2007).  
A report from India revealed a 25% prevalence of MBL-producing A. baumannii, 16% of which 
co-produced AmpC and 9% of which co-produced ESBL in combination with MBL in burn 
patients (Gupta et al., 2013). The prevalence of XDR-AB from clinical samples escalated from 
15% in 2005 to 41% in 2010 in Taiwan (Chan et al., 2014). A resistance rate of 100% MDRAB 
was reported in clinical samples in Pakistan where the main units affected were the neonatal 
intensive care unit (NICU) (42.85%), medical ICU (19.78%) and the out-patient department 
(9.8%) (Begum et al., 2013). Carbapenem-resistant A. baumannii (CRAB) was involved in 44% 
of infections in surgical units in Madagascar and 21.05 % of imipenem resistant A. baumannii was 
identified in intensive care unit in Cameroon (Andriamanantena et al., 2010; Ebongue et al., 2015). 
Class D ESBLs, specifically OXA-1 predominated in Tunisia and ranged from 3.3 to 93.3%, OXA-
48 has been described by Andriamanantema et al., (2010) in the rectal swabs from hospitalized 
patients in Libya. In South Africa, a study reported a 10.9% prevalence of A. baumannii although 
none were carbapenem-resistant, in bloodstream infections in neonates hospitalized in a tertiary 
care hospital (Ballot et al., 2012). However, Ramsamy et al. (2013) reported that A. baumannii 
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was detected in 46% of lower respiratory, 23% of surgical site and 30.7% of bloodstream infections 
among critically injured patients over a 12-month period in KwaZulu-Natal, South Africa. Of 
these, 10% were carbapenem-resistant and 27% were multi-drug resistant (Ramsamy, Muckart, & 
Han, 2013) confirming the seriousness of infections caused by these isolates. 
3.3.4. Metallo-beta-lactamase producing P. aeruginosa 
P. aeruginosa is one of the most frequent Gram-negative ESKAPE bacteria isolated in hospital 
settings. It has become resistant to carbapenems because of the production of MBL enzymes. 
MBLs are broad–spectrum enzymes hydrolysing most β-lactam antibiotics, except monobactams, 
and are not in-activated by commonly used β-lactamase inhibitors such as tazobactam, sulbactam 
and clavulanic acid (Curcio., 2014).  MBL-producing P. aeruginosa in ICUs is of concern. Their 
emergence is associated with the misuse and overuse of carbapenems while its persistence is due 
to sub-optimal infection prevention and control measures (Kali et al., 2013; Uddin et al., 2013). 
MDR P. aeruginosa (MDR-PA) is a major cause of nosocomial infections particularly ventilator-
associated pneumonia (VAP) in ICUs (Rizek, Fu et al., 2014; Sawa et al., 2014). The treatment 
options are limited constrained to a small number of antibiotics such as the fluoroquinolones and 
colistin. P. aeruginosa producing MBL was reported in surgical tertiary care hospitals in Saudi 
Arabia where the rate of carbapenems-producing P. aeruginosa was 33%, with 27% in young and 
middle-aged adults (19-65 years) with wound infections (Chan et al., 2014). The prevalence of 
MBL producing P. aeruginosa was 27% in Egypt in 2009, with 41.7% and 10.4% of these isolates 
carrying OXA-10 and VEB-1 genes respectively. In 2013, 37.03% carbapenemase- producing P. 
aeruginosa and 32.3% MBL-producing P. aeruginosa was described (Zafer et al., 2014). In India, 
a prevalence of 22.4% P. aeruginosa producing MBLs was reported in tertiary care hospitals (Kali 
et al., 2013; Slavcovici A et al., 2015).  
In South Africa, 57% of P. aeruginosa involved bacteraemia in an academic hospital were 
nosocomially-acquired and among these, 15% were MDR isolates (Perovic et al., 2008). Similarly, 
an outbreak due to MDR P. aeruginosa occurred in immunocompromised patients in a 
haematology intensive care unit of a South African tertiary academic hospital with an 80% case 
fatality rate (Mudau et al., 2013). The study revealed that all isolates were resistant to all antibiotics 
except colistin, and concluded that poor infection prevention and control measures may have 
contributed to the transmission to these resistant strains (Mudau et al., 2013). 
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3.3.5. ESBL-producing Enterobacter spp. 
Enterobacter spp. is a Gram-negative bacillus frequently observed in normal flora of the 
gastrointestinal tract of 40 to 80% of humans. It is also one of the main agents causing several 
resistant hospital-acquired infections and has been identified in high risk wards such as the ICU 
and neonatal unit (Qama et al., 2014). It is frequently isolated in different site infections including 
blood stream, abdomen, lower respiratory tract, urinary tract, meningeal, eye, bone, and surgical 
infections. It has been involved in the dissemination of MDR due to mobile genetic elements 
(transposons, plasmids, integrons) and has become a major threat of public health around the world 
(Khajuria et al., 2014) due to high level of resistance to various antibiotics among the family of β-
lactams particularly. The principal resistance genes described in Enterobacter spp. were blaCTX-
M, blaNDM, blaIMP and blaVIM and have been reported worldwide. For example, a 68.57% 
prevalence of carbapenemase-producing Enterobacter spp. was reported in India (Khajuria et al., 
2014). Singh et al. (2015), revealed a high prevalence (72%) of carbapenemase-producing E. 
cloacae harbouring blaOXA-48, blaVIM, and blaIMP in Eastern Cape hospitals in South Africa. The 
authors concluded that MBL-producing Enterobacter spp. are prevalent in South Africa and that 
horizontal transmission of resistant bacteria in healthcare settings is an important contributing 
factor (Singh et al., 2015).  Similarly, over the 2012-2015 period, a study investigating suspected 
carbapenemase-producing Enterobacteriaceae (CREs) revealed that 12% were Enterobacter spp. 
and blaIMP was the predominant carbapenemase gene (Singh-Moodley & Perovic, 2016). 
Controlling resistant bacteria in South Africa require intensive efforts.  
4. Concluding remarks 
Antimicrobial resistance is a major problem and MDR infections are a serious clinical challenge 
globally. MDR infections considerably increase therapeutic cost as well as morbidity and mortality 
in both developed and developing countries (World Health Organization., 2014). The treatment 
options are limited to a small number of antibiotics due to the diverse mechanisms involved in the 
resistance. The situation is exacerbated by the emergence of MDR bacteria from animals and the 
environment with their subsequent spread to humans in communities and hospitals (Kali et al., 
2013).  
Containing ABR in general and ABR in ESKAPE bacteria in particular, is an urgent priority in 
South Africa. Understanding the resistance mechanisms, resistance genes, virulence factors, risk 
factors and transmission routes of drug resistant ESKAPE pathogens in South Africa, may serve 
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as evidence for policy-makers to implement strategies to contain ABR in the country (Basseti et 
al. 2013). 
IV. Research aims and objectives of the study 
1. Overarching aim  
The aim of this study was to determine the risk factors, prevalence, phenotypic and genotypic 
profiles including but not limited to clonal relatedness, genetic diversity and resistance 
mechanisms associated with ESKAPE bacteria from carriage and clinical isolates from patients in 
a rural, district and tertiary urban hospital within the public health sector in uMgungundlovu 
District, Kwazulu-Natal, South Africa. 
2. Specific objectives 
More specifically, the study objectives are: 
1. To isolate resistant ESKAPE bacteria from carriage samples including nasal and rectal swabs 
of in-patients, using selective media and relevant biochemical tests. 
2. To collect resistant ESKAPE bacteria from different clinical samples routinely processed by 
the National Health Laboratories affiliated with the hospitals in question identified by the Vitek 
2 system. 
3. To establish the risk factors associated with colonization and infection by resistant ESKAPE 
bacteria including but not limited to socio-demographic and health system factors such as age, 
gender, profession, date of admission, date of discharge, duration of hospitalization, ward type, 
specimens source, diagnosis, co-morbidity and invasive procedures using a structured 
questionnaire. 
4. To determine the antibiotics resistance profiles of ESKAPE bacteria by performing antibiotic 
susceptibility testing through by broth micro-dilution and the Vitek 2 automated method in 
carriage and clinical isolates respectively. 
5. To undertake conventional, multiplex and real-time PCR as well as whole genome sequencing 
of isolates to delineate: 
o Antibiotic resistance genes 
o Virulence genes  
o Mobile genetic elements such as plasmids, transposons and integrons associated with 
resistance and virulence  
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o MLST profiles 
6. To additionally undertake a systematic review and meta-analysis to comprehensively analyze 
the published literature on the clinical and economic implications of ABR in developing 
countries. 
3. Study design and methodology 
This was an observational study that identified ESKAPE bacteria from carriage (nasal and rectal 
swabs) and clinical specimens of hospitalized patients between May and July 2017, in a rural, 
district, and an urban tertiary hospital in uMgungundlovu, South Africa. Risk factors for the 
carriage of ESKAPE bacteria were ascertained using chi-square test and univariate and 
multivariate logistic regression.  
Minimum inhibitory concentration (MICs) were determined via micro-broth dilution, and the 
ROSCO DIAGNOSTICA (Taastrup, Denmark) kits was used to identify ESBL, MBL, AmpC, 
VRE, MRSA and GISA isolates. Conventional, multiplex and real-time PCR were used to 
determine the presence of antibiotic resistance genes including blaCTX-M (group 1, 2, 9, 8/25), 
blaTEM, blaSHV, blaOXA-1-like, blaGES, blaIMP, blaOXA-48, blaAmp-C, VanA, VanA-1, VanB, VanC-1/2, 
associated with the relevant ESKAPE bacteria. Representative isolates underwent genomic 
fingerprinting via ERIC and REP-PCR and whole genome sequencing using an Illumina Miseq 
machine with multiplex paired-end libraries (2×300 bp) prepared from the genomic DNA. 
Assembling of the raw read was performed with the QIAGEN CLC Genomic Workbench and 
SPAdes, annotation was performed with NCBI PGAP, RAST, ARG-ANNOT and ResFinder to 
identify antibiotic resistance genes. VirulenceFinder and PlasmidFinder were used to determine 
virulence factors and plasmid elements, respectively. 
4. Thesis outline 
The thesis is in the form of published journal articles and unpublished manuscripts in six chapters 
as follows:  
▪ Chapter 2. Article I: Extended Spectrum β-lactamase Mediated Resistance in Carriage and 
Clinical Gram-Negative ESKAPE Bacteria Isolated in uMgungundlovu District, South Africa: 
A Comparative Study Between an Urban Tertiary and a Rural, District Hospital in 
uMgungundlovu District, South Africa. This original research paper has been submitted to 
PloS One and reports on the risk factors, prevalence, phenotypic profiles, genetic diversity and 
resistance mechanisms associated with ESBLs in Gram-negative ESKAPE bacteria from 
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faecal carriage and clinical samples obtained from hospitalized patients in the public health 
sector in KwaZulu-Natal, South Africa. It addresses objectives One, Two, Three, Four and 
Five. 
▪ Chapter 3. Article II: Faecal Carriage of VanC-1-Mediated Vancomycin-Resistant 
Enterococcus faecium and Enterococcus faecalis in Hospitalized Patients in uMgungundlovu 
District, KwaZulu-Natal, South Africa. This original research paper has been submitted to 
Frontiers in Microbiology and reports on the risk factors, phenotypic profiles, genetic diversity 
and resistance mechanisms associated with VRE carriage among hospitalized patients in the 
public health sector in KwaZulu-Natal, South Africa. It addresses objective One, Two, Three, 
Four, and Five. 
▪ Chapter 4. Article III: Whole Genome Sequencing of Methicillin-susceptible Staphylococcus 
aureus (MSSA) and methicillin resistant Staphylococcus haemolyticus Isolated from 
Hospitalized Patients in the uMgungundlovu District, South Africa. This original research 
paper will be submitted to Frontiers in Microbiology and reports on the resistance and 
virulence mechanisms as well as clonal relatedness of circulating S. aureus and S. haemolyticus 
isolates from hospitalized patients in the uMgungundlovu District, South Africa using whole 
genome sequencing. It addresses objective One, Four and Five. 
▪ Chapter 5. Article IV: Clinical and economic impact of antimicrobial resistance in developing 
countries: A systematic review and meta-analysis. This paper has been accepted for 
publication, pending corrections by PloSOne. This systematic review analysed the published 
literature on the clinical and economic implications of AMR in developing countries by 
highlighting the main bacteria incriminated and comparing the current prevalence of AMR 
among World Health Organization (WHO) regions and within the World Bank classification 
of countries and addresses objective Six. 
▪ Chapter 6. Conclusion: This chapter presents the extent to which the overarching aim was 
accomplished by highlighting the findings of each objective. It also delineates the limitations, 
recommendations and the significance of the study. 
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CHAPTER II. 
ARTICLE 1. Extended Spectrum Beta-lactamase Mediated Resistance in 
Carriage and Clinical Gram-Negative ESKAPE Bacteria: A Comparative 
Study of a Tertiary, Urban and a Rural, District Hospital in uMgungundlovu 
District, South Africa1 
 
Author contributions: 
- Raspail Carrel Founou, as the principal investigator, co-conceptualized the study, undertook 
sample collection, laboratory and statistical analyses, prepared tables and figures, and drafted 
the manuscript. 
- Luria Leslie Founou, undertook sample collection, laboratory analysis, vetting of the results, 
and reviewed the manuscript. 
- Sabiha Yusuf Essack, as the principal supervisor, co-conceptualized the study, contributed to 
vetting of the results and undertook critical revision of the manuscript 
 
Objectives met: This paper addresses objectives One, Two, Three, Four and Five. 
 
 
 
 
 
 
 
 
 
                                                          
1 This paper has been submitted to PloS One and is currently under review. 
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Abstract  
Background: Gram-negative ESKAPE bacteria are increasingly implicated in several difficult-
to-treat infections in developed and developing countries. They are listed by the World Health 
Organization as resistant bacteria of critical priority in research. 
Objectives: To determine the risk factors, prevalence, phenotypic profiles and genetic diversity of 
extended-spectrum β-lactamase (ESBL)-producing multi-drug resistant (MDR) Gram-negative 
ESKAPE bacteria in faecal carriage and clinical samples from patients in an urban, tertiary and a 
rural, district hospital in uMgungundlovu District, KwaZulu-Natal, South Africa. 
Methods: Gram-negative ESKAPE bacteria were screened for ESBL production on MacConkey 
agar supplemented with 2µl of cefotaxime and confirmed using ROSCO kits. Minimum inhibitory 
concentrations were determined, and real time and multiplex PCR were used to ascertain the 
presence of blaCTX-M group-1-2-9, blaCTX-M group 8/25, blaSHV, blaTEM, blaOXA-1-like, blaKPC, blaVIM, 
blaIMP, blaGES and AmpC genes. Genomic fingerprinting was also performed by ERIC-PCR. 
Results: Overall prevalence of carriage was 37.21% (16/43), 42.31% (11/26) and 57.14% (4/7) at 
admission, after 48 h and at discharge respectively. The prevalence of MDR ESKAPE bacteria in 
faecal carriage (46%) was higher than clinical samples (28%). Colonization was mainly associated 
with referral from district to tertiary hospital with high statistical significance (OR: 14.40, 95% CI 
0.98-210.84). blaCTX-M-group-9, blaCTX-M-group-1 and blaSHV were the main resistance genes identified. 
Several patients carried more than two different isolates. A K. pneumoniae (K1) clone was 
circulating within wards and between hospitals. 
Conclusions: The wide dissemination of ESBL-producing MDR Gram-negative ESKAPE 
bacteria in hospitals necessitates improvements in routine screening and reinforcement of 
infection, prevention and control measures.  
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Introduction  
The selective pressure exerted by the use of antibiotics and aggravated by the dearth of new active 
substances in the current therapeutic pipeline has led to a considerable increase in antibiotic 
resistance (ABR) worldwide [1,2]. A small group of bacteria, i.e., Enterococcus spp., 
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas 
aeruginosa and Enterobacter spp., termed “ESKAPE” due to their ability to escape the activity of 
and develop high levels of resistance to multiple antibiotics, have recently gained global attention 
[3-5]. Of the six infamous ESKAPE pathogens, the four Gram-negative bacteria, ie., K. 
pneumoniae, A. baumannii, P. aeruginosa, and Enterobacter spp., have been associated with four 
major types of multi-drug resistance (MDR), namely extended-spectrum β-lactamase (ESBL)-
producing K. Pneumoniae and Enterobacter spp., carbapenemase-producing A. baumannii and 
metallo-β-lactamase producing P. aeruginosa (MBL-PA) which limit therapeutic options and 
negatively affect clinical outcome [3-6]. Gram-negative ESKAPE bacteria are increasingly 
implicated in several difficult-to-treat infections in both developed and developing countries and 
were recently listed by the World Health Organization (WHO) as resistant bacteria of critical 
priority in research [3, 7-10]. 
Several resistance genes have been associated with the emergence of MDR Gram-negative 
ESKAPE bacteria globally. The bacterial production of enzyme hydrolysing antibiotics, 
particularly beta-lactam antibiotics, is the most common mechanism of resistance in Gram-
negative ESKAPE. Beta-lactamase enzymes have emerged following chromosomal mutation and 
acquisition of resistance genes carried on diverse mobile genetic elements (MGEs) such as 
plasmids, integrons, insertion sequences, transposons, genomic islands and bacteriophages [10].  
The aim of this study was to compare the prevalence, risk factors, phenotypic and genotypic 
profiles of ESBL-producing MDR Gram-negative ESKAPE bacteria in faecal carriage and clinical 
samples obtained from patients in an urban, tertiary and a rural, district hospital in uMgungundlovu 
District, South Africa. 
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Materials and methods 
Ethical approval  
Ethical approval was obtained from the Biomedical Research Ethics committee (BREC) (No. 
BF512/16, sub-study of BCA444/16). Permission to conduct the research was also granted from 
the Department of Health, uMgungundlovu District and hospital managers.  
Study population and settings  
This study was conducted in a rural, district and urban, tertiary hospital during two months from 
May 2017 to June 2017 in uMgungundlovu district, South Africa, encoded for ethical reasons as 
H1 and H2, respectively. The district hospital (H1) represents the smallest level of hospital and 
provides four services including obstetrics and gynaecology, paediatrics and child health, general 
surgery and general medicine with 141 beds. In contrast, the tertiary hospital (H2) offers several 
specialties, receives referral patients according to a nationally agreed referral plan and has 
approximately 505 beds. These two public hospitals belong to the Department of Health of South 
Africa. 
Patient enrolment and questionnaire survey 
Oral and written informed consent were obtained from all study participants after explanation of 
the procedure and purpose of the study. Patient information was gleaned from questionnaires 
completed by patients and data from patient records. Information was codified prior to analysis to 
maintain confidentiality. 
Sample collection  
The sample collection took place in both surgical and general medical wards during a two-month 
period, one month at each of the hospitals. Rectal swabs that were collected aseptically with Amies 
swabs from all admitted in-patients >18 years old, at three-time points, at admission, after 48h and 
at discharge (whenever possible) formed the carriage sample. Isolates routinely processed in the 
microbiological laboratory during the sampling period formed the clinical sample. 
Labor atory analysis 
Identification of Gram-negative ESKAPE bacteria 
During the sample collection, 76 rectal swabs were collected and directly cultured onto 
MacConkey agar with and without cefotaxime (2 mg/L). After incubation for 18-24h at 37°C, each 
morphotype gr owing on MacConkey with cefotaxime (MCA+CTX) was subjected to Gram 
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staining, catalase and oxidase tests, followed by biochemical identification with API 20E 
(bioMerieux, Marcy l’Etoile, France) according to the manufacturer’s instructions. Pure colonies 
were stored into Tryptone Soya Broth supplemented with 30% glycerol at −20°C for future use. 
Clinical isolates were identified via Vitek® 2 System (bioMérieux, Marcy l’Etoile, France) using 
the GN card according to the manufacturer’s instructions.  
Phenotypic screening  
All growing colonies were phenotypically screened for ESBL, AmpC, KPC, MBL, and OXA-48 
production using ROSCO DIAGNOSTICA (Taastrup, Denmark) using 0.5 McFarland on Mueller-
Hinton agar according to the manufacturer’s instructions. 
Antimicrobial susceptibility testing  
Minimum inhibitory concentrations (MICs) were determined via micro-broth dilution for all 
confirmed ESBLs and/or AmpCs, and/or MBL producers. Ampicillin, cefoxitin, cefuroxime, 
cefotaxime, ceftriaxone, imipenem, meropenem, amikacin, gentamicin, trimethoprim, 
ciprofloxacin, moxifloxacin, nitrofurantoin, tetracycline, tigecycline and colistin constituted the 
antibiotic panel for carriage isolates. The Vitek® 2 System and Vitek® 2 Gram negative 
Susceptibility card (AST-N255) were used to determine the MICs of clinical isolates. The results 
of MIC tests were interpreted according to the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) breakpoints [11]. E. coli ATCC 25922, K. pneumoniae ATCC 
700603 and K. pneumoniae ATCC 51503 were used as controls.  
Genomic characterization 
Genomic extraction 
Genomic DNA of selected strains were extracted using GenElute Bacterial Genomic DNA Kit 
(Sigma-Aldrich, St. Louis, MO, USA) according to the manufacturer’s instructions. Genomic 
DNA was stored at -20°C for future use. 
Multiplex polymerase chain reaction (M-PCR)  
The isolates were subjected to molecular testing using conventional and M-PCR assays to identify 
blaCTX-M group 8/25 (blaCTX-M-gp8/25), blaSHV, blaTEM, blaOXA-1-like, blaOXA-48, blaKPC, blaVIM, blaIMP 
and blaGES genes as previously described by Dallenne et al. (2010) [12] (S1 Table). 
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Real-time polymerase chain reaction (RT-PCR) 
RT-PCR was performed to ascertain blaAmpC, blaCTX-M-group-1 (blaCTX-M-gp1), blaCTX-M-group-2 (blaCTX-
M-gp2) and blaCTX-M-group-9 (blaCTX-M-gp9) resistance genes. Results were analysed on a programmable 
automate QuantStudio5TM (Applied Biosystems, CA, USA) using the Taqman Universal Master 
Mix 2× (Applied Biosystems, CA, USA) and ready-made assays (Thermo Scientific, CA, USA). 
Thermal temperature running conditions were as follows: UNG activation at 50 °C for 2 min, 
initial denaturation at 95 °C for 10 min, 30 cycles of denaturation at 95 °C for 10 s, 
annealing/extension at 60 °C for 1 min and a final extension at 60°C for 30 s. The results were 
interpreted with QuantStudioTM design and analysis software version 1.4 (Applied Biosystems, 
CA, USA).  
Genomic fingerprinting 
Enterobacterial Repetitive Intergenic Consensus-Polymerase Chain Reaction (ERIC-PCR) was 
used to establish the link of different strains within and between hospitals, wards, carriage and 
clinical samples as well as across sampling points. The primers ERIC1 
5’ATGTAAGCTCCTGGGGATTCAC3’ and ERIC2 
5’AAGTAAGTGACTGGGGTGAGCG3’13 were used and PCR reactions were carried out in a 10 
μl volume containing 5 μl of DreamTaq Green Polymerase Master Mix 2X (Thermo Fisher 
Scientific, Johannesburg, South Africa), 2.8 μl of nuclease free water, 0.1 μl of each primer (100 
μM), and 2 μl of DNA template. The reactions were carried out with the following cycling 
conditions: initial denaturation at 94°C for 3 min, 30 cycles consisting of a denaturation step at 
94°C for 30 s, annealing at 50°C for 1 min, extension at 65°C for 8 min, a final extension step at 
65°C for 16 min and final storage at 4°C. The generated amplicons were resolved by horizontal 
electrophoresis on 1.5% (wt/vol) Tris-Borate-EDTA (Merck, Germany) agarose gels together with 
the Quick-load®1-kb (Biolabs, New England) and run in an electric field of 110 V for 2 h 30 min. 
Electrophoresis gels were visualized by a UV light trans-illuminator, images were captured using 
a Gel DocTM XR+ system (BioRad Laboratories, CA, Foster City, USA) and analysed by Image 
LabTM Software (version 4.0, BioRad Laboratories, CA, Foster City, USA). 
ERIC-PCR profiles were normalized using the Quick-load®1-kb (Biolabs, New England) DNA 
molecular weight marker as external standard. For cluster analysis, data were exported to 
Bionumerics software (version 7.6, Applied Maths, TX, USA). Strains were allocated to different 
clusters by calculating the similarity coefficient from the homology matrix using the Jaccard 
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method. Dendrograms were constructed based on the average linkages of the matrix and using the 
Unweighted Pair-Group Method (UPGMA). Optimization and band tolerance were set at 1% 
(version 7.6, Applied Maths, TX, USA) and 80% similarity cut-off was used to define clusters. 
Data analysis 
Data was coded and entered on an Excel spreadsheet (Microsoft Office 2016) and analysed using 
STATA (version 14.0, STATA Corporation, TX, USA). Risk factors for ESBL-producing, MDR 
Gram-negative ESKAPE colonization were ascertained by univariate and multivariate logistic 
regression analyses. Prevalence of MDR carriage was compared between categories (viz. hospital, 
ward and time-point) using the chi-square and Fisher’s exact test as appropriate. A p-value < 0.05 
was regarded as statistically significant.  
Results 
Population characteristics  
A total of 75 hospitalized patients were recruited, amongst whom, 45 (60%) agreed to participate, 
answered the questionnaire and provided samples. Overall, males were more colonized than 
females at all time-points as were patients referred from another hospital (Table 1). Patients in 
tertiary hospital were more likely to be colonized by MDR ESKAPE bacteria at admission (50%) 
and discharge (67%) than those of the district hospital (Table 1). Further, patients admitted in the 
general medical ward were more colonized in the district hospital at all time-points whereas in the 
tertiary hospital, the prevalence in the surgical ward was higher at admission and discharge. 
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Table 1. Fecal carriage of resistant Gram-negative ESKAPE bacteria isolated from hospitalized patients in a rural district and a tertiary 
urban hospital. Out of the 45 patients enrolled, some refused rectal sampling, some were discharged or transferred after 48 hours, while other could 
not be sampled due to their condition, leading to variability in number.  
Variables 
District Rural Hospital n=27 Tertiary Urban Hospital n=18 
Admission, n 
(%) 
p 
After 48 
hours, n (%) 
p 
At 
discharge, n 
(%) 
p 
Admission, n 
(%) 
p 
After 48 
hours, n 
(%) 
p 
At 
discharge, n 
(%) 
P 
Socio-demographic factors 
Gender 
Female 3/14 (21.4) 
0.333 
3/9 (33) 
0.229 
2/4 (50) 
…. 
2/5 (40) 
0.590 
1/2 (50) 
0.571 
1/2 (50) 
0.386 
Male 5/13 (38.4) 5/8 (63) / 6/11 (55) 2/7 (29) 1/1 (100) 
Clinical history 
Previous hospitalization (within one year) 
Yes 1/8 (13) 
0.206 
0/5 (0) 
0.012 
0/1 
0.248 
1/5 (20) 
0.106 
1/4 (25) 
0.635 
1/1 (100) 
0.386 
No 7/19 (37) 8/12 (67) 2/3 (66.67) 7/11 (64) 2/5 (40) 1/2 (50) 
Antibiotic use (during hospital stay) 
Yes 3/18 (27.78) 
0.766 
2/6 (33.33) 
0.402 
1/2 (50) 
1.000 
1/3 (33) 
0.522 
1/3 (33) 
1.000 
1/1 (100) 
0.386 
No 3/9 (33.33) 6/11 (54.55) 1/2 (50) 7/13 (54) 2/6 (33) 1/2 (50) 
Underlying disease (co-morbidity) 
None 5/22 (23) 
0.132 
7/15 (47) 
0.365 
2/4 (50) 
… 
8/15 (53) 
0.302 
3/8 (38) 
0.453 
2/2 (100) 
0.083 
Respiratory disease 1/1 (100) / / / / / 
HIV 1/1 (100) / / 0/1 (0) 0/1 (0) 0/1 
HIV/Tuberculosis 0/1 0/1 (0) / / / / 
Hypoglycaemia 0/1 (0) / / / / / 
Diabetes 1/1 (100) 1/1 (100) / / / / 
Transferred from another hospital 
Yes 1/1 (100) 
0.116 
/ 
… 
/ 
…. 
6/8 (75) 
0.046 
2/4 (50) 
0.343 
1/1 (100) 
0.386 
No 7/26 (27) 8/17 (47) 2/4 (50) 2/8 (25) 1/5 (20) 1/2 (50) 
Diagnostic at admission 
Acute indisposition 2/3 (67) 
0.273 
2/3 (67) 
0.759 
1/2 (50) 
0.368 
1/1 (100) 
0.370 
/ 
0.441 
 
0.083 
Acute psychosis 1/1 (100) / / / /  
Malignancy 1/5 (20) / 1/1 (100) 0/2 (0) 0/2 (0)  
Diabetes 0/1 (0) / / / /  
Heart disease / / / 0/1 (0) 0/1 (0)  
Respiratory disease 1/2 (50) 1/1 (100) / 1/2 (50) 1/2 (50)  
Gastro-intestinal disease 1/1 (100) / / / /  
Chronic disorders 0/4 (0) 1/3 (33) / 0/1 (0) 0/1 (0) 0/1 
Wound 1/5 (20) 1/2 (50) / 1/1 (100) /  
Invasive surgery 1/5 (20) 1/4 (25) 0/1 (0) 5/8 (63) 2/3 (67) 2/2 (100) 
Hospital ward 
Medicine 6/15 (40) 
0.187 
5/9 (56) 
0.457 
1/2 (50) 
1.000 
2/5 (40) 
0.590 
2/5 (40) 
0.635 
1/2 (50) 
0.386 
Surgery 2/12 (17) 3/8 (38) 1/2 (50) 6/11 (55) 1/4 (25) 1/1 (100) 
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Risk factors for MDR Gram-negative ESKAPE bacteria carriage 
Patients at the tertiary hospital had an increased risk of being colonized by resistant bacteria at 
admission (OR=9, 95% CI 0.93-86.52) and discharge (OR=4; 95% CI 0.21-75.67, Table 2). 
Similarly, the gender (male) and Type of hospital wards (Surgical ward) increase the odds of being 
colonized at admission and after 48h in both district and tertiary hospitals (Table 2). 
The multivariate analysis further confirmed that referral from district to tertiary hospital was 
significantly associated with MDR Gram-negative ESKAPE bacteria at admission (OR=14.40, 
95% CI 1. 0.98-210.84) and after 48h (OR=5.72, 95% CI 0.17-189.00) as was the gender for these 
two time-points in the district hospital (Table 3).
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Table 2. Risk factors associated with fecal carriage of ESBL-producing Gram-negative ESKAPE bacteria (Univariate Logistic regression)  
Variables 
District hospital Tertiary hospital 
Admission After 48 hours Admission After 48 hours 
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Gender (F or M) 2.29 (0.42-12.50) 3.33 (0.45-24.44) 1.8 (0.21-15.40) 0.4 (0.16-10.02) 
Antibiotic use (Yes or No) 1.3 (0.23-7.32) 0.42 (0.05-3.31) 0.43 (0.03-5.98) 1 
Co-morbidity 1.05 (0.61-1.83) 1.03 (0.48-2.24) 1.05 (0.61-1.83) 1.03 (0.48-2.24) 
Previous hospitalization 0.24 (0.02-2.40) 1 0.14 (0.01-1.76) 0.5 (0.03-8.95) 
Transferred from another hospital 1 1 9 (0.93-86.52) 4 (0.21-75.67) 
Ward (Medicine or Surgery) 0.3 (0.05-1.88) 0.48 (0.07-3.35) 1.8 (0.21-15.40) 0.5 (0.03-8.95) 
 
Table 3. Predictive risk factors associated with fecal carriage of MDR Gram-negative ESKAPE bacteria in a district and tertiary hospital 
(Multivariate Logistic regression) 
Variables 
District Hospital Tertiary Hospital 
Admission; OR (95% 
CI) 
After 48 hours; OR (95% 
CI) 
Admission; OR (95% 
CI) 
After 48 hours; OR (95% 
CI) 
Gender (F or M) 7.12 (0.54-93.75) 3.61 (0.34-37.83) 1.21 (0.09-15.61) 0.29 (0.005-16.27) 
Antibiotic use (Yes or No) 4.73 (0.28-80.57) 0.93 (0.08-11.40) 0.26 (0.007-9.01) 0.41 (0.009-17.46) 
Transferred from another 
hospital 
1 1 14.40 (0.98-210.84) 5.72 (0.17-189.00) 
Hospital Ward (Medicine or 
Surgery) 
0.08 (0.004-1.39) 0.42 (0.05-3.81) 2.09 (0.10-42.29) 1.14 (0.03-49.14) 
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Prevalence of MDR Gram-negative ESKAPE bacteria 
Out of 159 non-duplicates resistant Gram-negative bacteria isolated, 31 (19.50%) were MDR 
Gram-negative ESKAPE bacteria of which 21. (67.74%) were clinical isolates (11 tissue, 2 bloods, 
3 urines, 3 intravenous catheters, 2 sputum) obtained from hospitalized patients (15 males and 6 
females) with symptomatic infections in different departments (medicine, surgery, intensive care 
units). Ten (32.26%) MDR Gram-negative ESKAPE bacteria were isolated from rectal swab of 
in-patients (6 females, 4 males). In the district hospital, seven isolates were identified, five 
(71.43%) in carriage and two (28.57%) in clinical samples. The main pathogens identified were 
K. pneumoniae and E. cloacae in carriage and clinical isolates respectively. In contrast, in the 
tertiary hospital, five (20.83%) isolates were identified in carriage and 19 (79.16%) in clinical 
samples. The main pathogen identified in carriage was E. aerogenes while P. aeruginosa and A. 
baumannii were the main clinical isolates.  
Antimicrobial resistance profiles  
In the tertiary hospital, especially in the medical ward, isolates expressed high resistance to 
ampicillin (100%), cefuroxime (100%), cefotaxime (100%), ceftazidime (100%), gentamicin 
(100%), amikacin (100%), ciprofloxacin (100%) and nitrofurantoin (100%) in both carriage and 
clinical samples (Table 4). In contrast, in the surgical ward in the same hospital, clinical samples 
showed lower resistance to ceftazidime (50%), gentamicin (50%), ciprofloxacin (50%), imipenem 
(33%), amikacin (33%), tigecycline (33 %) and ertapenem (0%). 
In the district hospital, the isolates identified in carriage samples in the surgical ward displayed 
maximum resistance (100%) to all antibiotics except colistin while those detected in medical ward 
exhibited high level of resistance to ampicillin (100%), cefuroxime (100%), cefotaxime (100%), 
ceftazidime (100%), amikacin (100%), gentamicin (100%), nitrofurantoin (100%) and tigecycline 
(100%) (Table 4).
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Table 4. Resistance to selected antibiotics in ESBL-producing Gram-negative ESKAPE bacteria isolated from carriage and clinical samples 
in a district and tertiary hospital 
Antibiotics 
Tertiary hospital District hospital 
Medical ward Surgical ward Medical ward Surgical ward 
Carriage Clinical Carriage Clinical Carriage Clinical Carriage 
MIC 
(µg/ml) 
range 
No. 
resistant 
isolates 
(%) 
MIC 
(µg/ml) 
range 
No. 
resistant 
isolates 
(%) 
MIC 
(µg/ml) 
range 
No. 
resistant 
isolates 
(%) 
MIC 
(µg/ml) 
range 
No. 
resistant 
isolates 
(%) 
MIC 
(µg/ml) 
range 
No. resistant 
isolates (%) 
MIC 
(µg/ml) 
range 
No. 
resistant 
isolates 
(%) 
MIC 
(µg/ml) 
range 
No. 
resistant 
isolates 
(%) 
Ampicillin ≥512 4 (100) ≥32 2 (100) ≥512 1 (100) 16-32 6 (100) ≥512 4 (100) 16-≥32 4 (100) ≥512 1 (100) 
Cefoxitin 8-512 3 (75) 4 0 (0) 16 1 (100) 8-≥64 5 (83.3) 128≥512 4 (100) ≥64 4 (100) ≥512 1 (100) 
Cefuroxime ≥512 4 (100) ≥64 2 (100) 128 1 (100) 8-64 6 (100) 256≥512 4 (100) 16-≥64 4 (100) ≥512 1 (100) 
Cefotaxime ≥512 4 (100) ≥64 2 (100) 128 1 (100) 1-≥64 5 (83.3) 32-≥512 4 (100) <1-32 3 (75) ≥512 1 (100) 
Ceftazidime 512 4 (100) ≥64 2 (100) 256 1 (100) 1-≥64 3 (50) 32-≥512 4 (100) ≤1-16 3 (75) ≥512 1 (100) 
Meropenem 0.5-2 2(50) 0.25 0 (0) 2 1 (100) 0.25≥16 4 (66.6) 0.25-16 2 (50) 0.25 0 (0) 16 1 (100) 
Imipenem 4-8 4 (100) 0.25 0 (0) 16 1 (100) 0.5-≥16 2 (33.3) 2-32 2 (50) 0.25-1 0 (0) 64 1 (100) 
Ertapenem 1-2 4 (100) 0.5 0 (0) 16 1 (100) ≤0.5 0 (0) 0.25-8 3 (75) 0.5 0 (0) 64 1 (100) 
Amikacin 8-128 4 (100) 8 2 (100) 64 1 (100) 2-≥64 2 (33.3) 8-128 2 (100) 2 0 (0) ≥512 1 (100) 
Gentamicin 128 4 (100) ≥16 2 (100) 8 1 (100) 1-≥16 3 (50) 4-16 4 (100) 1 0 (0) ≥512 1 (100) 
Ciprofloxacin 64-512 4 (100) ≥4 2 (100) 32 1 (100) 0.25-≥4 3 (50) 0.5-64 3 (75) ≤0.25 0 (0) 32 1 (100) 
Tigecycline 16-64 4 (100) 1 0 (0) 16 1 (100) 0.5-≥8 2 (33.3) 2-64 4 (100) 1 0 (0) 8 1 (100) 
Nitrofurantoin ≥512 4 (100) 128 2 (100) ≥512 1 (100) ≥512 6 (100) ≥512 4 (100) 16-≥512 1 (25) ≥512 1 (100) 
Colistin 8-512 4 (100) 0.5 0 (0) 8 1 (100) ≤0.5 0(0) 0(0) 0(0) ≤0.5 0 (0) ≤0.5 0 
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Genetic diversity of isolated MDR strains 
Overall, the predominant ESBL genes were blaCTX-M-gp9 (90%), blaSHV (60%), blaCTX-M-gp1 (50%), 
blaTEM (40%) and blaOXA-1-Like (40%) for both carriage and clinical samples. In the tertiary hospital, 
blaCTX-M-gp9 (100%), blaCTX-M-gp1 (87.5%), blaKPC (75%) and blaVIM (50%) were the main resistance 
genes detected in A. baumannii while K. pneumoniae strains harboured mainly blaCTX-M-gp8/25  
(66.6%), blaTEM (66.6%), blaSHV (66.6%), blaCTX-M-gp9 (50%) and blaCTX-M-gp1 (50%) (Table 5). It 
is noteworthy that all isolates harboured at least two resistance genes and a maximum of seven 
genes were detected in one E. aerogenes (G702R2B5) isolate (Figure 1B). In the district hospital, 
blaCTX-M-gp9 (100%), blaSHV (100%), and blaTEM (100%) were the predominant genes in K. 
pneumoniae whereas blaCTX-M-gp9 (100%), blaOXA-1-Like (50%), blaCTX-M-gp1 (50%) and blaCTX-M-
gp8/25 (50%) were the main genes identified in E. cloacae (Table 5). 
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Table 5. Resistance genes in ESBL-producing Gram-negative ESKAPE bacteria 
Bacteria 
No. of 
strains, 
n=31 (%) 
Resistance genes, n (%) 
AmpC TEM SHV 
CTX-M 
group-1 
CTX-M 
group-9 
CTX-M 
Group 
8/25 
IMP VIM KPC 
OXA-1-
like 
Tertiary hospital (n=24) 
K. pneumoniae 6 (25) 2 (33.3) 4 (66.6) 4 (66.6) 3 (50) 3 (50) 4 (66.6) 1 (16.6) 1 (16.6) 1 (16.6) 2 (33.33) 
A. baumannii 8 (33.3) 3 (37.5) / 3 (37.5) 7 (87.5) 8 (100) / / 4 (50) 6 (75) 2 (25) 
P. aeruginosa 7 (29.5) 1 (14.28) / / 7 (100) 7 (100) / / / / / 
E. aerogenes 2 (8.33) 2 (100) / 2 (100) / 2 (100) 2 (100) / / / 2 (100) 
E. cloacae 1 (4.16) / / / 1 (100) 1 (100) 1 (100) 1 (100) / 1 (100) / 
District hospital (n=7) 
K. pneumoniae 2 (28.57) / 2 (100) 2 (100) 1 (50) 2 (100) 1 (50) / / / 2 (33.33) 
P. aeruginosa 1 (14.28) / / / 1 (100) 1 (100) / / / / / 
E. aerogenes 2 (28.57) 1 (50) 1 (50) 1 (50) 1 (50) 2 (100) 2 (100) / / / / 
E. cloacae 2 (28.57) 1 (50) / 1 (50) 1 (50) 2 (100) 1 (50) / / / 1 (50) 
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Genomic fingerprint 
ERIC-profiles revealed a high similarity within species and transmission across patients, wards 
and hospitals. For K. pneumoniae, one main cluster showing high genetic similarities was observed 
(Fig 1A). K. pneumoniae strains A111R1B2 and A105R2B2 detected among two patients at 
admission for the former and after 48 h for the latter, in the medical ward of the district hospital 
showed 100% of similarity and shared common ancestors with one carriage and three clinical 
strains isolated in the tertiary hospital (Fig 1A). Similarly, one pair of E. aerogenes, A105R1B5 
and G702R1B5 isolated from two patients in the medical ward of the district and tertiary hospital, 
both at admission, also exhibited 100% of similarity and shared a common ancestor with another 
strain G702R2B5 collected after 48 h (Fig 1B). Although, A. baumannii (Fig 1C) and P. 
aeruginosa (Fig 1D) were more genetically diverse, some isolates shared a common ancestor 
within and between carriage and clinical samples. 
Figure 1A-1D: Dendrograms of ESBL-producing of Gram-negative ESKAPE bacteria 
isolated from carriage and clinical samples from hospitalized patients. A: K. pneumoniae, B: 
E. aerogenes and cloacae, C: A. baumannii, D: P. aeruginosa. 
 
Discussion   
Patient follow-up rates were 96%, 58% and 16 % of rectal swabs collected at admission, after 48 
h and at discharge, respectively. The overall prevalence of carriage at admission was 37.21% 
(16/43) and we found that 42.31% (11/26) and 57.14% (4/7) were still MDR ESKAPE carriers 
after 48 h and at discharge. Notwithstanding the small sample size, our results showed that the 
carriage of MDR Gram-negative ESKPAPE bacteria increased with the hospital length of stay. 
Our results are consistent with a Norwegian prospective cohort study carried out from 2009-2011 
investigating the risk factors for and duration of prolonged faecal carriage of ESBL-producing K. 
pneumoniae amongst patients with community acquired urinary tract infections which revealed 
high prevalence of ESBL faecal carriage (ranging from 15%-61%) at six different time points14. 
At hospital level, the rate of carriage at admission in the district (30%) hospital compared with the 
tertiary hospital (50%) suggests that patients admitted to the tertiary hospital are likely to be more 
colonized by MDR Gram-negative ESKAPE bacteria than those of the district healthcare facility 
(Table 1). Our findings could be explained by the fact that all patients admitted in this level of 
hospital are generally transferred from lower level healthcare facilities of the South African health 
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system. This is further confirmed by the increased odds of being colonized in the univariate 
(OR=9; %CI 0.93-86.52; Table 2) and multivariate analysis (OR=14.40; %CI 0.98-210.84; Table 
3). Similarly, at discharge, patients of the tertiary hospital (67%) were more colonized than those 
of the district hospital (50%). This could be explained by the complexity of cases with associated 
invasive medical procedures and greater antibiotic use in the tertiary hospital. However, after 48 
h, the prevalence of carriage was higher in patients in the district hospital (47%) compared with 
the tertiary hospital (33%) intimating. This contrast could point out sub-optimal infection 
prevention and control measures.  
Besides, tertiary hospital with its more complicated cases and subsequent higher antibiotic use 
would have likely created greater selection pressure for resistance, but an anomalously greater 
resistance was observed in carriage samples in the district hospital. The small sample numbers 
preclude nonetheless definitive conclusions about carriage rates and resistance patterns. 
The prevalence of MDR Gram-negative ESKAPE bacteria in faecal carriage (46%) was higher 
than that of clinical samples (28%) during the study period. Faecal carriage of resistant bacteria 
has been demonstrated to precede infections and consequently such high prevalence of 
asymptomatic fecal carriage is of critical significance. Our results concur with a study from France 
where the prevalence of MDR Gram-negative bacilli isolated from stool samples was higher than 
that of clinical samples during a non-outbreak situation in a French Hospital [15]. They are 
however higher than a report from Mahomed and Coovadia (2014) which demonstrated 4.7% of 
faecal carriage of ESBL producing Enterobacteriaceae amongst children from community in 
KwaZulu-Natal, South Africa [16]. Our findings may be an under-estimation because of different 
diagnostic, stewardship practices, preference for empirical treatment and budget constraints such 
that not every infection generates a microbiological sample. 
During the two-months period, 21 clinically relevant MDR Gram-negative ESKAPE bacteria out 
of 74 isolates were identified in both hospitals. Moreover, the prevalence of MDR A. baumannii 
and P. aeruginosa were 41.61% (10 out of 21 MDR Gram-negative ESKAPE bacteria) and 33.33% 
(7 out of 21 MDR Gram-negative ESKAPE bacteria) in clinical samples, respectively. The 
isolation of three A. baumannii strains, cluster A1, from tissue of three different patients 
(ED01498924, ED01498793, ED01498924) in surgery indicates, consolidate the likely 
dissemination of this cluster within this ward in the tertiary hospital (Table 6 and Fig 1C).  
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Table 6. Antibiotic Resistance Profiles and Resistance Genes of Isolates from Single Patients  
Patient ID 
Isolate (ID 
code) 
Hospital Ward Source 
MIC values (µg/ml) Beta-lactamase resistance genes 
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Carriage samples 
A105 
E. aerogenes 
(A105R1B5) 
District Medicine 
Admission ≥512 ≥512 ≥512 ≥512 16 16 16 32 64 16 - - - + + + + KPC E2 
K. 
pneumoniae 
(A105R2B2) 
After 48h ≥512 ≥512 ≥512 ≥512 32 16 8 8 64 64 - + + + + + + - K1 
A109 
P. aeruginosa 
(A109R1B4) 
District Medicine Admission ≥512 128 32 32 2 1 8 128 0.5 2 - - - + + - - - P2 
A111 
K. 
pneumoniae 
(A111R1B2) 
District Medicine Admission ≥512 ≥512 ≥512 32 2 0.25 4 8 32 16 - + + + - + + - K1 
A202 
E. aerogenes 
(A202R2B5) 
District Surgery After 48h ≥512 ≥512 ≥512 ≥512 64 16 ≥512 ≥512 32 8 - + + + + + - - E1 
G702 
K. 
pneumoniae 
(G702R1B2) 
Tertiary Medicine 
Admission ≥512 ≥512 ≥512 ≥512 4 2 ≥512 128 ≥512 16 + - - + + - - IMP K3 
E. aerogenes 
(G702R1B5) 
Admission ≥512 64 ≥512 ≥512 8 0.5 128 32 ≥512 32 + - + + + + + - E2 
E. aerogenes 
(G702R2B5) 
After 48h ≥512 ≥512 ≥512 ≥512 4 2 ≥512 128 ≥512 16 + - - + + + + GES E2 
K. 
pneumoniae 
(G702R3B2) 
Discharge ≥512 8 ≥512 512 64 0.5 512 8 64 64 - + + + + + + - K1 
G804 
A. baumannii 
(G804R1B3) 
Tertiary Surgery Admission ≥512 16 128 256 16 2 8 64 32 16 + - - + + - - - A3 
Clinical samples 
ED01498924 A. baumannii Tertiary Surgery  Tissue ≥32 ≥64 ≥64 ≥64 ≥16 ≥16 ≥16 ≥64 ≥4 ≤0.5 - - + + + - - 
VIM, 
KPC 
A1 
EA00306601 E. cloacae District Medicine  Blood ≥32 ≥64 32 16 1 ≤0.25 ≤1 ≤2 ≤0.25 1 - - + - + + + - E4 
EA00306600 E. cloacae District Medicine  Blood ≥32 ≥64 32 16 0.5 ≤0.25 
≤0.2
5 
≤2 ≤0.25 1 + - - + + - - - E3 
ED01499889-
2 
P. aeruginosa Tertiary Surgery  Suppuration ≥32 32 32 2 0.5 ≤0.25 2 8 ≥4 4 - - - + + - - - P3 
ED01501266-
2 
E. cloacae Tertiary Surgery  Suppuration 16 ≥64 ≤1 ≤1 0.5 ≥16 ≤2 ≤1 ≤0.25 1 - - - + + + - - E1 
ED01500733 
K. 
pneumoniae 
Tertiary ICU  Urine ≥32 ≤4 ≥64 16 ≤0.25 ≤0.25 ≥16 ≤2 2 ≤0.5 - + + + + + - - K1 
51 
 
ED01498793 A. baumannii Tertiary Surgery  Tissue ≥32 ≥64 ≥64 ≥64 ≥16 ≥16 ≥16 ≥64 ≥4 1 - - + + + - - 
VIM, 
KPC 
A1 
ED01498924 A. baumannii Tertiary Surgery  Tissue ≥32 ≥64 ≥64 ≥64 ≥16 ≥16 ≥16 ≥64 ≥4 ≤0.5 - - + + + - - 
VIM, 
KPC 
A1 
ED01502268 
K. 
pneumoniae 
Tertiary Medicine  Sputum ≥32 ≤4 ≥64 ≥64 ≤0.25 ≤0.25 ≥16 8 ≥4 1 + + + + +  + - K1 
ED01503757 
K. 
pneumoniae 
Tertiary Medicine  Sputum ≥32 ≤4 ≥64 ≥64 ≤0.25 ≤0.25 ≥16 8 ≥4 1 + + - + + + - - K2 
ED01501066 P. aeruginosa Tertiary 
Urology 
clinic 
 Urine ≥32 ≥64 8 2 ≤0.25 1 2 4 ≤0.25 ≥8 - - - + + - - - P2 
ED01504366 P. aeruginosa Tertiary Surgery  Suppuration ≥32 ≥64 32 4 ≤0.25 2 ≤2 2 ≤0.25 ≥8 - - - + + - - - / 
ED01504363 
K. 
pneumoniae 
Tertiary Medicine  Suppuration ≥32 8 ≥64 32 8 ≤0.25 ≥16 4 ≥4 ≤0.5 - - + + + - - 
VIM, 
KPC 
K3 
ED01507915 P. aeruginosa Tertiary ICU  Suppuration ≥32 ≥64 ≥64 ≥64 1 1 ≤1 ≤2 ≤0.25 ≥8 - - - + + - - - P1 
ED01507331 P. aeruginosa Tertiary Surgery  Suppuration ≥32 ≥64 32 4 1 ≤0.25 ≤1 ≤2 ≤0.25 ≥8 - - - + + - - - 
 
/ 
ED01507028-
1 
P. aeruginosa Tertiary ICU 
 Tracheal 
aspirate 
≥32 ≥64 32 4 1 1 ≥16 16 ≤0.25 ≥8 - - - + + - - - P1 
ED01506083 A. baumannii Tertiary 
Obstetrics 
and 
gynecology 
Catheter tip ≥32 ≥64 ≥64 ≥64 ≥16 ≥16 ≥16 ≤2 ≥4 4 - - - + + - - KPC A1 
ED01506443 A. baumannii Tertiary Surgery Catheter tip ≥32 ≥64 ≥64 ≥64 ≥16 ≥16 ≥16 ≥64 ≥4 2 - - - + + - - KPC A1 
ED01506571 A. baumannii Tertiary ICU  Suppuration ≥32 ≥64 ≥64 16 ≥16 ≥16 ≥16 ≤2 ≥4 1 - - - + + - - 
VIM, 
KPC 
A2 
ED01507028-
2 
A. baumannii Tertiary ICU 
 Tracheal 
aspirate 
≥32 ≥64 ≥64 16 ≥16 ≥16 ≥16 ≥64 ≥4 4 + - - + + - - - A2 
ED01506433 P. aeruginosa Tertiary ICU  Wound ≥32 ≥64 ≥64 4 2 ≤0.25 ≤1 ≤2 ≤0.25 ≥8 - - - + + - - - / 
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In carriage samples, MDR K. pneumoniae and Enterobacter spp. were the predominant bacteria 
in both hospitals. This is consistent with a South African study where K. pneumoniae was the main 
pathogen identified in stool samples of children from the community of KwaZulu-Natal, South 
Africa [16]. Similarly, a 68% prevalence of ESBL-producing Enterobacteriaceae faecal carriage 
was shown amongst Egyptian patients with community-acquired gastrointestinal complaints [17]. 
An interesting finding was the inter-hospital and inter-patient spread of K. pneumoniae (cluster 
K1) in carriage, which were isolated from two patients (A105R2B2 and A111R1B2) hospitalized 
in general medicine in district hospital, sharing common ancestor with a patient (G702R3B2) from 
tertiary hospital (Table 6). It is noteworthy that the isolated strains were identified in the medical 
ward and at different time-points, confirming the dissemination of this cluster across hospitals. In 
addition, K. pneumoniae strains from the same cluster (K1) were detected in urine (ED01500733) 
and sputum (ED01502268) of clinically ill patients hospitalized in intensive care unit (ICU) and 
medical ward in the tertiary hospital, respectively. This suggests that the K. pneumoniae K1 strains 
is circulating within wards and hospitals, and consequently could probably be source of 
nosocomial infections in hospitals.  
Two patients, A105R1B5 and G702R1B5 also carried Enterobacter spp. (cluster E2) at admission 
in both district and tertiary hospitals, specifically in the medical wards (Table 6) intimating the 
emergence of these strains in the community with subsequent entry into the district hospital, as the 
first level of care, and followed by spread to the tertiary hospital through referral (OR=14.40 %CI 
0.98-210.84). This result is consistent with our analyses which demonstrated that in the district 
hospital, the main risk factors were antibiotic use and gender while the referral and hospital ward 
were the principal risk factors at tertiary level (Tables 2 and 3). 
Overall, the predominant ESBLs detected in carriage were blaCTX-M-gp9 (90%), blaSHV (60%), 
blaCTX-M-gp1(50%), blaTEM (40%) and blaOXA-1-like (40%). CTX-M is predominantly reported in 
community-acquired infections which would be more prevalent in the district hospital as the first 
level of care. These results are consistent with global reports. For instance, blaCTX-M-group were 
recently observed in adults in a community in Netherlands and ambulatory patients in Egypt with 
both gastrointestinal complaints [17,18]. Similarly, studies from Guinee-Bissau (2012), Niger 
(2011), Gabon (2013) and Tanzania (2016), reported high prevalence of ESBL faecal carriage with 
blaCTX-M, blaTEM and blaSHV being the main genes identified [18-21]. The prevalence of AmpC was 
also higher in carriage (40%) compared to clinical samples (23.80%). Finally, carbapenemases 
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were identified in clinical samples from these hospitals, specifically, KPC and VIM in clinical A. 
baumannii isolates as well as IMP in a carriage K. pneumoniae isolate. An E. aerogenes isolate 
further showed blaGES along with blaCTX-M-gp1, blaCTX-M-gp9, blaCTX-M-gp8/25, blaSHV and blaOXA-1-like in 
a carriage sample. The faecal carriage of MDR Gram-negative ESKAPE bacteria appears to be a 
source of cross-transmission between patients. The substantial genetic similarity within and 
between carriage and clinical isolates as well as wards and hospital settings reveals their potential 
implications in future outbreak situations that may occur either in hospitals or in communities. 
Efforts should thus be made amongst communities and asymptomatic patients for better 
containment of antibiotic resistance dissemination.  
Gender, antibiotic use, type of healthcare settings and referral from another hospital were the main 
risk factors identified. These results suggest that routine screening for MDR Gram-negative 
ESKAPE bacteria at admission should be implemented, and infection, prevention and control 
measures reinforced to prevent potential outbreaks by these resistant pathogens [22].  
This study highlights the high prevalence of ESBL-producing MDR Gram-negative ESKAPE 
bacteria in carriage and clinical samples among hospitalized patients in uMgungundlovu. It is 
imperative to implement regular screening and surveillance of MDR Gram-negative ESKAPE 
bacteria in communities and hospitals, to monitor epidemiological changes, ascertain socio-
economic impact and inform antibiotic treatment. These screening and surveillance measures 
coupled with strict infection prevention and control programmes and antimicrobial stewardship 
programmes (ASP) are essential to address antibiotic resistance in these settings.  
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Figure 1: Dendrograms of ESBL-producing of Gram-negative ESKAPE bacteria isolated from carriage and clinical samples 
from hospitalized patients. A: K. pneumoniae, B: E. aerogenes and cloacae, C: A. baumannii, D: P. aeruginosa 
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CTX-M-gp1, CTX-M-gp9, CTX-M-gp8/25, IMP, KPC
CTX-M-gp1, CTX-M-gp9, CTX-M-gp8/25, KPC
AmpC, CTX-M-gp1, CTX-M-gp9, CTX-M-gp8/25, SHV, OXA-1-like
AmpC, CTX-M-gp1, CTX-M-gp9, CTX-M-gp8/25, SHV, OXA-1-like, GES
AmpC, CTX-M-gp1, CTX-M-gp9
CTX-M-gp8/25, CTX-M-gp9, OXA-1-like, SHV
 
ERIC
1
0
0
8
0
6
0
4
0
2
0
ERIC
Key
ED01507915
ED01507028-1
A109R1B4
ED01501066
ED01499889-2
LevelModified date
.
.
.
.
.
ID Lab WorkBacteria
P. aeruginosa
P. aeruginosa
P. aeruginosa
P. aeruginosa
P. aeruginosa
Hospital
H2
H2
H1
H2
H2
Ward
Paediatric ICU
Paediatric ICU
Medicine
Urology clinic
Surgery
Source
Clinical
Clinical
Carriage
Clinical
Clinical
Resistance patterns
.
.
.
.
.
codgen s
CTX-M-gp1, CTX-M-gp9
CTX-M-gp1, CTX-M-gp9
CTX-M-gp1, CTX-M-gp9
CTX-M-gp1, CTX-M-gp9
CTX-M-gp1, CTX-M-gp9 
ERIC
1
0
0
8
0
6
0
4
0
2
0
ERIC
Key
ED01498924
ED01501266-1
ED01498793
ED01506083
ED01506443
ED01506571
ED01507028-2
G804R1B3
LevelModified date
.
.
.
.
.
.
.
.
ID Lab WorkBacteria
A. baumannii
A. baumannii
A. baumannii
A. baumannii
A. baumannii
A. baumannii
A. baumannii
A. baumannii
Hospital
H2
H2
H2
H2
H2
H2
H2
H2
Ward
Surgery
Surgery
Surgery
Obstetrics & gynecology
Surgery
ICU
Paediatric ICU
Surgery
Source
Clinical
Clinical
Clinical
Clinical
Clinical
Clinical
Clinical
Carriage
Resistance patterns
.
.
.
.
.
.
.
.
codgen s
CTX-M-gp1, CTX-M-gp9, SHV, VIM, KPC
CTX-M-gp1, CTX-M-gp9, SHV, OXA-1-like, VIM, .
CTX-M-gp1, CTX-M-gp9, SHV, VIM, KPC
CTX-M-gp1, CTX-M-gp9, KPC
CTX-M-gp1, CTX-M-gp9, KPC
CTX-M-gp1, CTX-M-gp9, VIM, KPC
AmpC, CTX-M-gp1, CTX-M-gp9
AmpC, CTX-M-gp1,CTX-M-gp9
A1 
A2 
A3 
P1 
P2 
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Supplementary Table 1. Oligonucleotide sequences for ESBL and carbapenemase resistance genes included in multiplex PCR 
assays 
 
aY=T or C; R=A or G; S=G or C; D=A or G or T. 
 
 
 
PCR name Target gene Primer name Sequence (5’-3’) 
Amplicon 
size (bp) 
Ref. 
Multiplex I 
TEM, SHV, 
OXA-1-like 
TEM -1 and TEM-2 
MultiTSO-T_for 
MultiTSO-T_rev 
CATTTCCGTGTCGCCCTTATTC 
CGTTCATCCATAGTTGCCTGAC 
800 
13 
SHV-1 
MultiTSO-S_for 
MultiTSO-S_rev 
AGCCGCTTGAGCAAATTAAAC 
ATCCCGCAGATAAATCACCAC 
713 
OXA-1, OXA-4 and OXA-40 
MultiTSO-O_for 
MultiTSO-O_rev 
GGCACCAGATTCAACTTTCAAG 
GACCCCAAGTTTCCTGTAAGTG 
564 
Multiplex II 
CTX-M group 8/25 
CTX-M-8, CTX-M-25, CTX-M-26 
and 
CTX-M-39 to CTX-M-41 
CTX-Mg8/25_for 
CTX-Mg8/25_rev 
AACRCRCAGACGCTCTACa 
TCGAGCCGGAASGTGTYATa 
326 
Multiplex III 
GES and 
OXA-48-like 
GES-1 to GES-9 and GES-11 
MultiGES_for 
MultiGES_rev 
AGTCGGCTAGACCGGAAAG 
TTTGTCCGTGCTCAGGAT 
399 
OXA-48-like 
MultiOXA-48_for 
MultiOXA-48_rev 
GCTTGATCGCCCTCGATT 
GATTTGCTCCGTGGCCGAAA 
281 
Multiplex IV 
IMP, VIM and KPC 
IMP variants except 
IMP-9, IMP-16, IMP-18, IMP-22 
and IMP-25 
MultiIMP_for 
MultiIMP_rev 
TTGACACTCCATTTACDGa 
GATYGAGAATTAAGCCACYCTa 
139 
VIM variants including VIM-1 and 
VIM-2 
MultiVIM_for 
MultiVIM_revc 
GATGGTGTTTGGTCGCATA 
CGAATGCGCAGCACCAG 
390 
KPC-1 to KPC-5 
MultiKPC_for 
MultiKPC_rev 
CATTCAAGGGCTTTCTTGCTGC 
ACGACGGCATAGTCATTTGC 
538 
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Abstract 
Background: Vancomycin resistant enterococci (VRE) are categorized as high priority 
bacteria in the Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, 
Discovery, and Development of New Antibiotics published by the World Health Organization. 
VRE are members of the ESKAPE group of pathogens and are implicated in serious difficult-
to-treat infections.  
Objectives: This study assessed the carriage, phenotypic and genotypic profiles, and clonal 
lineages of vancomycin-resistant E. faecium and E. faecalis isolated from hospitalized patients. 
Methods: From May to June 2017, rectal swabs were collected from patients admitted to 
medical and surgical wards of an urban, tertiary and a rural, district hospital, in 
uMgungundlovu, South Africa. Enterococci were screened for vancomycin resistance on bile 
esculin azide agar supplemented with 6 mg/L of vancomycin and vancomycin resistance was 
confirmed using ROSCO kits. Conventional and real-time PCR assays were used to confirm 
the identification to species level and to ascertain the presence of VanA, VanB, VanC-2/3 and 
VanC-1 genes. REP-PCR was undertaken to ascertain the clonal relatedness and WGS was 
used to characterize the circulating sequence types (STS), resistance and virulence genes and 
plasmids. 
Results: Fifteen (39%) E. faecium and 23 (61%) E. faecalis, were detected. High levels of 
antibiotic-resistance were observed for cefoxitin (100%), erythromycin (100%), clindamycin 
(100%) and teicoplanin (100%) for isolates from both district and tertiary hospitals. Two E. 
faecium strains, A109R2B0 and A206R1B0, detected in two different patients, at two different 
time-points (admission and after 48h) and in two different wards (medicine and surgery) in the 
district hospital (H1), revealed high genetic similarity and suggested potential transmission 
across patients and wards within this hospital. Four single sequence types (STs) were identified 
among E. faecium in district hospital namely ST822, ST636, ST97 along with a novel ST 
assigned ST1386, while one lineage (ST29) was detected in the tertiary hospital. 
Conclusion: The study reveals the genetic diversity and high pathogenicity of circulating VRE 
in uMgungundlovu district, South Africa. It underlines the necessity to implement routine 
screening of admitted patients at all level of care to contain the spread of VRE in this district.  
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INTRODUCTION 
Enterococcus spp. are Gram-positive cocci, frequently isolated in the gastrointestinal tract of 
both humans and animals (Abebe et al., 2014; Abamecha et al., 2015). This genus encompasses 
approximately 16 species, but only E. faecalis and E. faecium have been identified as clinically 
important due to their implications in serious difficult-to-treat nosocomial infections such as 
endocarditis, urinary tract infections, peritonitis, bacteraemia, neonatal sepsis, meningitis, 
surgical wound and intra-abdominal infections in hospitals and communities (Abebe et al., 
2014; Abamecha et al., 2015). 
Enterococci are clinically relevant because of the  (i) emergence of vancomycin-resistant E. 
faecium (VRE), (ii) high-levels of resistance to multiple antibiotics, (iii) transfer of resistance 
gene from VRE to Staphylococcus aureus, (iv) presence of different selective pressures 
increasing the proliferation and rapid spread of VRE, (v) few therapeutic options for disease 
management, and (vi) limited success of VRE containment measures (Mundy et al., 2000; Van 
Schaik et al., 2010; Abebe et al., 2014; Yu et al., 2015). However, the foremost clinical 
relevance of VRE is its colonization in the gastrointestinal tract of humans and animals, 
creating reservoirs for VRE transmission. VRE were recently ranked as high priority in the 
Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery and 
Development of New Antibiotics by the World Health Organization (WHO)(World Health 
Organization, 2017). 
Van A phenotype strains of E. faecium were first detected from clinical cases of VRE infections 
in Europe in 1986, where they were associated with outbreaks in hospitals, particularly in 
patients with severe underlying diseases or an immunocompromised status (Corso et al., 2007; 
Abebe et al., 2014). In Africa, the first cases of VRE infections were described in South Africa 
where a 10.9% prevalence of VRE-colonized patients was reported at a hospital in 1997 (von 
Gottberg et al., 2000). VRE is associated with nosocomial infections in various hospital wards 
and risk factors include an immunocompromised status, urinary or central venous 
catheterization, intra-abdominal or cardio-thoracic surgical procedures, and co-morbidities 
such as HIV/AIDS, diabetes and cancers (Kuo et al., 2014).  
Leclerc et al, (1988) described nine operons capable of conferring resistance to glycopeptides 
(Leclercq et al., 1988). The differentiation of these operons is based on ligase genes encoding 
D-alanyl-D-lactate ligase (VanA, VanB, VanD, and VanM) or D-alanyl-D-serine ligases 
(VanC-1, VanC-2, VanC-3, VanE, VanG, VanN and VanL) (Sun et al., 2014). The resistance 
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to glycopeptides can be acquired except for VanC-type resistance which is chromosomal and 
intrinsic to E. gallinarum and casseliflavus (Sun et al., 2014). 
The overuse of glycopeptides and extended-spectrum cephalosporins in hospital settings has 
probably contributed to the increased prevalence and spread of these resistant pathogens 
(Shafiyabi et al., 2013). The VRE threat is relatively under-investigated in South Africa. This 
study therefore assessed the carriage, risk factors, resistance and virulence genes, and clonal 
lineages of vancomycin-resistant Enterococcus faecium and faecalis isolated from hospitalized 
patients in the uMgungundlovu District, KwaZulu-Natal, South Africa. 
I. Materials and Methods 
1. Ethical considerations  
Ethical approval was obtained from the Biomedical Research Ethics committee (BREC) (No. 
BF512/16, sub-study of BCA444/16). Permission to conduct the research was also granted 
from the Department of Health, uMgungundlovu District and hospital managers. 
2. Study population and settings  
This study was conducted during two months from May to June 2017 in a rural, district hospital 
and an urban tertiary hospital. The district hospitals (H1) covers four services i.e., obstetrics 
and gynaecology, paediatrics and child health, general surgery and general medicine with 141 
beds. The tertiary hospital (H2) offers several specialties, receives referral patients according 
to a nationally agreed referral plan and has approximately 505 beds.  
3. Patient enrolment and questionnaire data collection 
After explanation of the study, oral and written informed consent was obtained from all 
participants. Patients thereafter completed a questionnaire that yielded socio-demographic 
information while the clinical history was extracted from patient records. Information was 
codified prior to analysis to ensure confidentiality. 
4. Sample collection 
Sample collection took place in both surgical and general medical wards. Rectal swabs were 
aseptically collected with Amie swabs from all admitted in-patients >18 years old, at 
admission, after 48h and at discharge whenever possible. 
 
5. Laboratory analysis 
5.1 Culture and Identification  
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Rectal swabs (n=76 specimens) were cultured onto Bile-Esculin-Azide agar (Oxoid, Dardilly, 
France) with and without vancomycin (6 mg/L). After incubation for 18-24h at 37°C, each 
black colony growing on Bile-Esculin-Azide agar supplemented with vancomycin 
(BEA+VAN) that further hydrolysed and reduced 0.04% potassium tellurite, was selected for 
Gram staining, the oxidase and catalase tests and L-pyrrolidonyl-b-naphthylamidase activity. 
Biochemical identification was confirmed using API Strept (bioMérieux, Marcy l’Etoile, 
France). Pure colonies of E. faecium and E. faecalis were stored into tryptone soya broth (TSB) 
(Merck, Darmstadt, Germany) supplemented with 20% glycerol at −20°C for future use. 
5.2. Phenotypic screening  
All colonies were phenotypically screened for vancomycin, teicoplanin and daptomycin 
resistance using the package of MRSA, VISA, GISA, VRE ROSCO DIAGNOSTICA Kit 
(Taastrup, Denmark) using 0.5 McFarland on Mueller-Hinton agar (Oxoid, Dardilly, France) 
according to the manufacturer’s instructions. 
5.3. Antimicrobial susceptibility testing by microbroth dilution  
Minimum inhibitory concentrations (MICs) were determined by broth microdilution. 
Ampicillin, cefoxitin, gentamycin, streptomycin, ciprofloxacin, moxifloxacin, erythromycin, 
clindamycin, linezolid, teicoplanin, vancomycin, tetracycline, doxycycline, tigecycline, fusidic 
acid, trimethoprim, nitrofurantoin, and chloramphenicol, were tested and interpreted according 
to the European Committee on Antimicrobial Susceptibility Testing (EUCAST, 2017) 
breakpoints using E. faecium ATCC 29212 as the control strain.  
5.4. Genomic characterization 
5.4.1. Genomic extraction 
Genomic DNA of selected strains were extracted using the GenElute Bacterial Genomic DNA 
Kit (Sigma-Aldrich, St. Louis, MO, USA) according to the manufacturer’s instructions. DNA 
were stored at -20°C. 
5.4.2. Molecular identification of species 
Two simplex PCR reactions consisting of different primer sets were performed to identify 
isolates to the species level in a final volume of 10 μl consisting of 5 μl of DreamTaq Green 
Polymerase Master Mix 2X (Thermo Scientific Inc.), 1.8 μl of nuclease free water, 0.1 μl of 
each primer (100 μM), and 3 μl of DNA template. The oligonucleotide primers were 
synthesized by Inqaba Biotech (Pretoria, South Africa). Primer sequences were those 
previously described by Iweriebor et al. (2015) and are listed in Supplementary Table 1. 
Simplex PCR were performed in 0.2 ml PCR-tube in a programmable Bio-Rad Thermal Cycler 
65 
 
(BioRad Laboratories, CA, Foster City, USA) according to the following conditions: initial 
denaturation at 95 °C for 4 min, 30 cycles of denaturation at 95 °C for 30 s, annealing at 48 °C 
(E. faecium) or 52 °C (E. faecalis) for 1 min, and elongation at 72 °C for 1 min followed by a 
final extension at 72 °C for 7 min. Four microliters of amplification products were 
electrophoresed on a 2% (wt/vol) Tris-Borate-EDTA (Merck) agarose gel run at 110V for 45 
min along with the Quick-load®100bp molecular weight marker (Biolabs, New England). 
Electrophoresis gels were stained in a solution containing 0.5 μg/ml ethidium bromide. After a 
brief destaining in water gels were visualized by a UV light transilluminator images were 
captured using a Gel DocTM XR (BioRad Laboratories, CA, Foster City, USA) and analysed 
by Image LabTM Software (version 5.2, BioRad Laboratories, CA, Foster City, USA). 
5.4.3. Molecular characterization of vancomycin resistance genes  
   5.4.3.1. Conventional polymerase chain reaction (PCR) 
All confirmed VRE were screened by simplex PCR to identify associated vancomycin 
resistance genes with specific primers for VanA, VanB, and VanC2/3 as previously described 
(Iweriebor et al., 2015; Supplementary Table 1). The oligonucleotide primers were also 
synthesized by Inqaba Biotech (Pretoria, South Africa). PCR were performed in 0.2 ml PCR-
tube in a programmable BioRad Thermal Cycler (CA, Foster City, USA) with the following 
conditions: initial denaturation at 95 °C for 4 min, 30 cycles of denaturation at 95 °C for 30 s, 
annealing at 56.5 °C for 1 min, and elongation at 72 °C for 1 min followed by a final extension 
at 72 °C for 7 min and an infinite hold a 4 °C. Amplification products were electrophoresed 
and visualized as described above.   
5.4.3.2. Real-time polymerase chain reaction (RT-PCR) 
RT- PCR was performed to ascertain specific vancomycin resistance genes on a programmable 
automate QuantStudio5TM (Applied Biosystems, CA, USA) using the Taqman Universal 
Master Mix 2× (Applied Biosystems, CA, USA) and ready-made assays (Thermo Scientific, 
CA, USA). Thermal temperature running conditions were as follows: UNG activation at 50 °C 
for 2 min, initial denaturation at 95 °C for 10 min, 30 cycles of denaturation 95 °C for 10 s, 
annealing/extension at 60 °C for 1 min and a final extension at 60°C for 30 s. The results were 
interpreted with QuantStudioTM design and analysis software version 1.4 (Applied Biosystems, 
CA, USA).  
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5.4.4. Molecular fingerprinting 
Repetitive Element Palindromic-Polymerase Chain Reaction (REP-PCR) was performed to 
ascertain the relationship of isolates at each time points, within and between wards and 
hospitals. The (GTG)5 primer 5’-GTGGTGGTGGTGGTG-3’ (Versalovic, 1991) synthetized 
by Inqaba (South Africa) was used and PCR reactions performed in a final reaction mixture of 
10 μl consisting of 5 μl of DreamTaq Green Polymerase Master Mix 2X (Thermo Scientific 
Inc.), 1.8 μl of nuclease free water, 0.2 μl of (GTG)5 primer (100 μM), and 3 μl of DNA 
template. PCR were performed in 0.2 ml PCR-tube in a programmable Bio-Rad Thermal 
Cycler (BioRad Laboratories, CA, Foster City, USA) and according to the following protocol: 
initial denaturation at 94°C for 7 min, 30 cycles consisting of a denaturation step at 94°C for 1 
min, primer annealing at 40°C for 1 min, extension at 65°C for 8 min, a final extension step at 
65°C for 16 min and final storage at 4°C (Versalovic et al., 1991). The amplicons were resolved 
in by horizontal electrophoresis in a 1.5% (wt/vol) Tris-Borate-EDTA (Merck) agarose gel 
together with the Quick-load®1-kb molecular weight marker (Biolabs, New England) and run 
in an electric field of 110 V for 2 h 30 min. Electrophoresis gels were thereafter stained in a 
solution containing 0.5 μg/ml ethidium bromide. After a brief destaining in water, gels were 
visualized by a UV light transilluminator, images were captured using a Gel DocTM XR+ 
system (BioRad Laboratories, CA, Foster City, USA) and analysed by Image LabTM Software 
(version 5.2, BioRad Laboratories, CA, Foster City, USA). 
5.4.5. Computer-Assisted Image Analysis and Cluster Assignment 
REP-PCR profiles were normalized using the Quick-load®1-kb DNA molecular weight 
marker (Biolabs, New England) as standard. Fingerprint were assigned to isolates with Bio-
Rad’s Image LabTM software (version 5.2, BioRad). For cluster analysis, data were exported to 
Bionumerics software (version 7.6, Applied Maths, TX, USA). Isolates were allocated to 
different clusters by calculating the similarity coefficient from the homology matrix with Dice 
method. Dendrograms were generated based on the average linkages of the matrix and using 
the Unweighted Pair-Group Method (UPGMA). Optimization and band tolerance were set at 
1% (version 7.6, Applied Maths, TX, USA) and 80% similarity cut-off was used to define 
clusters. 
5.5.  Whole genome analysis 
The Nextera XT DNA sample preparation kit (Illumina, San Diego, CA, USA) was used for 
the preparation of multiplex paired-end libraries (2×300 bp). The Illumina MiSeq machine was 
used for library sequencing with 100× coverage. The generated reads were checked for quality 
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and trimmed using the CLC Genomics Workbench version 10 (CLC, Bio-QIAGEN, Aarhus, 
Denmark). De novo assembling was subsequently performed with CLC Genomics and SPAdes 
version 3.5.0 (Bankevich et al., 2012). The assembled reads were uploaded and annotated using 
the Bacterial Analysis Pipeline of GoSeqIt tools, NCBI PGAP 
(https://www.ncbi.nlm.nih.gov/genome/annotation_prok/) and ARG-ANNOT 
(http://en.mediterranee-infection.com). ResFinder (Zankari et al., 2012), VirulenceFinder 
(Joensen et al., 2014) and PlasmidFinder (Carattoli et al., 2014) were used for the identification 
of antibiotic resistance genes, virulence factors and plasmids, respectively. The multi-locus 
sequence type (MLST) was determined from the WGS data. Contigs of E. faecalis G702R1B0 
were mapped against the finished genome of E. faecalis DENG1 (CP004081.1) for 
visualization of the genomic structure (Figure 1). Phylogenetic analyses were performed to 
contextualize our strains against a collection from international complete genomes (accession 
no.: CP004081; NC017316; NC004668; CP003351; NC017960; CP019988) (Figure 1). 
5.6.       Nucleotide sequence accession number  
This whole-genome shotgun project PRJNA417366 of E. faecalis and E. faecium isolates 
A113R1B0, G701R2B0C1, G702R1B0, A206R2B0, A201R2B0, A108R2B0, and 
A209R1B0C1 has been deposited at DDBJ/EMBL/GenBank under accession numbers 
PGCX00000000, PGCW00000000, PGCV00000000, PGCU00000000, PGCT00000000, 
PGCS00000000, and PGCR00000000, respectively. The version described in this paper are the 
version PGCX01000000, PGCW01000000, PGCV01000000, PGCU01000000, 
PGCT01000000, PGCS01000000, and PGCR0000000, respectively. 
5.7.Data analysis 
Data was coded and entered in Excel spreadsheet (Microsoft Office 2016) and analysed using 
STATA (version 14.0, STATA Corporation, TX, USA). Risk factors for VRE colonization 
were ascertained by univariate and multivariate logistic regression analysis. Prevalence of VRE 
carriage was compared between categories (viz. hospital, ward and time-point) using the chi 
square test, and a p-value < 0.05 was regarded as statistically significant.  
 
 
II. Results  
1. Study population and risk factors for VRE in carriage 
A total of 75 patients hospitalized were contacted. Of these, 45 (60%) agreed to participate, 
answered the questionnaire and provided at least one sample at admission. Overall, males were 
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more colonized than females at admission and at discharge as were patients referred from 
another hospital (Table 1). The mean age of patient was 50.7 years range (19-70). Out of 45 
patients, 31(69%) were treated with an antibiotic during their hospitalization. Patients in the 
district hospital were more likely to be colonized by VRE bacteria at admission (44%), after 
48h (64%) and discharge (100%) than those at the tertiary hospital (Table 1). Gender, 
antibiotics use, co-morbidity, previous hospitalization, transfer from another hospital were the 
main risk factors identified at admission in both hospitals while the odds of VRE colonization 
were higher in surgical wards after 48h (Tables 2 and 3). 
Of the 45 participants, 24 (53%) were asymptomatic faecal carriers of VRE with some 
harbouring multiple strains, yielding a total of 38 non-duplicate VRE in both hospitals. Of these 
15 (39%) and 23 (61%) were confirmed E. faecium and E. faecalis, respectively. More 
specifically, 14 (54%) E. faecium and 12 (46%) E. faecalis were isolated in the district hospital 
while 11 (92%) E. faecalis and one (8%) E. faecium were identified in the tertiary hospital 
(Table 4).  
2. Antimicrobial susceptibility and resistance genes 
High levels of antibiotic resistance were observed among isolates in both the district and 
tertiary hospitals. In the district hospital, 100% resistance to cefoxitin, erythromycin, 
clindamycin, teicoplanin was evident in both bacterial species while 100% resistance was 
observed against all antibiotics except moxifloxacin, gentamicin, erythromycin, and ampicillin 
in E. faecium in the tertiary hospital (Table 4).  
VanC1 was the only glycopeptide resistant gene detected in all VRE isolates. In addition, the 
E. faecalis ST6 (G702R1B0) carried VanG together with the vancomycin tolerance locus 
(vex2, vex3), macrolide, lincosamide, sterptogramines B (ermB, Isa, emeA), tetracycline 
(TetM), fosfomycine (fosB), fluoroquinolones (ParC, ParE, gyrA, gyrB) resistance genes as 
well as the multidrug resistant efflux pumps (MATE, MFS, mepA, emeA) encoding for 
resistance to several antibiotic classes (Table 5 and 6). Similarly, all E. faecium harboured 
Vex2 and Vex3 concurrently with fluoroquinolone resistance genes (ParC, ParE, gyrA, gyrB, 
Lde) and the multidrug resistant efflux pumps (MATE, MFS, pmrA) (Table 6). 
3. Genomic fingerprint  
Two E. faecium strains, A109R2B0 and A206R1B0, detected in two different patients, at two 
different time-points (admission and after 48h) and in two different wards (medicine and 
surgery) in the district hospital (H1), revealed high genetic similarity and suggested potential 
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transmission across patients and wards within this hospital (Figure 1). In contrast, E. faecalis 
isolates showed similarity across hospitals and wards since two strains, G812R3B0 isolated in 
surgical ward of the tertiary hospital, and A107R1B0 detected in medical ward of the district 
hospital were closely related and shared common ancestors with a third isolate (A210R1B0C2) 
from the surgical ward in the district hospital (Figure 2). This suggests the probable inter-
hospital transmission of VRE between the tertiary and district hospitals, as well as inter-ward 
dissemination across surgery and medical wards. Seven E. faecalis isolates identified in tertiary 
and three in district hospitals were unique.  
4. Multi-locus sequence typing (MLST) 
MLST-analyses were performed for four E. faecium (A206R2B0, A201R2B0, A108R2B0, 
A209R1B0C1) and three E. faecalis (A113R1B0, G701R2B0C1, G702R1B0) strains that were 
selected based on their relatedness on REP-PCR (Table 5). Four single sequence types (ST) 
were identified among E. faecium in district hospital namely ST822, ST636, ST97 along with 
a novel ST assigned ST1386 detected in district hospital based on seven house-keeping genes 
including adk, atpa, ddl, gdh, gyd, psts, purk. Similarly, three different STs were observed in 
E. faecalis based on the variation amongst the seven house-keeping genes (aroe, gdh, gki, gyd, 
psts, xpt, yqil). Two singletons namely ST563 and ST6 were identified in tertiary hospital while 
ST21 was also identified in the district hospital. 
5. Virulence factors  
WGS data revealed that E. faecalis strains were more virulent than E. faecium, with a total of 
16 virulence genes for the former compared to two for the latter. The distribution of virulence 
genes among these isolates are presented in Table 6. Overall, all E. faecalis carried at least 14 
virulence genes including ace, cad, camE, cCF10, cOB1, ebpA, ebpB, ebpC, efaAfc, ElrA, 
gelE, hylA, SrtA, tpx. Furthermore, 25% of these isolates were also biofilm formers (fsrB) and 
hyaluronidase (hylB) producers. In contrast, all E. faecium concomitantly harboured only two 
virulence genes (efaAfm and acm) and none produced biofilm or hylB. 
6. Plasmid detection 
Only two E. faecalis, ST6 and ST563, isolated in tertiary hospital medical ward harboured 
multiple plasmids. The E. faecalis ST6 hosted CDS16(pTEF3) and repA2(pTEF2) while the 
E. faecalis ST563 carried four plasmid replicon types namely CDS16(pTEF3), repA2(pTEF2), 
rep(pUB110), rep(pKH7) and a single open reading frame (ORF) in contig 1183. E. faecium 
(ST29) carried two plasmid replication proteins namely repE (pAMbeta1) and, rep(pUB110) 
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with an additional ORF in contig 287. The remaining strains (ST822, ST636, ST97) harboured 
only repE (pAMbeta1).  
III. Discussion 
VRE is an important bacterial species implicated in severe, difficult-to-treat infections globally. 
To the best of our knowledge, this study is the first report of VRE-harbouring VanC-1 genes 
in South Africa. Hospitalized patients who were followed-up at three-time points for 
colonization with VRE showed an overall prevalence of 50%, 57% and 83% VRE at admission, 
after 48H and at discharge respectively. These findings are higher than a South African 
prevalence study reported in 2000 which revealed 11% of high-risk patients colonized by VRE 
(von Gottberg et al., 2000) and generally lower than an Argentinian study that showed a 77% 
prevalence of VRE from rectal swabs of hospitalized patients, with the ICU (47%) and general 
medicine wards (36%) being the main affected units.  
Gender, antibiotic use, co-morbidity, previous hospitalization, referral from district to tertiary 
hospital were the main risk factors identified at admission while hospitalization in a surgical 
ward increased the odds of VRE colonization after 48h (Table 2). Our results are consistent 
with an Australian hospital-wide point prevalence study which revealed that age, duration of 
hospitalisation, antibiotic use and ward type were the main risk factors for VRE colonisation 
in a tertiary hospital in Melbourne (Karki et al., 2012). 
None of the isolates tested positive for VanA and VanB genes but exhibited vancomycin- 
resistance as evident from the MICs (Table 3 and 4). Although the VanC-1 gene is an intrinsic 
chromosomal gene of E. gallinarum and E. casseliflavus, its presence in our E. faecium could 
probably be attributed to horizontal gene transfer. The VanC-1 gene was first described in 
vancomycin susceptible E. faecalis isolated from pig manure (De Moura et al., 2013; Sun et 
al., 2014) intimating that the chromosomal location of intrinsic resistant genes does not 
preclude horizontal genes tranfer to other species, therby contributing to species diversification 
(De Moura et al., 2013; Sun et al., 2014). The mobility of the VanC-1 gene may result in 
laboratory misidentification of E. gallinarum and E. casseliflavus whose identification is 
premised on the presence of this gene. The presence of multidrug resistant efflux pumps 
harboured by all isolates could explain the high level of multi-drug resistance our isolates 
(Tables 2 and 3). 
The most interesting finding of the study, was the inter-ward, inter-patient and intra-hospital 
spread of E. faecalis strains (cluster B1), isolated from two patients (A100R3B0 and 
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A105R2B0) hospitalized in medical ward in the district hospital, which were closely related 
and shared a common ancestor with one patient (A200R3B0) from the surgical ward of the 
same hospital. Of note is the fact that these strains were identified at different time-points (after 
48h and discharge), confirming the dissemination of this cluster within this hospital. Similarly, 
E. faecalis strains from another cluster (B2) were detected in two patients (A107R1B0 and 
A210RB0C2) hospitalized in the medical and surgical wards in this hospital, respectively. This 
suggests that E. faecalis B2 strains are circulating within wards in the district hospital, and 
could be implicated in future nosocomial infections. 
MLST-analyses revealed that E. faecalis isolated from patient hospitalized in the district 
hospital belonged to the ST21. This concurs with other studies where the E. faecalis ST21 has 
been described in community patients in Denmark (Jesper et al., 2011) and in clinical samples 
in Cuba where it concomitantly harboured four virulence factors (esp, efaAfs, gelE, agg, acc) 
(Quiñones et al., 2009). In addition, one study in Norway implicated this clonal lineage in 
peripheral periodontitis in hospitalised patients. The authors suggested that this strain could be 
a potential source of transferable antimicrobial resistance due to carriage of several plasmid 
elements (Song et al., 2013). 
The E. faecalis strain (G702R1B0) isolated in the tertiary hospital belonged to the ST6. This 
ST was described in VRE isolated in small mammals in Spain although it harboured the vanB2 
gene (Lozano et al., 2015). It has also been identified in clinical samples in Cuba and carried 
the esp, efaAfs, acc and virulence genes (Quiñones et al., 2009). E. faecalis ST6 maybe an 
example of the selection of an enterococcal sub-population with increased resistance, virulence, 
and mobility to easily spread among humans. 
The fact that all E. faecalis STs detected in this study carried a minimum of 14 virulence genes 
attests to their high pathogenicity (Table 7). The camE gene encoding for sex pheromone 
activates the conjugation of the plasmid pAM373 that drives the transfer of virulence and 
resistance determinants among enterococci (Wardal et al., 2010). Additionally, the fsrB gene 
encoding for biofilm formation was associated with ST6 and ST583 with the former isolated 
in the tertiary hospital and the latter in the district hospital (Table 7). 
The E. faecium strains, A109R2B0, A201R2B0, A206R1B0 and A206R2B0 belonging to 
cluster A1, evidenced intra-hospital and inter-ward dissemination in the district hospital (Table 
2). However, the detection of one isolate at admission and the other after 48h intimated that 
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they probably emerged in the community, entered the district hospital, as the first level of care, 
where they spread across wards (Tables 2 and 3).  
MLST analysis of E. faecium isolates confirmed a high level of genetic diversity. An 
interesting finding of this study was the characterization of a novel lineage E. faecium ST1386 
(1-4-9-6-1-20-3) isolated in the rural, district hospital. In addition, the ST 822, 636, and 97 
were identified in the same hospital but in different wards, suggesting that different clonal 
lineages of E. faecium are circulating in this hospital. The detection of these different STs along 
with two virulence genes (acm and efaAfm) suggests that various clonal lineages of 
vancomycin-resistant E. faecium are actively disseminating within the communities and could 
enter hospital settings where they could increasingly be associated with high mortality and 
morbidity rates. The scarcity of data on the population structure of these E. faecium STs in 
African countries makes it difficult to discuss the regional dissemination of these lineages 
detected in South Africa. Although these STs have rarely been reported in other countries to 
date, the variability in their allelic profiles shows high levels of diversity amongst E. faecium, 
suggesting non-human origin. This result is similar to the study of Weng et al. (2013) who 
demonstrated 27 pulsotypes and four STs (ST17, ST78, ST203, ST601) associated with E. 
faecium isolated from clinical samples in a tertiary teaching hospital in Malaysia (Weng et al., 
2013).  
Our study established the genetic diversity and clonal dissemination of various E. faecalis and 
E. faecium lineages across wards and within hospitals in uMgungundlovu district. The presence 
of plasmids in two E. faecalis and all E. faecium further contributed to the phenotypic and 
genotypic plasticity of these resistant bacteria which could be linked to easy transfer of 
resistance genes and virulence factors. 
Conclusion 
We report here the faecal carriage of VRE-harboring VanC-1 gene among hospitalized patients 
in uMgungundlovu district. VRE isolates were genetically diverse and highly pathogenic. 
Infection control procedures, antimicrobial stewardship and awareness should be strengthened 
to prevent and/or contain the carriage and spread of VRE in hospitals and communities in South 
Africa. 
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Table 1. Faecal carriage of vancomycin-resistant Enterococcus spp. isolated from 
hospitalized patients in relation to socio-demographic factors, clinical history and diagnosis 
at admission in a rural district, and an urban tertiary hospital. Out of the 45 patients enrolled, 
some refused rectal sampling after 48 h and/or at discharge, while some were discharged or 
transferred after 48 hours, leading to variability in number throughout the sampling period. 
Variables 
District Rural Hospital; n=27 Tertiary Urban Hospital; n=18 
Admission, 
n (%) 
After 48 hours, 
n (%) 
At discharge, 
n (%) 
Admission, 
n (%) 
After 48 
hours, n (%) 
At discharge, 
n (%) 
 
Total 12/27 (44) 9/14 (64) 4/4 (100) 7/18 (39) 3/7 (43) 1/2 (50) 
Gender 
Female 5 (36) 6 (67) 4 (100) 2 (50) 0 (0) 0 (0) 
Male 7 (64) 3 (60) 0 (0) 5 (56) 3 (60) 1 (100) 
Previous hospitalization (within one year) 
Yes 3 (50) 1 (50) 1 (100) 3 (75) 1 (33) 0 (0) 
No 9 (47) 8 (67) 3 (100) 4 (44) 2 (50) 1 (50) 
Antibiotic use (during hospital stay) 
Yes 4 (50) 2 (50) 2 (100) 2 (67) 0 (0) 0 (0) 
No 8 (47) 7 (70) 2 (100) 5 (50) 3 (75) 1 (50) 
Referral from another hospital 
Yes 1 (100) 0 (0) 0 (0) 3 (50) 1 (33) 0 (0) 
No 11 (46) 9 (64) 4 (100) 4 (57) 2 (40) 1 (50) 
Hospital ward 
Medicine 8 (53) 5 (56) 2 (100) 3 (60) 2 (40) 0 (0) 
Surgery 4 (40) 4 (80) 2 (100) 4 (50) 1 (50) 1 (100) 
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Table 2. Univariate logistic regression of potential risk factors for VRE carriage in the district and tertiary hospital 
Variables 
District hospital Tertiary Hospital 
Admission 
OR (95% CI) 
After 48 hours 
OR (95% CI) 
Admission 
OR (95% CI) 
After 48 hours 
OR (95% CI) 
Gender (F or M) 3.15 (0.61-16.31) 0.75 (0.08-7.21) 1.25 (0.11-13.24) 1 
Antibiotic use (Yes or No) 1.13 (0.20-6.04) 0.43 (0.04-4.64) 2 (0.13-29.80) 1 
Previous hospitalization 1.11 (0.17-6.97) 0.50 (0.02-10.25) 3.75 (0.27-51.37) 0.5 (0.02-11.08) 
Transferred from another hospital (Yes or 
No) 
1 1 0.75 (0.08-6.71) 0.5 (0.02-11.08) 
Hospital Ward (Medicine or Surgery) 0.58 (0.11-2.95) 3.2 (0.25-41.21) 0.66 (0.07-6.40) 1.25 (0.05-40.63) 
Hospital (Rural District or Urban Tertiary) 1.26 (0.33-4.84) 0.42 (0.06-2.66) 0.90 (0.14-5.71) 0.35 (0.37-14.65) 
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Table 3. Multivariate logistic regression of predictors of VRE carriage at admission in the district and tertiary hospital 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables 
District hospital  
OR (95% CI) 
Tertiary Hospital; 
OR (95% CI) 
Gender (F or M) 4.44 (0.59-33.21) 1.19 (0.09-14.69) 
Previous hospitalization (Yes or No) 1.87 (0.09-36.58) 3.41 (0.14-81.94) 
Current Antibiotic use (Yes or No) 1.46 (0.07-27.66) 1.05 (0.03-32.62) 
Referral from another hospital 1 0.95 (0.07-12.83) 
Hospital ward (Medicine or Surgery) 0.4 (0.05-2.97) 0.76 (0.05-10.05) 
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Table 4. Antibiotic resistance profiles of vancomycin-resistant E. faecium and E. faecalis isolated from hospitalized patients 
*HLR: High-Level resistance 
 
 
 
 
 
 
Antibiotics 
District hospital, n=26 Tertiary hospital, n=12 
E. faecalis (n=12) E. faecium (n=14) E. faecalis (n=11) E. faecium (n=1) 
MIC (µg/ml) 
range 
No. resistant 
isolates (%) 
MIC (µg/ml) 
range 
No. resistant 
isolates (%) 
MIC (µg/ml) 
range 
No. resistant 
isolates (%) 
MIC (µg/ml) 
range 
No. resistant 
isolates (%) 
Ampicillin 4-≥512 8 (67) 0.5-256 6 (43) 1-≥512 3 (27) 8 0 (0) 
Cefoxitin 32-≥512 12 (100) 128-≥512 14 (100) 16-≥512 11 (100) ≥512 1 (100) 
Erythromycin 4-≥512 12 (100) 2-≥512 14 (100) 1-≥512 10 (91) 0.5 0 (0) 
Clindamycin 2-≥512 12 (100) 8-≥512 14 (100) 4-≥512 11 (100) 128 1 (100) 
Teicoplanin 4-≥512 12 (100) 2-≥512 14 (100) 4-≥512 11 (100) 32 1 (100) 
Vancomycin 8-≥512 10 (83) 8-≥512 10 (71) 8-≥512 10 (91) 32 1 (100) 
Tigecycline 8-128 7 (58) 2-64 10 (71) 8-≥512 10 (91) 16 1 (100) 
Fusidic acid 64-≥512 10 (83) 16-≥512 10 (83) 2-256 9 (82) 256 1 (100) 
HLR*-Gentamicin 128-≥512 8 (67) 32-≥512 9 (64) 8-≥512 7 (64) 64 0 (0) 
HLR-Streptomycin 256-≥512 8 (67) 64-≥512 9 (64) 16-≥512 10 (91) 256 1 (100) 
Chloramphenicol 64-≥512 10 (83) 64-≥512 10 (71) 64-≥512 10 (91) 128 1 (100) 
Ciprofloxacin 128-≥512 10 (83) 128-≥512 10 (71) 64-≥512 10 (91) 128 1 (100) 
Moxifloxacin 16-≥512 10 (83) 8-≥512 10 (71) 2-≥512 10 (91) 2 0 (0) 
Doxycycline 16-256 10 (83) 0.5-256 9 (64) 2-512 9 (82) 4 1 (100) 
Tetracycline 32-≥512 9 (75) 4-≥512 10 (71) 4-≥512 10 (91) 16 1 (100) 
Nitrofurantoin 32-≥512 9 (75) 64-≥512 10 (71) 64-≥512 10 (91) 128 1 (100) 
Trimethoprim ≥512 11 (92) 128-≥512 14 (100) ≥512 11 (100) ≥512 1 (100) 
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Table 5. Resistance to selected antibiotics in vancomycin-resistant E. faecium and E. faecalis isolated from single patients 
 
Patient 
ID 
Isolate Hospital Ward 
Time-
points 
REP 
Cluster 
Antibiotics (MIC µg/ml) 
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O X
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A100 
E. faecalis 
(A100R1B0) 
District 
 
Medicine 
 
Admission / 16 8 8 ≥512 256 ≥512 ≥512 512 256 128 256 256 
E. faecalis 
(A100R2B0) 
After 48h / 8 8 8 ≥512 128 ≥512 ≥512 ≥512 256 128 ≥512 128 
E. faecalis 
(A100R3B0) 
Discharge B1 16 32 ≥512 ≥512 512 ≥512 ≥512 ≥512 256 128 ≥512 128 
A101 
E. faecalis 
(A101R1B0) 
District Medicine Admission B2 32 256 ≥512 128 512 ≥512 ≥512 256 256 128 ≥512 256 
A105 
E. faecalis 
(A105R1B0) 
District Medicine 
Admission B3 16 8 8 256 256 ≥512 256 ≥512 256 16 32 ≥512 
E. faecalis 
(A105R2B0) 
After 48h B1 16 8 8 256 ≥512 ≥512 ≥512 ≥512 64 16 32 ≥512 
A107 
E. faecalis 
A107R1B0 
District Medicine 
Admission B2 ≥512 8 16 256 128 ≥512 ≥512 ≥512 128 128 ≥512 32 
E. faecalis 
A107R2B0 
After 48h / 16 4 4 256 128 ≥512 ≥512 ≥512 128 256 512 ≥512 
A108 
E. faecium 
A108R1B0C1 
District Medicine 
Admission A4 16 4 16 ≥512 128 256 128 128 128 8 64 128 
E. faecium 
A108R2B0 
After 48h A2 16 8 2 512 32 512 ≥512 256 128 16 16 64 
A109 
E. faecium 
A109R1B0 
District Medicine 
Admission / 16 8 16 8 128 256 128 128 32 64 512 512 
E. faecium 
A109R2B0 
After 48h A1 ≥512 8 32 32 ≥512 ≥512 ≥512 128 16 4 16 ≥512 
E. faecium 
A109R3B0 
Discharge / ≥512 8 8 32 ≥512 ≥512 ≥512 ≥512 16 4 16 ≥512 
A110 
E. faecium  
(A110R1B0) 
District Medicine Admission / 16 8 ≥512 ≥512 ≥512 ≥512 ≥512 ≥512 32 256 ≥512 256 
A113 
E. faecalis  
(A113R1B0) 
District Medicine Admission Singleton 1 16 8 4 256 128 512 128 128 64 128 512 128 
A200 
E. faecalis  
(A200R3B0) 
District Surgery Discharge B1 ≥512 ≥512 ≥512 2 256 ≥512 ≥512 16 128 32 64 32 
A201 
E. faecium  
(A201R2B0) 
District Surgery After 48h A1 8 4 16 8 128 256 512 512 32 2 4 512 
A202 
E. faecium 
(A202R2B0) 
District Surgery 
After 48h / ≥512 ≥512 4 128 64 128 ≥512 128 ≥512 64 128 512 
E. faecium 
(A202R3B0) 
Discharge / 8 2 ≥512 64 128 ≥512 ≥512 ≥512 128 128 ≥512 ≥512 
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Table 5. Resistance to selected antibiotics in vancomycin-resistant E. faecium and E. faecalis isolated from single patients (End) 
 
 
 
Patient 
ID 
Isolate Hospital Ward Time-points 
REP 
Cluster 
Antibiotics (MIC µg/ml) 
V
A
N
 
T
E
I 
E
 
C
L
I 
C
N
 
S
T
R
 
C
IP
 
M
O
X
 
F
A
 
D
O
X
 
T
E
T
 
F
T
 
A203 
E. faecalis 
(A203R2B0) 
District Surgery After 48h Singleton 2 ≥512 ≥512 4 128 ≥512 ≥512 ≥512 ≥512 ≥512 128 ≥512 ≥512 
A206 
E. faecium 
(A206R1B0) 
District Surgery 
Admission 
A1 
8 32 16 128 64 256 ≥512 256 64 2 8 ≥512 
E. faecium 
(A206R2B0) 
After 48h 8 8 16 8 64 ≥512 ≥512 256 32 0.5 4 128 
A207 
E. faecalis 
(A207R1B0) 
District Surgery Admission Singleton 3 16 16 4 256 128 ≥512 ≥512 ≥512 128 64 32 256 
A209 
E. faecium 
(A209R1B0C1) 
District Surgery Admission A3 ≥512 4 8 32 64 128 128 8 64 128 32 ≥512 
A210 
E. faecalis 
(A210RB0C2)  
District Surgery Admission B2 / 32 16 2 128 256 ≥512 ≥512 64 256 ≥512 512 
G700 
E. faecalis 
(G700R1B0C2) 
Tertiary Medicine 
Admission Singleton 4 16 4 8 256 128 512 256 ≥512 64 32 512 256 
E. faecalis 
(G700R2B0) 
After 48h / ≥512 ≥512 2 256 64 512 ≥512 ≥512 128 256 ≥512 ≥512 
G701 
E. faecalis 
(G701R1B0C1) 
Tertiary Medicine 
Admission Singleton 5 16 64 ≥512 ≥512 ≥512 256 ≥512 128 32 512 ≥512 512 
E. faecalis 
(G701R2B0C1) 
After 48h Singleton 6 8 4 ≥512 ≥512 ≥512 512 ≥512 128 64 128 256 256 
G702 
E. faecalis 
(G702R1B0) 
Tertiary Medicine Admission Singleton 7 16 256 ≥512 ≥512 ≥512 ≥512 ≥512 512 64 128 512 256 
G802 
E. faecalis 
(G802R1B0) 
Tertiary Surgery Admission Singleton 8 16 64 ≥512 4 8 16 ≥512 32 2 64 ≥512 128 
G803 
E. faecalis 
(G803R1B0) 
Tertiary Surgery Admission Singleton 9 16 4 2 256 128 ≥512 ≥512 256 256 8 32 128 
G805 
E. faecalis 
(G805R1B0) 
Tertiary Surgery Admission Singleton 12 8 8 ≥512 ≥512 ≥512 256 128 64 128 128 ≥512 64 
G809 
E. faecalis 
(G809R1B0C2) 
Tertiary Surgery Admission / ≥512 ≥512 16 64 64 256 256 ≥512 16 256 ≥512 ≥512 
G812 
E. faecalis 
(G812R2B0C1) 
Tertiary Surgery After 48h Singleton 13 32 8 1 64 64 256 64 2 128 2 4 128 
G812 
E. faecium 
(G812R3B0) 
Tertiary Surgery Discharge B2 32 32 0.5 128 64 256 128 2 256 4 16 128 
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Table 6. Resistance profiles and plasmids associated with vancomycin-resistant E. faecium and E. faecalis isolated from hospitalized 
patients 
 
*New ST 
 
 
 
 
 
 
 
 
 
 
Isolate MLST 
Resistance genes 
Plasmids 
VanC-1 VanG Vex2 Vex3 emeA Isa TetM fosB ParC ParE gyrA gyrB ermB MATE MFS pmrA mepA Lde 
E. faecalis 
A113R1B0 ST21 + - - - - - + - + + + + + + + + - - - 
G701R2B0C1 ST563 + - - + - - + - + + + + + + + + - - 
rep(pUB110); 
CDS16(pTEF3); 
repA2(pTEF2); 
rep(pKH7) 
G702R1B0 ST6 + + + + + + + - + + + + + + + - + - 
repA2(pTEF2); 
CDS16(pTEF3) 
E. faecium 
A206R2B0 ST822 + - + + - - - - + + + + - + + + - + - 
A201R2B0 ST636 + - + + - - - - + + + + - + + + - + - 
A108R2B0 ST1386* + - + + - - - - + + + + - + + + - + - 
A209R1B0C1 ST97 + - + + - - - - + + + + - + + + - + - 
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Table 7. Virulence profiles and plasmids associated with vancomycin-resistant E. faecium and E. faecalis isolated from hospitalized 
patients 
 
*New ST 
 
 
 
Isolate MLST 
Virulence genes 
Plasmids 
Ace camE cCF10 cOB1 ebpA ebpB ebpC efaAfs ElrA gelE hylA SrtA tpx fsrB hylB acm efaAfm 
E. faecalis 
A113R1B0 ST21 + + + + + + + + + + + + + - - - - - 
G701R2B0C1 ST563 + + + + + + + + + + + + + + - - - 
rep(pUB110); 
CDS16(pTEF3); 
repA2(pTEF2); 
rep(pKH7) 
G702R1B0 ST6 + + + + + + + + + + + + + + + - - 
repA2(pTEF2); 
CDS16(pTEF3) 
E. faecium 
A206R2B0 ST822 - - - - - - - - - - - - - - - + + - 
A201R2B0 ST636 - - - - - - - - - - - - - - - + + - 
A108R2B0 ST1386* - - - - - - - - - - - - - - - + + - 
A209R1B0C1 ST97 - - - - - - - - - - - - - - - + + - 
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Figure 1. E. faecalis G702R1B0 ring representation using CGView Server version 1.0 (Grant et al., 2012). 
The inner ring shows the percent of identity comparing E. faecalis G702R1B0 and the finished genome of E. 
faecalis DENG1 (CP004081.1). The first two inner rings show the GC content and GC skew. The next inner 
ring, alternating blue and green regions represents the contigs delimitation of G702R1B0. The last outer ring 
presents the genome of E. faecalis G702R1B0. 
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Figure 2. Dendograms of vancomycin-resistant E. faecium (A) and E. faecalis (B) from faecal carriage of 
hospitalized patients in South Africa. 
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CHAPTER IV. 
ARTICLE III. Whole Genome Sequence Analysis of Methicillin 
Susceptible Staphylococcus aureus and Methicillin Resistant Staphylococcus 
haemolyticus Isolated from Hospitalized Patients in uMgungundlovu 
District, South Africa3 
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- Sabiha Yusuf Essack, as the principal supervisor, co-conceptualized the study, contributed 
to vetting of the results and undertook critical revision of the manuscript 
 
Objectives met: This paper addresses objectives Two, Three, Four, Five. 
 
 
 
 
 
 
 
 
 
 
                                                          
3 This paper has been submitted to Frontiers in Microbiology and is currently under review. 
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Abstract 
Resistance genes, virulence factors and plasmids of Staphylococcus aureus and Staphylococcus 
haemolyticus isolated from hospitalized patients in uMgungundlovu District, South Africa, 
were investigated by whole genome sequencing (WGS). 
From May to June 2017, 45 nasal swabs were collected from patients hospitalized in an urban, 
tertiary and a rural, district hospital in uMgungundlovu District, KwaZulu-Natal, South Africa. 
Four isolates (two S. aureus and two S. haemolyticus) were subjected to WGS using an Illumina 
MiSeq machine with multiplex paired-end libraries prepared from the genomic DNA. The raw 
reads were assembled using the Qiagen CLC Genomics Workbench and SPAdes. The 
assembled contigs were annotated with NCBI PGAP, RAST and ARG-ANNOT. ResFinder, 
VirulenceFinder and PlasmidFinder were used for identification of antibiotic resistance genes, 
virulence factors and plasmids, respectively.  
High resistance to antibiotics attributed to multi-drug resistant efflux pumps mepA, mexE, 
AcrB, MATE, qac and qacA, were observed. S. aureus belonged to the ST121 and S. 
haemolyticus to ST25. There was chromosomal integration of several plasmid replicon types 
in both species. In addition, S. aureus isolates harboured more virulence factors than S. 
haemolyticus, with a total of 18 virulence genes identified whereas the latter was more resistant. 
Although there was no clear evidence of genetic exchange of resistance or virulence genes from 
one species to another, there appears to be the potential for horizontal gene transfer that could 
create a highly resistant and virulent S. aureus and/or S. haemolyticus strain. Horizontal transfer 
of antibiotic resistance genes from haemolyticus to S. aureus or virulence factors from S. 
aureus to S. haemolyticus should thus be further investigated. 
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Introduction 
Staphylococcaceae is a ubiquitous Gram-positive family that are natural inhabitants of skin, 
mucosa and anterior nares. Staphylococcal species have been involved in a variety of 
pathologies including pimples, abscesses, septicaemia, meningitis, pneumonia and toxicosis 
(Kejela and Bacha, 2013; Njoungang et al., 2015) and are a major cause of infections in hospital 
and community settings (Cavanagh et al., 2014). The emergence of methicillin resistant 
staphylococci including S. aureus and S. haemolyticus are of global public health concerns 
(Kejela & Bacha, 2013; Njoungang et al., 2015). Methicillin resistant S. aureus (MRSA) are 
one of the most clinically important pathogens in hospital and community settings. In contrast, 
methicillin resistant S. haemolyticus (MRSH) are important nosocomial bacteria in hospitals 
(Kejela and Bacha, 2013; Cavanagh et al., 2014; Njoungang et al., 2015). Methicillin resistance 
results from the recombinase-mediated insertion of staphylococcal cassette chromosome mec 
(SCCmec), the mobile genetic element carrying mecA, at the 3’ end of a chromosomal open 
reading frame designated as orfX. The mecA gene encodes for complete resistance to the β-
lactam family and various level of co-resistance to other antibiotics. It has been postulated that 
coagulase-negative staphylococci including S. haemolyticus could act as reservoirs of 
resistance genes harboured on mobile genetic elements (MGEs) including the SCCmec, 
plasmids, prophages, transposons and pathogenicity islands which enable the horizontal 
transmission of resistance genes within staphylococcal species (Cavanagh et al., 2014; Rossi 
et al., 2016).  
In South Africa, the molecular epidemiology of S. aureus and haemolyticus is quite complex, 
and depends on the geographical location, population and medical practices. The objectives of 
this study were to investigate antibiotic resistance and virulence genes as well as plasmids and 
clonal lineages of S. aureus and S. haemolyticus isolated from hospitalized patients in 
uMgungundlovu District, South Africa using whole genome sequencing (WGS).  
Materials and Methods 
Ethical considerations  
Ethical approval was obtained from the Biomedical Research Ethics committee (BREC) (No. 
BF512/16, sub-study of BCA444/16). Permission to conduct the research was also granted 
from the Department of Health, uMgungundlovu District and hospital managers.  
Informed consent was obtained from all participants of the study and a questionnaire survey 
was undertaken upon verbal and written consent. Data on clinical history were extracted from 
patient records and data were codified prior to analysis to maintain confidentiality. 
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Study population and settings  
This study conducted over from May to June 2017, at a tertiary and district hospital in 
uMgungundlovu district, South Africa ascertained the carriage of Staphylococcus spp. in 
patients admitted to surgical and medical wards at admission, after 48h and at discharge as far 
as possible. Nasal swabs were aseptically collected using Amies medium.  
Microbiological analyses 
Bacterial identification  
Nasal swabs were cultured onto mannitol salt agar (Merck, Darmstadt, Germany) with and 
without antibiotics using cefoxitin (6 mg/L) and incubated for 18-24h at 37°C to screen for 
methicillin resistance. Mannitol-fermenting colonies were subjected to Gram staining, catalyse, 
coagulase, oxidase and DNase tests. API Staph (BioMerieux, Marcy-L’etoile, France) was used 
to confirm species identification. Pure S. aureus and S. haemolyticus colonies were stored at 
−20°C in tryptone soya broth supplemented with 20% glycerol. 
Phenotypic screening  
The package of MRSA, VISA, GISA, ROSCO Diagnostica Kits (Taastrup, Denmark) was used 
to screen MRSA, VISA, GISA according to the manufacturer instructions.  
Antimicrobial susceptibility testing  
Minimum inhibitory concentrations (MICs) were determined by the broth micro-dilution 
method for ampicillin, cefoxitin, ciprofloxacin, erythromycin, fusidic acid, gentamycin, 
linezolid, moxifloxacin, oxacillin, rifampicin, streptomycin, tetracycline, teicoplanin, 
trimethoprim-sulfamethoxazole and vancomycin. The European Committee on Antimicrobial 
Susceptibility testing (EUCAST) breakpoints (EUCAST, 2016) were used for interpretation of 
the results and S. aureus ATCC 29213 was used as the control. 
Genomic analyses 
DNA Isolation  
The GenElute® bacterial genomic DNA kit (Sigma-Aldrich, St. Louis, MO, USA) was used 
for genomic DNA extraction according to the manufacturer’s instructions. The extracted 
genomic DNA was verified by agarose gel electrophoresis and quantified via NanoDrop 
spectrophotometer and fluorimetric analysis (Qubit®).  
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Genome Sequencing  
Genomic DNA was used for library preparation with multiplexed paired-end libraries (2×300 
bp) prepared using the Nextera XT DNA sample preparation kit (Illumina, San Diego, CA, 
USA). An Illumina MiSeq machine was used for the sequencing with 100× coverage, at the 
National Institute of Communicable Diseases Sequencing Core Facility, South Africa. 
Genome Assembly  
The raw reads were checked for quality, trimmed and de novo assembled using the CLC 
Genomics Workbench version 10 (CLC, Bio-QIAGEN, Aarhus, Denmark) and SPAdes 
version 3.5 (Bankevich et al., 2012) to overrule any gaps from both software. 
Genome Analysis  
The de novo assembled reads were uploaded to the NCBI PGAP 
(https://www.ncbi.nlm.nih.gov/genome/annotation_prok/), RAST (http://rast.nmpdr.org/; 
Aziz et al., 2008) and ARG-ANNOT (http://en.mediterranee-infection.com/) for annotation. 
ResFinder (Zankari et al., 2012), VirulenceFinder (Joensen KG et al., 2014), PlasmidFinder 
(Carattoli et al., 2014) were used for identification of resistance genes, virulence factors and 
plasmids. The multi-locus sequence type (MLST) was determined from the WGS data. The S. 
aureus G703N1B1 contigs were mapped against the MSSA AUS0325 (Accession number: 
NZ_LT615218) for visualization of the genome. 
Nucleotide sequence accession number  
This whole-genome shotgun project PRJNA417366 of S. aureus and S. haemolyticus strains 
G703N2B1, G703N1B1, G811N2B1 and A109N1B1 has been deposited at 
DDBJ/EMBL/GenBank under accession numbers PGWZ00000000, PGXA00000000, 
PGWX00000000 and PGWY00000000, respectively. The version described in this paper are 
the versions PGWZ01000000, PGXA01000000, PGWX01000000 and PGWY01000000, 
respectively. 
Results  
Phenotypic and genotypic analyses 
A total of 45 nasal swabs were obtained from 75 patients at three-time points. Multiple 
mannitol-fermenting colonies growing on selective agar were isolated from 9 (20%) patients 
at different time-points. Intriguingly, although all isolates were mannitol-fermenting, S. aureus 
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was isolated from only one patient (11%) at admission (G703N1B1) and after 48 hours 
(G703N2B1) in the tertiary hospital, with the other mannitol-fermenting colonies being S. 
haemolyticus, S. epidermidis, and S. hominis. The S. haemolyticus selected for the molecular 
characterization were the most resistant and were isolated from two patients in the tertiary 
(G811N2B1) and district (A109N1B1) hospitals, at admission and after 48h. 
The WGS analyses identified several resistance genes in both S. aureus isolates, G703N1B1 
and G703N2B1. More specifically, the beta-lactamase (blaZ), tetracycline (tetK), 
fluoroquinolone including Topo-isomerase (ParC, ParE, norA) and DNA gyrase (gyrA, gyrB), 
fosfomycin (fosD, fosB) Teicoplanine (TcaA, TcaB, TcaR), trimethoprim (dfrG) and multi-
drug resistance efflux pumps (MATE, AcrB) genes were detected (Table 1). In addition, both 
isolates of S. aureus harboured eighteen virulence genes including aureolysin (aur), beta-
hemolysin (hlb), gamma-hemolysin chain II precursor (hlgA), gamma-hemolysin component 
B precursor (hlgB), gamma-hemolysin component B precursor (hlgC), leucocidin D 
component (lukD), leucocidin E component (lukE), staphylokinase (sak), staphylococcal 
complement inhibitor (scn), enterotoxin G (seg), enterotoxin I (sei), enterotoxin M (sem), 
enterotoxin N (sen), enterotoxin O (seo), enterotoxin U (seu), serine protease splA, serine 
protease splB and exfoliative toxin A (eta) (Table 1).  
In contrast, S. haemolyticus isolates carried more resistance genes than S. aureus especially 
against aminoglycosides [ant(6)-Ia, aac(6')-aph(2''), aph(3')-III, aac(6')-aph(2'')], fusidic acid 
(fusB), MLS [(msr(A), mph(C), vga(A)], fluoroquinolones (parC, parE, gyrA and gyrB), 
teicoplanin (TcaS, TcaB). The multidrug and toxin extrusion (MATE) transport protein, mepA 
encoding for resistance to tigecycline, the multidrug exporter AcrB and mexE from the 
resistance-nodulation-cell division (RND) family, the multi-drug resistant (MDR) efflux pump 
(qacA) and small MDR (SMR) family (qac) were additionally detected (Table 1). It is 
important to mention that none of the S. haemolyticus carried virulence factors. 
Three plasmid replication proteins including repL(pDLK1), rep(SAP060B), rep(SAP015B) 
were detected in the S. aureus isolate G703N2B1. PlasmidFinder detected repA(VRSAp) in 
one S. haemolyticus isolate (A811N2B1). MLST-analyses revealed that both MSSA strains 
belonged to ST121 with 100% identity among all seven housekeeping genes (6-5-6-2-7-14-5) 
and all S. haemolyticus were assigned to ST25. 
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Discussion  
This study undertook the molecular characterization of S. aureus and S. haemolyticus isolated 
from hospitalized patients in uMgungundlovu district, South Africa. Our results show that the 
highly-virulent community-acquired methicillin susceptible S. aureus (CA-MSSA) ST121 is 
present in South Africa. This concurs with the study from Rao et al., (2015) which revealed 
that the genetic lineage ST121 is an emerging and hypervirulent clone. Our S. aureus ST121 
isolates are, in contrast to the rest of the world, implicated in nasal carriage from where they 
could subsequently cause infections ranging from minor superficial to severe invasive 
infectious diseases. To the best of our knowledge, this is the first report of CA-MSSA ST121 
isolated from a nasal carriage sample in the country.  
The detection of 18 virulence genes in the CA-MSSA ST121 in carriage samples of 
hospitalized patients revealed that this genetic lineage could probably contribute to severe 
outbreak situations not only in communities but also in hospitals if this clone spreads to 
immune-compromised people and infection control measures are not sufficiently implemented. 
Although not methicillin resistant, the CA-MSSA ST121 isolates were resistant to several 
antibiotics including erythromycin, gentamicin, ciprofloxacin, tigecycline, chloramphenicol, 
vancomycin, doxycycline and tetracycline, and were consequently MDR. We speculated that 
the presence of the numerous MDR efflux pumps belonging to MATE such as mepA, as well 
as the multidrug exporter AcrB fitting into the RND family, could have likely contributed to 
the observed multi-drug resistance. 
Despite the fact that both CA-MSSA isolates were detected in the same patient at admission 
and after 48h in the district hospital, and harbored similar resistance genes, the S. aureus 
A703N2B1C1 isolated after 48h additionally carried the tet(K) gene and three plasmid 
incompatibility groups [rep(pDLK1, rep(SAP060B) and rep(SAP015B)] while the S. aureus 
A703N1B1C1 detected at admission did not harbor plasmid. This intimated the acquisition of 
the tet(K) gene and plasmids by horizontal transmission between bacterial species. In fact, since 
numerous staphylococcal species are natural colonizers of the human flora, they are close 
enough to allow for genetic exchange to occur through conjugation, transduction and 
transposition. Several studies have already revealed the possible horizontal transmission of 
resistance genes between S. haemolyticus and S. aureus (Berglund and Söderquist, 2008; Rossi 
et al., 2016). A Swedish study showed that MRSH had horizontally transferred the SCCmec to 
an MSSA ST45 strain, resulting in MRSA responsible of an outbreak (Berglund and 
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Söderquist, 2008). Similarly, Rossi et al., (2016) described horizontal transmission of 
mupirocin resistance from S. haemolyticus to S. aureus through conjugative and mobilizable 
plasmids (Rossi et al., 2016). Even though direct evidence for S. haemolyticus mediated 
horizontal gene transfer to S. aureus is missing, this is indeed possible because of the genomic 
plasticity of the identified S. haemolyticus, especially the isolates A109N1B1 and G811N2B1 
which harbored a total of 20 and 25 resistance genes, respectively (Table 1). 
Our study showed that all MRSH isolates belonged to ST25 were not only methicillin resistant 
but also MDR (Table 1). They possessed many antibiotic resistance genes responsible for the 
high resistance to antibiotics observed (Table 2). The identification of the S. haemolyticus ST25 
in two different levels of care and at two different time-points (admission and after 48h), 
demonstrates that they probably disseminate in South African public hospitals. S. aureus 
virulence factors were highlighted and contextualized against what is considered a “benign” 
specie, S. haemolyticus. Although there was no clear evidence of genetic exchange of resistance 
or virulence genes from one species to another, there appears to be the potential for horizontal 
gene transfer that could create a highly resistant and virulent S. aureus and/or S. haemolyticus 
strain. Horizontal transfer of antibiotic resistance genes from S. haemolyticus to S. aureus or 
virulence factors from S. aureus to S. haemolyticus should thus be further investigated. 
Genomic data of these bacteria could provide better understanding of their evolution to guide 
interventions for their containment. 
Conclusion 
The study evidenced the presence of highly-virulent S. aureus and MDR S. haemolyticus in 
nasal carriage samples in South African public hospitals. The possibility of horizontal transfer 
of antibiotic resistance genes from S. haemolyticus to S. aureus or virulence factors from S. 
aureus to S. haemolyticus should be investigated in order to palliate to potential outbreaks. The 
observed resistance to last resort antibiotics is of concern, necessitating antibiotic stewardship, 
routine screening of patients and stringent infection control measures.  
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Table 1. Demographic, phenotypic and genotypic data of the MSSA and MRSH isolates 
 
 
 
 
 
 
 
 
 
Isolate name 
Patient’s 
details Hospital 
Time-
points 
Resistance genes Virulence factors Plasmids MLST 
Gender Age 
S. aureus 
G703N1B1C1 
F 37 Tertiary 
Admission 
blaZ, nor(A), fosD, dfrG, parC, parE, gyrA, 
gyrB, fosB, TcaA, TCaB, MATE, AcrB 
Aur, hlb, hlgA, hlgB, hlgC, lukD, 
lukE, sak, scn, seg, sei, sem, sen, 
seo, seu, splA, splB, eta 
/ ST121 
G703N2B1C1 After 48h 
blaZ, nor(A), fosD, dfrG, tet(K), parC, parE, 
gyrA, gyrB, fosB, TcaA, TCaB, MATE, AcrB 
Aur, hlb, hlgA, hlgB, hlgC, lukD, 
lukE, sak, scn, seg, sei, sem, sen, 
seo, seu, splA, splB, eta 
repL(pDLK1), 
rep(SAP060B), 
rep(SAP015B) 
ST121 
S. haemolyticus 
A109N1B1 F 
78 
District 
Admission 
mecA, blaZ, aac(6')-aph(2''), aac(6’)-Ia,  ant(6)-
Ia, norA, msr(A), mph(C), dfrG, mepA, qac, 
bacA, MATE, AcrB, TcaA, TcaB, parC, parE, 
gyrA, gyrB 
/ / ST25 
G811N2B1 F 30 Tertiary After 48h 
mecA, blaZ, aac(6')-aph(2''), aac(6’)-Ia, aph(3’)-
IIIa,  ant(6)-Ia, norA, fusB, msr(A), mph(C), 
vga(A), dfrG, mepA, qac, qacA, mexE, fusB, 
MATE, AcrB, TcaA, TcaB, parC, parE, gyrA, 
gyrB 
/ RepA(VRSAp) ST25 
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Table 2. Antimicrobial susceptibility to selected antibiotics in individual staphylococcal isolates 
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Antibiotic resistance genes 
S. aureus 
G703N1B1C1 ≥64 4 0.5 0.5 ≥512 32 ≥512 2 32 64 16 ≥512 128 128 128 ≥512 64 
blaZ, nor(A), fosD, dfrG, parC, parE, gyrA, 
gyrB, fosB, TcaA, TCaB, MATE, AcrB 
G703N2B1C1 ≥64 2 0.25 0.5 ≥512 32 ≥512 2 32 64 16 ≥512 128 64 128 ≥512 32 
blaZ, nor(A), fosD, dfrG, tet(K), parC, parE, 
gyrA, gyrB, fosB, TcaA, TCaB, MATE, AcrB 
S. haemolyticus 
A109N1B1 ≥512 32 256 128 ≥512 32 256 2 16 64 16 8 4 16 32 ≥512 64 
mecA, blaZ, aac(6')-aph(2''), aac(6’)-Ia,  
ant(6)-Ia, norA, msr(A), mph(C), dfrG, mepA, 
qac, bacA, MATE, AcrB, TcaA, TcaB, parC, 
parE, gyrA, gyrB 
G811N2B1 32 2 1 2 8 0.5 1 1 32 64 8 16 1 2 64 ≥512 32 
mecA, blaZ, aac(6')-aph(2''), aac(6’)-Ia, 
aph(3’)-IIIa,  ant(6)-Ia, norA, fusB, msr(A), 
mph(C), vga(A), dfrG, mepA, qac, qacA, 
mexE, fusB, MATE, AcrB, TcaA, TcaB, parC, 
parE, gyrA, gyrB 
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Figure 1. MSSA G703N1B1 ring representation using CGView Server V 1.0 (Grant et al., 2012). 
The inner ring shows the percent of identity comparing MSSA G703N1B1 and the complete genome of 
MSSA AUS0325 (NZ_LT615218). The first inner rings show the GC content. The next inner ring, 
alternating green and purple represents the GC skew. The last outer ring presents the genome of S. aureus 
G703N1B1. 
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Abstract  
Introduction: Despite evidence of the high prevalence of antibiotic resistant infections in 
developing countries, studies on the clinical and economic impact of antibiotic resistance (ABR) 
to inform interventions to contain its emergence and spread are limited. The aim of this study was 
to analyze the published literature on the clinical and economic implications of ABR in developing 
countries. 
Methods: A systematic search was carried out in Medline via PubMed and Web of Sciences and 
included studies published from January 01, 2000 to December 09, 2016. All papers were 
considered, and a quality assessment was performed using the Newcastle-Ottawa quality 
assessment scale (NOS).  
Results: Of 27 033 papers identified, 40 studies met the strict inclusion and exclusion criteria and 
were finally included in the qualitative and quantitative analysis. Mortality was associated with 
resistant bacteria, and statistical significance was evident with an odds ratio (OR) 2.828 (95%CI, 
2.231-3.584; p= 0.000). ESKAPE pathogens was associated with the highest risk of mortality and 
with high statistical significance (OR 3.217; 95%CIs; 2.395-4.321; p=0.001). Eight studies showed 
that ABR, and especially antibiotic-resistant ESKAPE bacteria significantly increased health care 
costs.  
Conclusion: ABR is associated with a high mortality risk and increased economic costs with 
ESKAPE pathogens implicated as the main cause of increased mortality. Patients with non-
communicable disease co-morbidities were identified as high-risk populations.  
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Introduction 
Antimicrobial resistance (AMR) is the ability of bacteria, parasites, viruses and fungi to grow and 
spread in the presence of antimicrobial medicines that are normally active against them. AMR 
occurs via a range of resistance mechanisms, such as a modified antimicrobial target, enzymatic 
hydrolysis/degradation, efflux and impermeability. This resistance is mediated by diverse 
resistance genes that evolve as a result of antimicrobial selection pressure exerted by the 
appropriate and/or inappropriate use of antimicrobial medicines, and is aggravated by the void of 
new antimicrobial agents in the current therapeutic pipeline (1, 2). AMR increases health-care 
costs, length of stay in hospitals, morbidity and mortality in both developed and developing 
countries (3). A recent report estimated that 10 million deaths will be attributed to AMR by 2050, 
and 100 trillion USD of the world’s economic outputs will be lost if substantive efforts are not 
made to contain this threat (1, 4, 5). 
The World Health Organization (WHO) published the first global surveillance report on antibiotic 
resistance (ABR) in 2014 to show the clinical impact of resistant bacteria in WHO regions across 
the world. This report showed that five out of the six WHO regions had more than 50% resistance 
to third generation cephalosporins and fluoroquinolones in Escherichia coli and methicillin 
resistance in Staphylococcus aureus in hospital settings. Similarly, more than 50% resistance to 
third generation cephalosporins and carbapenems was reported in Klebsiella pneumoniae. The 
report attributed 45% of deaths in both Africa and South-East Asia to multi-drug resistant (MDR) 
bacteria. It further revealed that K. pneumoniae resistant to third generation cephalosporins was 
associated with elevated deaths in Africa (77%), the Eastern Mediterranean region (50%), South 
East Asia (81%) and Western Pacific region (72%) (2).  
Several resistant bacteria have been increasingly involved in infectious diseases in humans, 
specifically, Enterococcus spp., S. aureus, K. pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa and Enterobacter spp. They are collectively termed ESKAPE and 
recently gained further global attention by being listed by the WHO as priority antibiotic-resistant 
bacteria to guide research, discovery, and development of new antibiotics (5). The particularity of 
these bacteria is their ability to develop high level resistance to multiple drugs, thereby limiting 
therapeutic options and increasing morbidity and mortality. Numerous studies have confirmed that 
ESKAPE bacteria and their resistant clones, are actively transmitted in hospitals and communities 
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in both developed and developing countries. The threat posed by these resistant bacteria is however 
exacerbated in developing countries due to sub-optimal hygiene conditions, poor infection, 
prevention and control measures, lack of surveillance and the dearth antimicrobial stewardship 
programs (6, 7). Reports have shown high isolation rates of methicillin resistant S. aureus (MRSA) 
in healthcare settings in Cameroon (72%), South Africa (52%), Ethiopia (42.8%), Nigeria (29.6%), 
Kenya (27.7%), Ivory Cost (16.8%) and Morocco (14.4%) (2, 8-10). In 2008, the prevalence of 
nosocomial acquired and MDR infections due to Enterobacteriaceae isolated from blood cultures 
were 57.1% and 15.4% respectively, in South Africa (11). Likewise, rapid increases in the rates of 
infections due to carbapenemase-producing K. pneumonia, metallo-beta-lactamase-producing A. 
baumannii (MBL-AB), metallo-beta-lactamase-producing P. aeruginosa (MBL-PA), and 
extended-spectrum beta-lactamase (ESBL) producing Enterobacter spp. have been reported across 
the world (12-14). In Saudi Arabia, the rate of P. aeruginosa producing carbapenemase was 33%, 
of which 27% were MBL-producers (15), while in India, a 22.4% prevalence of P. aeruginosa 
producing MBLs was reported in tertiary care hospitals (16).  
MDR-ESKAPE bacteria have been reported in hospital acquired infections (HAI), particularly in 
intensive care units (ICUs) where immune-compromised patients suffering from some non-
communicable diseases (NCDs) including diabetes, cancers, chronic lung, cardiovascular and 
kidney diseases were highly affected (6, 17-22). The emergence and spread of these highly 
resistant bacteria in hospital care settings could thus have negative health repercussions and be an 
obstacle for the treatment of infections of patients with these NCDs (18, 23).  
Despite the evidenced threat posed by ABR, information on its clinical and economic impact is 
limited in developing countries, and thus impede appropriate interventions for its containment (24, 
25). Heightened awareness of policy-makers, health care workers, and the general population 
about the risks associated with ABR is essential to preserve antibiotics for future generations (26, 
27). Hence, the aim of this study was to analyze the published literature on the clinical and 
economic impact of ABR in developing countries, in order to inform containment strategies such 
as antimicrobial stewardship programs and infection prevention and control measures in these 
nations. 
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Methods  
The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) and Meta-
analysis of Observational Studies in Epidemiology (MOOSE) guidelines were followed (28, 29).  
Ethical consideration 
This systematic review and meta-analysis was based on published reports, and was therefore 
exempt from ethical approval. 
Systematic review of the literature 
A systematic search was carried out independently by RF and LF, in Medline via PubMed and 
Web of Sciences from January 2000 to December 09, 2016, using a combination of boolean 
operators (AND/OR), Medical Subject Heading (MeSH) and pre-defined keywords. Only papers 
published after 2000 were considered to ensure that the analysis focuses on contextual literature 
that depict current resistance patterns, infection rates, prevention measures, and clinical practice 
guidelines. Peer-reviewed papers in English and French on the clinical and/or economic impacts 
of ABR in developing countries were retrieved and independently evaluated for eligibility by RF 
and LF based on titles and abstracts (Table 1). Thereafter, the full-texts of eligible papers were 
assessed according to pre-defined inclusion and exclusion criteria (Table 1), with inconsistencies 
and disagreements being resolved by consensus. Efforts were made to contact the authors when 
data was missing and full-texts could not be retrieved, and a hand search was conducted in the 
reference list of all selected papers. 
Table 1. Eligibility criteria 
Inclusion criteria 
- Original research 
- Minimum of 20 patients 
- Studies conducted in developing countries as defined by World Bank criteria 
- Report on association between resistant bacteria and clinical outcome and/or financial impact 
- Antimicrobial susceptibility testing done by either disk diffusion, broth micro-dilution, agar 
dilution, E-test or VITEK using 
- CLSI/EUCAST/SFM guidelines 
- Papers published in French and English  
- Studies published from January 1, 2000 
Exclusion criteria 
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Screening and data extraction process 
Papers were managed using EndNote (version X7.7.1, Thomson Reuters) and the data from 
eligible papers was abstracted independently by two authors (RF and LF) using a standardized data 
extraction spreadsheet in Excel® (Microsoft® Office Excel 2016). Relevant data from papers 
included countries, WHO regions, World Bank classification, publication year, type of study, 
participant characteristics (number of participant, diseases, age), hospital’ ward, bacteria, follow-
up period, length of stay in hospital, mortality related to resistant bacteria, and, costs as described 
in Table 2. 
 
 
 
- Reports of antibiotic resistance unrelated to clinical outcome nor economic impact  
- Reports on parasites, viruses and fungi 
- Reports on treatment comparisons  
- Studies conducted in developed countries as defined by World Bank criteria  
- Reports published in languages other than French and English 
- Antibiotic resistance in wildlife, companion and aquatic animals 
- Grey literature, conference abstracts, reviews, meta-analysis, letters to editor, correspondence, 
editorials, comments and case reports. 
- Studies published before January 1, 2000 
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Table 2. Description of eligible papers included in the systematic review 
Country Year Type of study 
Study 
population 
Infection type Hospital’ ward Bacteria 
Sample 
size 
cases/ 
controls 
Length of stay2 
(%) 
Mortality3 
n/N (%) 
References 
Case 
group 
Control 
group 
Case 
group 
Control 
group 
STUDIES REPORTING IMPACT OF ABR ON THE MORBIDITY ONLY 
Turkey 2015 
Retrospective 
cohort 
NR Nosocomial BSI ICU A. baumannii 41/45 
25.49 
days 
(%NR) 
22.80 
days 
(%NR) 
NR NR 
Gulen et al., 
2015 
(3) 
Turkey 2008 
Prospective 
case—control 
Adults>16 
years old 
Nosocomial 
Infections 
ICU and others A. baumannii 66/57 
20.8 
days 
(65.2%) 
15.4 
days 
(40.4%) 
NR NR 
Baran et al., 
2008 
(30) 
STUDIES REPORTING IMPACT OF ABR ON THE MORTALITY ONLY 
Brazil 2009 
Retrospective 
case-control 
Adults >14 
years old 
Nosocomial 
infections 
Medical-
surgical ICU 
P. aeruginosa 63/182 NR NR 
31/63 
(49%) 
61/182 
(33%) 
Furtado et 
al., 2009 
(31) 
Brazil 2009 Case-control 
Adults > 18 
years old 
BSI NR 
E. coli and K. 
pneumoniae 
30/64 NR NR 
7/30 
(23.3%) 
12/64 
(18.8%) 
Serefhanoglu 
et al., 2009 
(32) 
China 2004 
Case-control and 
Retrospective 
cohort 
All ages MDR-HAI Various wards1 P. aeruginosa 44/68 NR NR 
24/44 
(54.5%) 
11/68 
(16.2%) 
Cao et al., 
2004 
(33) 
China 2012 Retrospective 
Children < 
15 years 
old 
Pneumonia Pediatric ICU A. baumannii 115/45 NR NR 
21/115 
(18.26%
) 
2/45 
(4.44%) 
Cai et al., 
2012 
 (34) 
China 2015 
Retrospective 
Case-Control 
NR 
MRSA 
infections 
Various S. aureus 57/116 NR NR 
12/57 
(21%) 
9/116 
(8%) 
Yao et al., 
2015 
 (35) 
Colombia 2014 Case-Control All ages CR-KP Infection ICU 
K. 
pneumoniae 
61/122 NR NR 
31/61 
(50.8%) 
25/122 
(20.4%) 
Gomez et al., 
2014 
 (36) 
India 2014 NR Neonates BSI Neonatal ICU A. baumannii 33/32 NR NR 
9/33 
(27.3%) 
3/32 
(9.4%) 
Kumar et al., 
2014 
(37) 
Malaysia 2009 Case-control NR 
Nosocomial AB 
BSI 
NR A. baumannii 53/56 NR NR 
25/53 
(47.2%) 
14/56 
(25%) 
Deris et al., 
2009 
(38) 
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Malaysia 2011 
Cross-sectional 
descriptive and 
case-control 
NR 
IR-A. baumannii 
BSI 
NR A. baumannii 15/41 NR NR 
9/15 
(64.3%) 
15/41 
(40.5%) 
Deris et al., 
2011 
 (39) 
Mexico 2000 Case-control Children Pneumoniae NR 
S. 
pneumoniae 
25/24 NR NR 
11/25 
(44%) 
7/24 
(29%) 
Gomes et al., 
2000 
(40) 
Thailand 2011 Case-control  
Adults >15 
years old 
MDR-A. 
baumannii 
bacteremia 
In and out-
patient 
departments 
A. baumannii 24/25 NR NR 
22/24 
(91.7%) 
12/25 
(48%) 
Anunnatsiri 
et al., 2011 
(41) 
Thailand 2012 Case-control 
Adults >15 
years old 
ESBL-producing 
bacteria in  
septicemia 
In and out-
patient 
departments 
E. coli 32/113 NR NR 
9/32 
(29%) 
13/113 
(11.5%) 
Anunnatsiri 
et al., 2012 
 (42) 
Thailand 2015 Case-control 
Adults>18 
years old 
HAI 
ICU and 
general wards 
A. baumannii 139/132 NR NR 
79/139 
(57%) 
3/132 
(2%) 
Chusri et al., 
2015 
(43) 
Thailand 2015 
Retrospective 
cohort 
Adults 
Ventilator 
Associated 
Pneumoniae 
ICU A. baumannii 220/33 NR NR 
125/220 
(56.8%) 
7/33 
(21.2%) 
Inchai et al., 
2015 
(44) 
STUDIES REPORTING IMPACT OF ABR ON THE MORBIDITY AND MORTALITY 
Brazil 2015 Case-control 
Cancer 
children 
<18 years 
old 
MDR-GNB 
Infection 
Oncology 
pediatric ICU 
Gram 
Negative 
Bacteria 
47/54 
8 days 
(63.8%) 
2 days 
(37%) 
12/47 
(25.5%) 
9/54 
(16.7%) 
Costa et al., 
2015 
(17) 
Brazil 2006 
Retrospective 
cohort 
>1-year-old BSI Various wards1 S. aureus 61/50 
>10 
days 
(65.9%) 
>10 
days 
(34.1%) 
33/61 
(54.9%) 
12/50 
(24.7%) 
Guilande et 
al., 2006 
(45) 
Brazil 2006 
Retrospective 
cohort 
All ages BSI Various wards1 
K. 
pneumoniae 
56/52 
>10 
days 
(56.2%) 
>10 
days 
(43.8%) 
18/56 
(69.2%) 
8/52 
(30.8%) 
Marra et al., 
2006 
(46) 
Brazil 2008 Case-control Adults VAP ICU S. aureus 29/32 
>8 days 
(89.7%) 
>8 days 
(90.6%) 
11/29 
(37.9%) 
8/32 
(25%) 
Moreira et 
al., 2008 
(47) 
Brazil 2012 Case-control 
Adults > 18 
years old 
Bacteremia ICU P. aeruginosa 29/48 
43 days 
(NR) 
43.1 
days 
(NR) 
13/29 
(44.8%) 
26/48 
(54.2%) 
 Tuon et al., 
2012 
(22) 
China 2012 
Retrospective 
cohort 
> 1 year old BSI Various wards1 S. aureus 75/43 
55.3 
days 
(NR) 
38.7 
days 
(NR) 
25/75 
(33.3%) 
8/43 
(18.6%) 
Chen et al., 
2012 
 (48) 
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China 2015 Retrospective 
Geriatric 
inpatients 
Bacteremia Various wards1 A. baumannii 39/86 
36.7 
days 
(NR) 
36.1 
days 
(NR) 
31/39 
(79.5 %) 
38/86 
(44.2%) 
Fu et al., 
2015 
(49) 
China 2015 
Retrospective 
case-control 
NR 
Enterococci 
infections 
Various wards1 Enterococci 44/176 
37 days 
(NR) 
17 days 
(NR) 
3/44 
(6.8%) 
3/176 
(1.7%) 
Jia et al., 
2015 
(50) 
Colombia 2014 
Prospective 
cohort 
Adult 
CR-A. 
baumannii 
Infections 
ICU A. baumannii 104/61 
19 days 
(NR) 
16.2 
days 
(NR) 
42/104 
(40%) 
13/61 
(21%) 
Lemos et al., 
2014 
(51) 
India 2014 Observational Adults Septicemia Various wards 
GNB and 
GPB 
133/87 
14 days 
(NR) 
11 days 
(NR) 
16/133 
(12%) 
2/87 
(2%) 
Chandy et 
al., 2014 
(52) 
Jordan 2015 
Matched case-
control 
Cancer 
patients 
Nosocomial A. 
baumannii 
infections 
Medical-
surgical ICU 
A. baumannii 161/262 
12 days 
(NR) 
3 days 
(NR) 
118/161 
(73.3%) 
142/232 
(61.2%) 
Nazer et al., 
2015 
(53) 
Palestine 2009 
Prospective 
case—control 
Neonates 
Nosocomial 
septicemia 
 
Neonatal ICU A. baumannii 40/100 
20 days 
(62.5%) 
20 days 
(35%) 
15/40 
(37.5%) 
12/100 
(13.2%) 
Aljarousha et 
al., 2009 
(54) 
Senegal 2016 
Classic 
retrospective 
cohort and 
retrospective 
parallel cohort 
All ages 
ESBL- 
producing 
Enterobacteriace
ae  
Various wards1 
K. 
pneumoniae 
Enterobacter 
E. coli 
110/76 
22.6 
days 
(NR) 
14 days 
(NR) 
52/110 
(47.3 %) 
17/76 
(22.4 %) 
Ndir et al., 
2009 
(55) 
Thailand 2007 
Prospective 
case—control 
Adults HAI Various wards1 
E. coli and K. 
pneumoniae 
74/74 
22.5 
days 
(NR) 
17.5 
days 
(NR) 
26/74 
(35.1%) 
12/74 
(16.2%) 
Apisarnthana
rak et al., 
2007 
(56) 
Thailand 2008 Cohort Adults 
Community-
onset BSI 
Various wards1 
E. coli and K. 
pneumoniae 
36/108 
8 days 
(NR) 
6 days 
(NR) 
13/36 
(36%) 
16/108 
(15%) 
Apisarnthana
rak et al., 
2008 
 (57) 
Thailand 2014 
Retrospective 
cohort 
Adults>18 
years old 
HAI Various wards1 
A. 
nosocomialis 
and A. pittii 
25/58 
9 days 
(NR) 
4 days 
(NR) 
3/25 
(12%) 
20/58 
(35%) 
Chusri et al., 
2014 
(58) 
Thailand 2009 
Retrospective 
cohort 
Adult> 15 
years old 
Nosocomial BSI Various wards1 A. baumannii 67/131 
37 days 
(NR) 
27 days 
(NR) 
35/67 
(52.2%) 
26/131 
(19.9%) 
Jamulitrats et 
al., 2009 
(59) 
Thailand 2006 Cross-sectional All ages 
Community-
acquired 
pneumoniae 
NR 
S. 
pneumoniae 
22/42 
12.2 
days 
(NR) 
15.5 
days 
(NR) 
2/22 
(9.1%) 
4/42 
(9.5%) 
Reechaipichi
kul et al., 
2006 
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(60) 
Thailand 2009 Case-control 
Adult>18 
years old 
Nosocomial BSI Various wards1 
E. coli and K. 
pneumoniae 
51/94 
26 days 
(NR) 
16 days 
(NR) 
26/51 
(51.0%) 
28/94 
(29.8%) 
Superti et al., 
2009 
(61) 
Thailand 2013 
Retrospective 
Case-control 
Neonates 
CR- A. 
baumannii 
Bacteremia 
Neonatal ICU A. baumannii 14/44 
34 days 
(NR) 
24.5 
days 
(NR) 
6/14 
(42.9%) 
3/44 
(5.9%) 
Thatrimontri
chai et al., 
2013 
(62) 
Thailand 2016 
Retrospective 
Case-control 
Neonates VAP Neonatal ICU A. baumannii 63/25 
51 days 
(NR) 
41 days 
(NR) 
10/63 
(15.9%) 
0/25 
(0%) 
Thatrimontri
chai et al., 
2016 
 (19) 
Turkey 2015 
Observational 
retrospective 
cohort 
All ages HAI ICU 
K. 
pneumoniae 
47/51 
19 days 
(37.3%) 
11 days 
(29.94%
) 
21/47 
(44.7%) 
26/51 
(51%) 
Candevir et 
al 2015 
(63) 
Turkey 2000 Retrospective Adults Bacteremia ICU S. aureus 46/55 
50.3 
days 
(NR) 
32.7 
days 
(NR) 
15/46 
(32.6%) 
7/55 
(12.7%) 
Topeli et al., 
2000 
(21) 
Turkey 2015 NR NR 
Nosocomial 
infections 
Emergency ICU 
and Pediatric 
ICU 
P. aeruginosa 32/8 
20.58 
days 
(NR) 
6.33 
days 
(NR) 
14/32 
(43.8%) 
2/8 
(25%) 
Amer et al., 
2015 
(64) 
LOS: Length of stay; NR: Not reported; BSI: Bloodstream infection, HAI: Hospital-acquired infection, VAP: Ventilator-Associated Pneumoniae; CR: Carbapenem-
resistant; GNB: Gram negative bacteria; GPB: Gram positive bacteria, 1 various wards; 2 LOS attributed to the specific bacteria responsible of the infections, 3: 
Overall mortality attributed to the specific bacteria responsible of the infections, ICU: Intensive Care Unit. 
 
112 
 
Statistical analysis  
Meta-analyses were undertaken using Comprehensive Meta-analysis software (Biostat, Inc., New 
Jersey, USA) version 3 for Windows, to determine overall mortality risk associated with 
resistance. Sub-group analyses for mortality were conducted for the data by WHO region, World 
Bank classification, countries, group of bacteria, and bacterial species where there were three or 
more studies that could be combined. Forest plots were performed to assess the significance of the 
results and generated using 95% confidence intervals (CIs). Analyses were undertaken across sub-
groups for the selected outcome and the results presented as odds ratios. Studies were weighted in 
favor of those with narrower confidence intervals (more precise results), and the random-effects 
method was used to provide more confident data considering heterogeneity within and between 
reports. The I-square (I2) statistic with cut-off values of 25, 50 and 75% was used to assess low, 
moderate and high heterogeneity respectively, and a p-value of <0.05 was considered statistically 
significant. Publication bias was evaluated using the funnel plot and statistical egger’s test.  
Quality assessment 
Quality assessment was performed independently by RF and LF using the Newcastle-Ottawa 
quality assessment scale (NOS) for each study included in the systematic review and meta-analysis 
(65). NOS assesses methodological quality, based on three-dimensional criteria and included (i) 
selected population, (ii) comparability of groups, and (iii) outcome/exposure of interest. Studies 
were scored using a scale with a possible maximum of eight points where a score ≥ 6 indicated 
high-quality studies, a score between 3-6 as moderate and a score ≤ 3 as low quality.  
Results 
Literature search and study selection 
The systematic search conducted in the two electronic databases generated 27 033 papers. A total 
of 24 057 papers were screened for probable inclusion according to titles and abstracts after de-
duplication. Of these, the full texts of 92 eligible papers were fully evaluated based on predefined 
inclusion and exclusion criteria. One article was added following a hand-search in the reference 
lists of included papers. Forty studies were finally eligible for the qualitative and quantitative 
analysis (Fig 1), of which 18 were of high quality, while 15 and seven were moderate and low 
quality respectively.  
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Fig 1. Prisma Flow-chart illustrating the study selection process. 
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Description and characteristics of studies included in systematic review 
The majority of data analyzed were obtained from single center studies conducted in 11 countries. 
Thirty percent (n=12) of the observational studies on ABR were conducted in hospitals and 
communities in Thailand, the rest were performed in 10 different-countries namely Brazil (n=7; 
17.5%), China (n=6; 15%), Turkey (n=5; 12.5%), Colombia (n=2; 5%), Malaysia (n=2; 5%), India 
(n=2; 5%), Mexico (n=1; 2.5%), Jordan (n=1; 2.5%), Palestine (n=1; 2.5%), and Senegal (n=1; 
2.5%) (Table 2 and Fig 2). 
Fourteen studies investigated the impact of ABR on mortality, two reported its impact on morbidity 
only (Table 2) while 24 considered both morbidity and mortality concomitantly. Eight studies 
reported on the economic consequences of ABR (Table 3). A. baumannii (n=14; 35%), K. 
pneumoniae (n= 6; 15%), S. aureus (n=5; 12.5%), P. aeruginosa (n=4; 10%) represented the main 
pathogens reported with ICUs being the principal hospital ward concerned (Tables 2 and 3). 
Fig 2. Graphical representation of AMR in developing countries included in the study. 
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Table 3. Studies describing mortality rate associated with resistant and MDR ESKAPE bacteria 
 
 
Authors Hospital Wards Bacteria Mortality rate P-value References 
Al Jarousha et al. (2009) Neonatal ICU 
MDR-A. baumannii (15/40) 37.5% 
0.001 (54) 
Susceptible A. baumannii (12/100) 12% 
Anunnatsiri et al. (2011) 
 
ICU 
MDR-A. baumannii (22/24) 91.7% 
0.001 (41) 
Susceptible A. baumannii (12/25) 48% 
Amer et al. (2015) 
Emergency 
ICU /Pediatric ICU 
CR-MBLP-P. aeruginosa (14/32) 43,8% 
0.2 (64) 
CR-MBLN-P. aeruginosa (2/8) 25% 
Furtado et al. (2009) ICU 
Imipenem-resistant P. aeruginosa 
(31/63) 
49% 
0.02 (31) 
Imipenem-susceptible 
P. aeruginosa (61/182) 
33% 
Marra et al. (2006) ICU 
ESBL-producing K. pneumoniae 
(18/56) 
32.14% 
0.042 (46) 
Non-ESBL K. pneumoniae (8/52) 15.38% 
Moreira et al. (2008) ICU 
ORSA (11/29) 37.9% 
0.41 (47) 
OSSA (8/32) 25% 
Serefhanoglu et al. (2009) ICU 
MDR-ESBL-producing-E. coli and 
K. pneumoniae (7/30) 
23.3% 
0.606 (32) 
Non-MDR-ESBL- producing-E. 
coli and K. pneumoniae (12/64) 
18.8% 
Tuon et al. (2012) ICU 
Carbapenem-resistant 
P. aeruginosa (13/29) 
54.2% 
0.043 (22) 
Carbapenem-susceptible 
P. aeruginosa (26/48) 
44.8% 
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Table 3. End 
Authors Hospital Wards Bacteria 
Mortality 
rate 
P-value References 
Chen et al. (2012) ICU 
MRSA (25/75) 33% 
0.01 (48) 
MSSA (8/43) 18.6% 
 
Fu et al. (2015) 
 
ICU 
XDR A. baumannii (31/39) 79.5% 
0.1 (49) 
Non-XDR A. baumannii (38/86) 44.2% 
Jia et al. (2015) ICU 
Linezolid non-susceptible 
Enterococci (3/44) 
6.8% 
0.521 (50) 
Linezolid-susceptible Enterococci 
(2 /44) 
4.5% 
Un-infected Control patients 
(3/176) 
1.7% 
Yao et al. (2015) ICU 
MRSA (12/57)) 21% 
0.002 (35) 
MSSA (9/116) 8% 
Gomez Rueda et al. (2014) ICU 
Carbapenem resistant  
K. pneumoniea (31/61) 
50.8% 
0.042 (36) 
Carbapenem-susceptible  
K. pneumoniae (20/61) 
32.7% 
Un-infected control patients 
(25/122) 
20.4% 
Kumar et al. (2014) ICU 
Carbapenem-resistant  
A. baumannii (9/33) 
27.3% 
0.074 (37) 
Carbapenem-susceptible  
A. baumannii (3/32) 
9.4% 
Nazer et al. (2015) ICU 
MDR-A. baumannii (118/161) 73.3% 
0.015 (53) 
Non-MDR-A. baumannii(142/232) 61.2% 
Deris et al. (2011) ICU 
Imipenem-resistant -A. baumannii 
(6/15) 
42.9% 0.201 (39) 
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CR: Carbapenem-resistant; CS: Carbapenem susceptible; MBL: Metallo-beta-lactamase; IS: imipenem sensitive; IR: imipenem resistant; ICU: Intensive Care Unit; 
OSSA: Oxacillin-sensitive-S. aureus; ORSA: Oxacillin-resistant-S. aureus; PDR: Pan drug resistant; XDR: Extensive drug resistant  
Imipenem-susceptible  
A. baumannii (9/41) 
24.3% 
Inchai et al. (2015) ICU 
MDR-A. baumannii (10/72) 13.9% 
0.001 (44) XDR- A. baumannii (88/220) 40% 
PDR-A. baumannii (7/12) 58.3% 
Jamulitrat et al. (2009) 
 
ICU 
Imipenem-resistant-A. baumannii 
(35/67) 
52.2% 
0.001 (59) 
Imipenem-susceptible  
A. baumannii (26/131) 
19.9%% 
Thatrimontrichai et al. (2016) 
 
ICU 
Carbapenem-resistant 
A. baumannii (10/63) 
15.9% 
0.01 (19) Carbapenem-susceptible  
A. baumannii (1/13) 
7.7% 
Un-infected control patients (0/25) 0% 
Topeli et al. (2000) ICU 
MRSA (15/46) 32.6% 
0.02 (21) 
MSSA (7/55) 12.7% 
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Statistical analysis 
Primary analyses 
Pooled estimates revealed 90% prevalence (95%CI, 2.852-3.557; p=0.000) of mortality 
attributable to infections in developing countries with greater mortality associated with ABR at an 
odds ratio (OR) 2.828 (95%CI, 2.231-3.584; p= 0.000) (Fig 3A).  
Subgroup analyses 
The subgroup analyses were performed by World Bank classification, WHO region, country, 
group of bacteria and bacterial species. Figure 3B presents a forest plot of mortality due to AMR 
categorized per World Bank classification. The risk of mortality due to resistant bacteria was high 
in upper middle-income countries (OR 2.769, 95% CIs, 2.142-3.579; p= 0.000), with studies from 
lower-middle and low-income nations not being evaluated due to insufficient data.  
Four out of the six WHO regions were included in the analysis, with three showing a high risk of 
mortality (Fig 3C). High statistical significance was observed in the Americas (OR 2.126, 95% 
CIs; 1.546-2.925; p=0.000), South East Asia (OR 3.754, 95% CIs; 2.333-6.041; p=0.000) and the 
Western Pacific (OR 3.746, 95% CIs; 2.463-5.697; p=0.000) (Fig 3C). Results from Europe were 
not statistically significant and insufficient reports precluded analysis in Africa. 
Subgroup analyses per country showed high statistical significance (OR 2.665, 95%CIs; 2.074-
3.425, p=0.000) (Fig 3D) in favor of mortality. Brazil, China and Thailand, had statistically 
significant risk of mortality with OR being 1.825 (95%CIs; 1.239-2.689; p=0.002), 3.746 
(95%CIs; 2.463-5.697; p=0.000), 3.928 (95%CIs; 2.116-7.293; p=0.000) respectively, in contrast 
to Turkey, which was not statistically significant (Fig 3D). In other countries, the number of reports 
was insufficient (less than three) to perform the meta-analysis. 
Studies were categorized into three groups of bacteria namely ESKAPE, non-ESKAPE, and mixed 
(both ESKAPE and non-ESKAPE). The ESKAPE group was associated with the highest risk of 
mortality with a high statistical significance (OR 3.217; 95%CIs; 2.395-4.321; p=0.001) (Fig 3E). 
Although, the non-ESKAPE group was not associated with the risk of mortality (OR 1.167; 
95%CIs; 0.385-3.534; p=0.000), when combined with ESKAPE within a study, it became 
statistically significant (OR 2.634; 95%CIs; 1.858-3.734; p=0.000) (Fig 3E). 
High risk of mortality due to antibiotic-resistant A. baumannii was observed with high statistical 
significance (OR 4.636; 95%CIs; 2.954-7.277; p=0.000), followed by S. aureus (OR 2.842; 
95%CIs; 1.868-4.324; p=0.000). P. aeruginosa (OR 2.076; 95%CIs; 0.833-5.177; p=0.117) and 
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K. pneumoniae (OR 2.026; 95%CIs; 0.733-5.598; p=0.173) were not significantly associated with 
mortality (Fig 3F). 
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Fig 3. Forest plot of Impact of ABR on Mortality and sub-group analyses per World Bank Classification, WHO regions, Countries, group 
of bacteria and bacteria species. 3A. Forest plot of overall impact of antibiotic-resistance on mortality in included studies. 3B. Forest plot of 
impact of ABR on mortality analyzed per World Bank Classification. 3C. Forest plot of impact of ABR on mortality analyzed per WHO regions. 
3D. Forest plot of impact of ABR on mortality analyzed per countries. 3E. Forest plot of impact of AMR on mortality analyzed per group of 
bacteria. 3F. Forest plot of impact of ABR on mortality analyzed per bacteria species. 
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Discussion 
AMR is a global public health threat that affects human health, particularly hospitalized patients, 
and has substantive health and financial consequences. This study analyzed the published literature 
on the clinical and economic implications of ABR in developing countries from 40 eligible studies. 
Antibiotic-resistant bacteria were associated with increased mortality (OR 2.8341, 95%CIs; 
2.2180-3.6213; P=0.000), consistent with several reports in both developed and developing 
countries (66-69). The main ward involved was the ICU, possibly due to the heavy use of 
antibiotics and hence the selection pressure for ABR development and prevalence in these units 
(4, 23, 70, 71). This concurred with studies from Mexico, Brazil, China, Thailand, France and 
Serbia, that reported high mortality due to antibiotic-resistant bacteria in ICUs (17, 49, 67, 71-73). 
The study further showed that ABR research is neglected in developing countries with only one 
report from low-income (Senegal), two from lower-income (Palestine and Jordan), and 37 from 
upper-middle income nations (Table 1 and Figure 2). Developing countries are thus far behind 
high resource settings in the fight against AMR and that requiring considerable efforts to reduce 
its consequences (74). Three WHO regions, i.e., the Americas, South East Asia and the Western 
Pacific region showed the highest risk of mortality associated with MRSA and K. pneumoniae 
resistant to third generation cephalosporins. Our results concurred with the 2014’s WHO report, 
which showed a significant increase of mortality due to antibiotic-resistant K. pneumoniae and S. 
aureus in hospitals particularly in ICU across WHO regions (2). Resistance levels could be 
explained by the practices of self-medication and the purchase of antibiotics over-the-counter 
common in these settings. Policies and regulations promoting rational antibiotic use are also 
minimal or non-existent. Additionally, limitations in managing nosocomial infections, sub-optimal 
infection control measures, unsafe water, poor hygienic conditions, lack of knowledge and 
inadequately trained personnel might also be associated with the prevailing resistance in these 
regions. Comprehensive studies are needed to provide accurate and reliable data to inform 
decision-makers about the danger of ABR in developing countries and suggest a way forward for 
the alleviation of the resulting implications.  
Resistant ESKAPE bacteria including carbapenem-resistant A. baumannii, MBL- producing P. 
aeruginosa, ESBL-producing K. pneumoniae, and MRSA represented the most common resistant 
bacteria associated with increased mortality. These bacteria were the main cause of morbidity and 
mortality in bloodstream infections in hospital settings, with a high statistical significance (OR 
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2.978, 95%CIs; 2.362-3.753; p=0.000) (Fig 3F). This concurred with the WHO Global 
Antimicrobial Surveillance System (GLASS), which recognized A. baumannii, K. pneumoniae, 
and S. aureus, as priority pathogens in blood specimens and list them together with P. aeruginosa 
as priority antibiotic resistant-bacteria for research and development in 2017 (4, 5).  
According to the meta-analysis, MDR-ESKAPE were associated with a greater risk of mortality 
than mono-drug (including imipenem, methicillin, and linezolid) resistant bacteria, with a high 
statistical significance (OR 2.846, 95% CIs; 1.744-4.643; p= 0.000; versus OR 2.301; 95%CIs; 
1.718-3.082; p=0.000; Table 3). Moreover, when comparing the mortality risk between resistant- 
and susceptible-ESKAPE pathogens (Table 3), results showed that carbapenem-resistant A. 
baumannii (CRAB) were associated with higher mortality risk than susceptible strains with a high 
statistical significance (2, 5). The pooled estimate of mortality rate ranged from 15.9 to 91.7% 
(p=0.001), consistent with a report from Taiwan, where a significant increase of mortality from 
14% to 46% (p=0.0001) was associated with carbapenem-resistant-A. baumannii implicated in 
HAIs during 2003-2008 (75).  
Although the mortality attributable to ESKAPE pathogens is indisputable compared to non-
ESKAPE pathogens, we observed that when these two groups infected patients concomitantly, 
they were associated with a long length of hospital stay (LOS) and a higher mortality. This 
concurred with studies from Senegal (55), Turkey (3) and China (35, 50) which have reported high 
LOS and death due to MDR-A. baumannii, ESBL-producing Enterobacteriaceae and MRSA, 
respectively.  
Eight studies reported that ABR increased health care costs with resistant ESKAPE bacteria being 
the main causative agents associated with high hospital costs (Table 4). Four out of the eight 
revealed that length of stay had an impact on hospital costs. LOS was also a risk factor for 
acquisition of nosocomial infections, and thereby increased mortality. Overall, health-care costs 
in all studies for case and control groups were 8,107.375 USD versus 5,469.487 USD respectively. 
Two studies indicated health care costs >10 000 USD in Thailand and Colombia (19, 51) while 
one report showed cost ≥ 35 000 USD in Turkey (3). In contrast, three studies reported overall 
hospital costs ≤ 1000 USD (55-57), with one below 250 USD in Senegal (55). These differences 
are attributed to the diverse socio-economic characteristics of the countries concerned. 
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Table 4. Summary of data on health care costs associated with resistant infections 
Country WHO Region 
World Bank 
classification 
Settings 
Follow-up 
period 
Overall Health care costs 
References 
Case group Control group p-value 
Colombia 
Americas 
(PAHO) 
Upper Middle 
Income 
Tertiary hospital 30 days 11 822 USD 7 178 USD < 0.001 (51) 
India 
South East Asia 
(SEARO) 
Upper middle 
income 
Tertiary hospital NR 1 478 USD 790 USD < 0.001 (52) 
Senegal Africa (AFRO) Low income Hospital NR 228 USD 122 USD < 0.0001 (55) 
Thailand 
South East Asia 
(SEARO) 
Upper middle 
income 
University Hospital 34 days 935 USD 122 USD < 0.05 (56) 
Thailand 
South East Asia 
(SEARO) 
Upper middle 
income 
University Hospital 43 days 615 USD 214 USD < 0.05 (57) 
Thailand 
South East Asia 
(SEARO) 
Upper middle 
income 
University Hospital NR 2731 USD 1 199 USD < 0.001 (58) 
Thailand 
South East Asia 
(SEARO) 
Upper middle 
income 
University Hospital NR 11 773 USD 7 797.9 USD < 0.05 (19) 
Turkey 
Europe 
(EURO) 
Upper middle 
income 
University Hospital 28 days 35 277 USD 26 333 USD <0.282 (3) 
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In terms of the limitations of the study, several papers were not included in the meta-analysis 
because they did not provide sufficient information regarding clinical and/or economic impact of 
ABR in developing countries. We were unable to present the genomic characteristics of antibiotic-
resistant bacteria due to the scarcity of data. In addition, we did not focus on antibiotic classes and 
resistance patterns due to the lack of standard methods for identification and interpretation in 
developing countries. Moderate heterogeneity (I²=58.88%, p=0.000) was reported, which could 
be due to various external factors, such as different type of studies (retrospective, retrospective 
cohort, retrospective case-control, prospective cohort, prospective case-control, etc.), diverse 
populations (adult, children, neonates), infection prevention and control measures and 
antimicrobial stewardship practices. Moreover, minor publication bias was observed in the funnel 
plot (fig 4) which could possibly be attributed to the lack of reports from lower-middle and low-
income countries. We tried to limit the influence of heterogeneity and publication bias in our 
statistical analysis by using the random effects model that considers differences within and 
between studies, as well as by including articles in different languages (English and French).  
 
 
 
 
 
 
 
 
 
 
  
Fig 4. Funnel plot of Standard Error by log odds ratio 
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Conclusion and recommendations 
The key findings of this study confirm that ABR, particularly antibiotic-resistant ESKAPE 
pathogens are associated with a high risk of mortality and greater economic costs. Developing 
countries need to optimize their management of communicable and non-communicable diseases, 
implement infection, prevention and control (IPC) measures, as well as antimicrobial stewardship 
programs (ASP) in both hospital and community settings to reduce morbidity, mortality and the 
costs associated with ABR. Furthermore, optimization of rational antibiotic use at regional and 
national levels, is essential to ensure a high quality and effective of therapeutic options (76). 
Substantial and sustainable efforts to develop rapid diagnostics, new antibiotics and vaccines are 
required. An international platform for global real-time surveillance and monitoring of 
antimicrobial resistance could advance containment of this threat.   
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CHAPTER VI. CONCLUSION 
 
I. Introduction and key findings 
A total of 71 non-duplicate ESKAPE bacteria collected from carriage samples (nasal and rectal 
swabs) at three time-points (admission, after 48h and discharge) as well as from clinical specimens 
in a rural district and an urban, tertiary hospital in uMgungundlovu, South Africa, between May 
and July 2017, were investigated via conventional, multiplex and real-time PCR, as well as WGS 
with a view to delineate antibiotic resistance genes, virulence factors, plasmids and MLST profiles. 
The following are the main conclusions from the study: 
- The overall prevalence of carriage of MDR Gram-negative ESKAPE bacteria was 37.21% 
(16/43), 42.31% (11/26) and 57.14% (4/7) at admission, after 48 h and at discharge 
respectively.  
- The prevalence of MDR Gram-negative ESKAPE bacteria in faecal carriage (46%) was higher 
than clinical samples (28%).  
- Colonization was mainly associated with referral from district to tertiary hospital with high 
statistical significance (OR: 14.40, 95% CI 0.98-210.84).  
- blaCTX-M-group-9, blaCTX-M-group-1 and blaSHV were the main resistance genes identified through 
conventional, multiplex and real-time PCR.  
- Several patients carried more than two different isolates in both district and tertiary hospitals 
and the clonality reveals that K. pneumoniae (K1) was circulating within wards and between 
hospitals. 
- ESBL-producing MDR Gram-negative ESKAPE bacteria are widespread in public hospitals 
in uMgungundlovu district. 
- The overall prevalence of faecal VRE carriage was 53% with patients of the district hospital 
being more likely to be colonized by VRE at admission (44%), after 48h (64%) and discharge 
(100%) than those of the tertiary level.  
- High genetic diversity and clonal dissemination of various E. faecalis and E. faecium lineages 
were observed across wards and within hospitals in uMgungundlovu district. 
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- Gender, antibiotics use, co-morbidity, previous hospitalization, referral from district to tertiary 
hospital were the main risk factors identified at admission in both hospitals while 
hospitalization in the surgical wards increased the odds to being colonized by VRE after 48h. 
- High level of antibiotic resistance in S. aureus were attributed to the multi-drug resistant efflux 
pumps mepA, mexE, AcrB, MATE, qac and qacA. 
- Genome analysis revealed that the circulating S. aureus isolates belonged to the extremely 
virulent ST121 clone with a total of 18 virulence genes identified. Chromosomal integration 
of several plasmid replicons was also evident. 
- ABR is associated with a high mortality risk and increased economic costs in developing 
countries with ESKAPE pathogens implicated as the main cause of increased mortality with 
high statistical significance (OR 3.217; 95%CIs; 2.395-4.321; p=0.001). 
- ABR, and especially antibiotic-resistant ESKAPE bacteria significantly increased health care 
costs.  
- Patients with non-communicable disease co-morbidities were identified as high-risk 
populations. 
These findings are comparable to those reported elsewhere in Africa and South Africa, particularly 
in terms of the predominance of CTX-M among Gram-negative ESKAPE bacteria. However, the 
detection of VRE harbouring VanC-1 gene and genetic lineage S. aureus ST121 in carriage 
samples are unprecedented in South Africa.  
II. Study significance  
This study presents an overview of the current status of antibiotic-resistant ESKAPE bacteria in a 
rural, district and an urban, tertiary public hospitals in uMgungundlovu district, KwaZulu-Natal, 
South Africa. The study adds new knowledge on the different resistance mechanisms associated 
with ESKAPE pathogens and confirms these bacteria as serious health treat. The results provide 
preliminary evidence for policy-makers to consider ABR containment strategies on the basis of 
screening for and surveillance of EKAPE pathogens. 
. 
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III. Limitations 
The main limitation of this study is that the sample size was relatively small and limited to a two-
month period for two public hospitals. Although giving an interesting overview of the 
epidemiology of antibiotic resistance at two levels of care in uMgungundlovu District, the results 
generated preclude extrapolation to the province and the country as a whole. 
. 
IV. Recommendations  
- The high genetic diversity and pathogenicity of circulating ESKAPE bacteria, especially E. 
faecalis, E. faecium and S. aureus, underlines the urgent necessity to develop and implement 
policies, guidelines, activities and interventions to contain their spread in South African 
hospitals. 
- Similarly, the high prevalence of ESBL-producing MDR Gram-negative ESKAPE bacteria in 
carriage and clinical samples among hospitalized patients urges the implementation of regular 
screening and surveillance of MDR Gram-negative ESKAPE bacteria in communities and 
hospitals, to monitor epidemiological changes, ascertain socio-economic impact and inform 
antibiotic treatment. 
- Screening and surveillance measures should be coupled with strict infection prevention and 
control programmes and antimicrobial stewardship programmes (ASP) essential to address 
ABR in South African healthcare settings. 
- Heightening awareness and education of policy-makers, prescribers, pharmacists, laboratory 
scientists, both in- and out-patients and the general population about rational antibiotic use and 
ABR as well as associated clinical and societal implications is essential to curb emergence and 
spread of ABR and preserve potent antibiotics and secure the health of future generations on 
the country. 
- Forthcoming whole genome sequencing-based epidemiological studies should be initiated 
together in public and private hospitals to delineate the true burden of antibiotic-resistant 
ESKAPE bacteria in the country. 
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V. Conclusion 
The sub-optimal infection prevention and control measures as well as extensive antibiotic use not 
only in hospitals but in communities lead to the wide dissemination of antibiotic-resistant ESKAPE 
bacteria in carriage and clinical samples of hospitalized patients in South Africa. Consequently, 
patients, healthcare workers and the general population are at high risk of being infected with these 
resistant bacteria which are associated with high mortality rates. Similarly, the asymptomatic 
carriage of resistant ESKAPE bacteria among hospitalized patients could lead to hospital acquired 
infections especially in immune-compromised patients. These bacteria could ultimately cause 
outbreaks in both communities and healthcare settings where they will increase healthcare costs, 
morbidity and mortality.  
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Appendix 5. Information sheet 
 
Date: _____/_____/_____ 
 
Dear volunteers 
My name is Raspail Carrel Founou Zangue; I am a Doctoral student of the University of KwaZulu-
Natal (UKZN) School of Health Sciences, College of Health Sciences in South Africa. I am the 
principal investigator of a Doctoral Research Project entitled “MOLECULAR 
EPIDEMIOLOGY OF ANTIBIOTIC RESISTANT ESKAPE PATHOGENS ISOLATED 
FROM PUBLIC SECTOR IN UMGUNGUNDLOVU DISTRICT IN KWAZULU-NATAL”. 
This project is under the supervision of Professor Sabiha Yusuf Essack from University of 
KwaZulu-Natal, the College of Health Sciences and with the support the University. All the 
information about the different ethical approvals obtained in South Africa is detailed above.  
This study is carried out in three hospitals namely Greys, Edendale, Appelbosch in 
uMgungundlovu district. During two-months, we will look at ESKAPE group of bacteria and their 
resistant clones in hospital particularly on in-patients. The latter have been recently identified like 
main agents of hospital acquired infection. These bacteria are able to perpetuate infection in spite 
of antibiotic therapy because they have become resistant to numerous antibiotics and involved in 
higher length of stay, hospitalization costs, in hospital mortality. Find out the clinical and economic 
impacts of these bacteria in hospital particularly in-patient, will serve to implement effective 
prevention measures, strategies to counteract nosocomial infection, reduce antibiotics use in the 
hospital, reduce consequently the mortality due to antimicrobial resistance in hospitals.  
The objective of this study is to identify these bacteria in hospitals to reduce the incidence 
of the latter, optimize the success of treatment. Before taking part to this study, it is important to 
read and understand very well all the information concerning the project. This information sheet 
presents and explains the objectives, procedures, potential risks, benefits and inconvenience of the 
study. If you feel that something is unclear while reading this document, please do not hesitate to 
ask for more clarification from the study personnel. If you would like to participate to the study, 
please sign as appropriate below.  
OVERARCHING AIM AND OBJECTIVES OF THE STUDY 
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The principal objective of this study is to find out if you have any infection and whether or not it 
has resistant to antibiotics caused by the ESKAPE group pathogens involved diseases for the 
hospitalized patients. I am soliciting your voluntary participation in this research because you 
comply with the inclusion criteria of the study. Please, be sure that your participation is completely 
voluntary. If you decline your participation in this study, there will not have any negative 
consequences for you. However, if you agree, please, you also need to be conscious of the fact that 
you may stop participating at any time and you may decide not to answer any question. 
If you voluntary to participate in this study, you should know the following acts will occur:  
- You will have automatically a unique participant identification number; this number will 
be used to ensure the traceability of your results and provide confidentiality. Your name 
will not be asked or recorded on any study materials.  
- You will receive a questionnaire— including sex, age, residence location, principal 
profession, date of recent hospitalization, recent surgery, etc.   
- Your samples including rectal swab or stool sample and nasal swab will be collected 
according to the decision of the doctor. 
TIME REQUIRED FOR PARTICIPATION 
The time of your participation will take about 30 minutes above to respond to the questionnaire. 
POTENTIAL RISKS OF THE STUDY 
The procedure to record your information and collect your sample has been done by the researcher 
to minimize the risk of discomforts for yourself. If any act and question that you should answered, 
make uncomfortable yourself, you could able to skip this question and stop the collect.  
BENEFITS 
For yourself, no payment will be asked and no reimbursement will be made for your participation 
in the study. Your participation is necessary to improve data on the different pathogens and 
resistance mechanisms existing in public hospitals in South Africa in order to implement strategies 
and policies to contain antimicrobial drug resistance. Your results will allow the doctor to choose 
the correct antibiotics and provide information on the most appropriate therapy. 
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CONFIDENTIALITY 
After the study, if you decide to withdraw at any time, all the material required concerning your 
identification —questionnaire, informed consent, data recorded and sample—will be destroyed 
except if you give authorization to the researcher to use it after your withdrawal. If you choose to 
be enrolled, all your responses and information will be confidential and kept properly with limited 
access to allowed person only. Neither your name nor your address will be recorded, and no other 
person will know your answers. Your data will be conserved as described by the following 
measures which are applied for all applicants. 
During the research: 
- Your name will be codified, and nobody will know your answers. 
- All the research document and material will be stored in a workbook with key. 
- The database containing numerical data will have an access granted by a password 
detained by the researcher only. 
- Numerical data will be protected in files with access granted by a password detained by 
the researcher. 
- Only the researcher and authorized persons will have access to the data containing names 
and codes which will be stored separately from the material of research, from the data and 
informed consent. 
During the dissemination of the results: 
- The participant names will never appear in a report, publication or scientific presentation 
- The results will be presented globally to avoid the identification of participant  
- The results of the study will be published in scientific journals and nobody will be 
recognized. 
- The participants desirous to have their resume of the results should provide their Email or 
Postal address in the blank space provided below. 
THE ELECTRONIC OR POSTAL ADDRESS IF YOU WOULD LIKE TO RECEIVE A 
RESUME OF THE RESULTS: 
---------------------------------------------------------------------------------------------------------------- 
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At the end of the study: 
- The collected data and materials used during the research may be used later for other 
research 
- All the material and data will be destroyed at later in 10 years. 
- Measures have been done for persons desirous to know their results.  
i. The results will be sent to participants who will have done the request by indicating 
their address at the space provided.  
ii. The results will not be available before the end of the year 2017.  
iii. If this address changes by this date, I encourage you to inform us of your new address. 
VOLUNTARY CONSENT AND PARTICIPATION IN THE STUDY  
You have read the information sheet above concerning the study; you have received an opportunity 
to ask for any questions and explanation about the procedure, benefits and risks of the study; you 
understand the purpose, process and risks of the study. If you would like to be freely enrolled in 
the study, please sign the informed consent form below. A copy of this consent will be given to 
you for your record.  
For further interrogation concerning the study, your rights as participant or the researcher, please 
be free to contact the researcher or the Biomedical Research Ethics Committee as detailed below: 
Principal Investigator: Raspail Carrel Founou Zangue 
BSc., MSc., PhD Student 
Discipline of Pharmaceutical Sciences 
School of Health Sciences 
College of Health Sciences 
University of KwaZulu-Natal 
Durban 4000 
South Africa 
Tel: +237 675 94 35 67 
Email: czangue@yahoo.fr 
 
Supervisor: Prof. Sabiha Yusuf Essack 
B. Pharm., M. Pharm., PhD (Pharmaceutical Microbiology) 
Professor: Pharmaceutical Sciences 
South African Research Chair in Antibiotic Resistance & One Health 
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University of KwaZulu-Natal 
South Africa 
Tel: +27(0) 31 2602486 
Fax: +27 (0) 31 2604609 
Email: essack@ukzn.ac.za 
 
Biomedical Research Ethics Administration  
Research Office, Westville Campus  
Govan Mbeki Building  
University of KwaZulu-Natal 
Private Bag X 54001, Durban, 4000  
KwaZulu-Natal, South Africa  
Email: BREC@ukzn.ac.za 
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Appendix 6. Informed consent 
 
I ___________________________________certify that I have been invited to participate in a 
study entitled “MOLECULAR EPIDEMIOLOGY OF ANTIBIOTIC RESISTANT ESKAPE 
PATHOGENS ISOLATED FROM PUBLIC SECTOR IN UMGUNGUNDLOVU 
DISTRICT IN KWAZULU-NATAL” with Mr Raspail Carrel Founou Zangue from the School 
of Health Sciences, College of Health Sciences of the University of KwaZulu-Natal in Durban-
South Africa as Principal Investigator. 
- I certify that I have read and understood the purpose, procedures, benefits and risks of the 
study 
- I have been given an opportunity to ask for more clarification and I have received answers 
to my satisfaction 
- I understand that my participation is completely voluntary, that my information will be 
strictly confidential and that I may withdraw at any time without affecting my treatment 
and legal rights, 
- I understand that if I have further interrogations concerning the study I may freely contact 
the researcher Raspail Carrel Founou Zangue at the address below: 
Principal Investigator: Raspail Carrel Founou Zangue 
BSc., MSc., PhD Student 
Discipline of Pharmaceutical Sciences 
School of Health Sciences 
College of Health Sciences 
University of KwaZulu-Natal 
Durban 4000 
South Africa 
Tel: +237 675 94 35 67 
Email: czangue@yahoo.fr 
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- I additionally understand that for any questions about my rights as participant or about the 
researcher, I may contact the UKZN Biomedical Research Ethics Committee at the address 
mentioned below: 
Biomedical Research Ethics Administration  
Research Office, Westville Campus  
Govan Mbeki Building  
University of KwaZulu-Natal 
Private Bag X 54001, Durban, 4000  
KwaZulu-Natal, South Africa  
Tel: +27(0) 31 2602486   
Fax: +27 (0) 31 2604609 
  
By signing this document, I freely agree to be enrolled in this study and give the authorization 
under the specified conditions to the PhD student researcher Mr Raspail Carrel Founou Zangue 
from the University of KwaZulu-Natal to use my samples and isolates (where applicable) for the 
actual and where necessary, future studies concerning antimicrobial resistance. 
____________________      ____________________ 
Signature of Participant                              Date 
____________________   _____________________ 
Signature of guardian     Date 
(Where applicable) 
 
Participant code: ________________________ 
Location: ________________________ 
Gender:  Male       Female 
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Appendix 7. Questionnaire 
 
Date: ________/________/_______ 
Patient ID ___________________________ 
 
Please, understand that questions are personal to you and please be assured that your answers will 
be confidential. We would appreciate your honesty and complete response to each question. It 
should take approximately 30 minutes to complete. 
Instructions to all participants:  Check  the appropriate box or write your answer in the space 
provided.  
Part I: On admission 
Section 1: Demographic Information  
These questions are about socio-demographic information. Remember, your answers will remain 
strictly confidential.  
1. What is your gender?  
 Male 
 Female 
2. What is your age? 
______________ 
3. Your current residence location is UMgungundlovu?   
 Yes 
 No  
4. What is your principal profession?   
___________________________ 
5. Do you have an occupation related to hospital? 
 Yes  
 No   
Section 2: Clinical History  
The next questions concern your medical history.   
6. In the past 12 months have you been hospitalized? (If no, skip to the next question) 
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No  yes 
7. In which ward have you been hospitalized? 
 Intensive care unit 
 Paediatric unit 
 Endocrinology 
 Emergency 
General medicine 
 Surgical unit 
 Other units_________________  
8. Are you currently under antibiotic treatment?  
Yes   No   (if no, skip to the next question) 
9. Which antibiotic? 
________________________________ 
Part II: On discharge  
10. Have you received antibiotics during your hospitalization?  Yes   No  
If yes, which drug have you received? 
Name _______________________ 
Route_______________________ 
 Duration ____________________ 
11. How many antibiotics have you received during your hospitalization?  
one 
two 
more than three 
12. How many days have you been hospitalized? 
one week 
two weeks 
three weeks 
more than three weeks 
Are you currently under antibiotic treatment? Yes   No  
